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 Summary/Resumen  
  
The β-adrenergic system plays an important role in the regulation of heart 
function. The early intravenous administration of ß1-adrenergic receptor 
(ADRB1)-antagonist, metoprolol, in patients with ST-segment elevation acute 
myocardial infarction (AMI) reduces the extent of infarct size.  The prevailing 
view has been that metoprolol acts mainly on cardiomyocytes function, 
reducing cardiac output. This work presents evidence that metoprolol reduces 
ischemia/reperfusion injury by targeting the hematopoietic compartment, 
specifically by inhibiting neutrophil function through an ADRB1 signalling-
dependent manner. Metoprolol acts during early phases of neutrophil 
recruitment, impairing structural and functional rearrangements necessary for 
effective interactions with circulating platelets to occur. Metoprolol, “stuns” 
neutrophils that cannot engage the structural conformation necessary to 
infiltrate tissues, triggering erratic intravascular dynamics and overall blunted 
inflammation. The in vitro functional assays confirm direct effect on 
neutrophils through an ADRB1-dependent mechanism. The depletion of 
circulating neutrophils, the lack of the Adrb1 in hematopoietic cells and the 
blockade of P-selectin glycoprotein ligand-1, the receptor involved in 
neutrophil-platelet interactions, result in a complete abrogation of 
metoprolol´s infarct-limiting effect. Moreover, the association between 
neutrophil count and microvascular obstruction is abolished in early 
metoprolol-treated AMI patients. Metoprolol has no direct effect on platelet 
function, but inhibits neutrophil-platelet interactions in AMI patients by 
targeting neutrophils directly. Identification of the relevant role of ADRB1 in 
hematopoietic cells during acute injury and the protective role upon its 
modulation offers potential for developing new therapeutic strategies. 
  
  
El sistema β-adrenérgico juega un papel importante en la regulación de la 
función cardíaca. La administración intravenosa y previa a la reperfusión del 
antagonista ß1-adrenérgico (ADRB1) específico metoprolol, en pacientes con 
infarto agudo de miocardio con elevación del segmento ST, reduce el tamaño 
final del infarto. Clásicamente se ha considerado que el metoprolol actúa 
principalmente sobre los miocardiocitos disminuyendo el gasto cardíaco. Este 
trabajo presenta por primera vez evidencia de que el metoprolol reduce el 
daño por isquemia/reperfusión cardiaco actuando directamente sobre el 
compartimento hematopoyético, inhibiendo de manera específica la cascada 
de señalización dependiente del ADRB1 en los neutrófilos. El metoprolol actúa 
durante las primeras etapas del reclutamiento de células inflamatorias al 
miocardio. Altera la conformación estructural y función neutrofílica, impidiendo 
que se establezcan interacciones eficientes entre los neutrófilos y las plaquetas 
circulantes. El metoprolol "aturde" los neutrófilos circulantes, provocando un 
comportamiento errático que termina abortando su infiltración y por tanto su 
acción inflamatoria general en los tejidos. Los ensayos funcionales in vitro 
realizados confirman un efecto directo del metoprolol sobre los neutrófilos 
dependiente de ADRB1. La depleción de neutrófilos circulantes, la falta de 
Adrb1 en las células hematopoyéticas y el bloqueo del ligando-1 de la 
glucoproteína P-selectina, el cual está involucrado en las interacciones de 
neutrófilos con las plaquetas circulantes, inhiben el efecto limitante sobre el 
tamaño de infarto del metoprolol. Estos resultados indican que la presencia de 
ADRB1 en los neutrófilos es indispensable para que el metoprolol ejerza su 
acción protectora. Además, pacientes con infarto agudo de miocardio (IAM) 
tratados con metoprolol presentan abrogación de la asociación entre las 
cuentas de neutrófilos en sangre y la obstrucción microvascular. Por último, el 
metoprolol no tiene efecto directo sobre la función plaquetaria, e inhibe las 
interacciones de neutrófilos y plaquetas en pacientes con IAM ejerciendo su 
efecto directamente sobre los neutrófilos. La identificación del papel de ADRB1 
en las células hematopoyéticas durante la lesión aguda y la función protectora 
de su modulación ofrece el potencial para desarrollar nuevas estrategias 
terapéuticas. 
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Abbreviation  Meaning 
 
 
 
CNIC  Spanish National Center for Cardiovascular Research 
AMI  Acute myocardial infarction 
IAM  Infarto agudo de miocardio 
ADRB  ß-adrenergic-receptor 
ADRB1  ß1-adrenergic-receptor 
Adrb1  ß1-adrenergic-receptor gene 
ADRB2  ß2-adrenergic-receptor 
Adrb2  ß2-adrenergic-receptor gene 
IR  Ischemia/reperfusion 
MVO  Microvascular obstruction 
i.v.  Intravenous 
PCI  Percutaneous coronary intervention 
IS  Infarct size 
AAR  Area at risk 
LAD  Left anterior descending  
TTC  Triphenyl-tetrazolium chloride 
BM  Bone marrow 
CMR  Cardiac magnetic resonance 
LV  Left ventricle 
LVEF  Left ventricular ejection fraction 
LysM  Lysozyme-M 
PSGL1  P-selectin glycoprotein ligand-1 
GFP  Green fluorescent protein 
IVM  Intravascular microscopy 
CXCL1  Chemokine (C-X-C motif) ligand 1 
ROS  Reactive oxygen species 
s.e.m.  Standard error of the mean 
TNFα  Tumor necrosis factor alpha 
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The topic of study covered in this doctoral thesis is the role of β-adrenergic 
(ADRB) system modulation with ADRB-antagonists (ß-blockers) in acute 
myocardial infarction (AMI), with special focus to the effect on 
ischemia/reperfusion (IR) injury-associated deleterious processes. Specifically, 
this work focuses on the study of the mechanisms underlying the benefits of 
early intravenous (i.v.) administration of the ß1-adrenergic receptor (ADRB1)-
antagonist, metoprolol, as a cardioprotective strategy and evaluates its effect 
on neutrophil dynamics, tissue infiltration and neutrophil-platelet interactions 
and coaggregates formation. Further, the implications of these phenomena on 
myocardial microvascular obstruction (MVO) as a key factor for final 
myocardial infarct size (IS) and subsequent outcome in patients with ST-
segment elevation AMI are evaluated. 
Acute myocardial infarction 
Cardiovascular disease is a growing healthcare problem. It is the leading cause 
of morbidity and mortality worldwide, and is projected to account for 
approximately 25 million deaths annually by 2030 (1). Heart attack is caused 
by intraluminal coronary artery occlusion, frequently due to a disrupted 
atherosclerotic plaque (2) (Fig. 1). Insufficient oxygen and nutrients supply 
into the capillaries (ischemia) limits both energy supply (mainly glucose and 
free-fatty acids) and energy production (adenosine triphosphate, ATP) 
essential for cellular viability. The heart, a high oxygen-demanding organ, can 
suffer irreversible damage if ischemia is maintained for several minutes (3). 
The amount of infarcted tissue, that is, the infarct size, is the main 
determinant of poor outcome and adverse events post AMI (4) and is mainly 
determined by the duration of the ischemic insult. Seminal studies performed 
three decades ago with animal models demonstrated that an early reperfusion 
(restoration of the blood flow) was able to limit myocardial IS (5) and improve 
prognosis. Several years later, pharmacological reperfusion with the 
administration of fibrinolytics was indisputably associated with a reduction in 
mortality in patients with AMI (6). A decade later, primary angioplasty 
(mechanical reperfusion by percutaneous coronary intervention (PCI) in the 
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cathlab) resulted to be superior to fibrinolysis (7) (8). Thereon, clinical 
practice guidelines, advocate to reduce the ischemia duration by re-
establishing coronary artery blood flow, as the cornerstone of AMI 
management (9), in order to reduce myocardial damage and complications 
and improve survival (10). Despite these achievements, AMI is still one of the 
major clinical manifestations of cardiovascular disease (7) and a chief 
contributor to mortality and morbidity worldwide. Except for early reperfusion 
therapies, few additional therapies have shown mortality reduction or 
improved long-term prognosis of patients with AMI. The development of 
therapies able to reduce infarct size and to prevent cardiac dysfunction after 
myocardial infarction are, therefore, a matter of intense research (11) (12) 
(13) (14). 
 
 
Figure 1.! Acute myocardial infarction concepts 
Illustration of a heart defining different AMI-related concepts. Heart attack is 
caused by intraluminal coronary artery occlusion, frequently due to a 
disrupted atherosclerotic plaque. The myocardial zone irrigated by the 
occluded artery, the area at risk (AAR) is in jeopardy of becoming irreversibly 
injured if ischemia is not relieved. Most of the patients suffering from an AMI 
receive timely reperfusion therapy allowing part of the myocardial AAR to 
remain free of necrosis, i.e. to survive (salvaged myocardium). In white, the 
extent of infarcted myocardium. 
Coronary artery occlusion
Myocardial area at risk
Necrotic myocardium
Salvaged myocardium
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Myocardial ischemia/reperfusion injury 
Since the demonstration of the benefits of blood flow restoration to salvaged 
myocardium (15) (16), most of the patients suffering from AMI undergo 
reperfusion therapy allowing part of the myocardial area at risk (amount of 
tissue irrigated by the occluded artery in jeopardy of becoming necrotic due to 
the ischemic insult, AAR), to remain free of necrosis. Paradoxically, reperfusion 
of the occluded coronary artery, further contributes to myocardial injury (3), 
something known as reperfusion injury. Reperfusion-injury is defined as “the 
injury caused by the restoration of blood flow after an ischemic episode, 
leading to the death of cardiac cells that were reversibly injured at the time of 
blood flow restoration”. The potential of reperfusion as a phenomenon able to 
induce subsequent injury following to ischemic damage is supported by strong 
evidence that interventions applied at the end of the ischemic period (i.e. 
coinciding with reperfusion) can significantly reduce infarct size (17) (18) (19) 
(20) (21). Clinical and experimental non-invasive cardiac magnetic resonance 
(CMR) recent studies have shown that shortly after myocardial reperfusion 
drastic myocardial tissue composition changes occur (22) (23) (24). Although 
experimental studies have shown reperfusion injury to contribute up to 50% of 
the total IS (25) (Fig. 2), the actual impact of reperfusion has not been fully 
determined. Ischemia duration (time that runs between onset of symptoms 
and reperfusion), brief episodes of spontaneous reperfusion, tissue 
temperature during ischemia and hemodynamic situation, as well as the area 
at risk, and the amount of residual blood flow through the collateral arteries 
and the extent of microvascular dysfunction, are all important reperfusion 
injury contributing factors (11). Overall, the injury inflicted to the myocardium 
during AMI is the result of both ischemia- and reperfusion-related phenomena, 
and is known as myocardial ischemia/reperfusion (IR) injury (8) (26) (27) (28) 
(29). The development of effective therapies to reduce myocardial IR injury is 
therefore an unmet clinical need (11).  
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Inflammation as a contributor to reperfusion injury 
Inflammation is a physiological process of self-protection in response to 
harmful stimuli, endogenous tissue damage, irritants or pathogen infection. 
Inflammation also promotes the healing process. Polimorphonuclear 
leukocytes, particularly neutrophils, constitute a great portion of circulating 
Figure 2.! Myocardial death during ischemia and reperfusion 
When coronary artery occlusion occurs, myocardium is capable to maintain its 
performance for certain amount of time. Beyond this time, myocardial death 
grows exponentially due to ischemia. If there is no reperfusion, the entire 
myocardium irrigated by the occluded coronary artery myocardium (Area at 
risk, AAR) will become infarcted (striped line); If reperfusion occurs in a 
reasonable range of time, ischemia injury is reduced and therefore IS limited 
(dotted line).  Paradoxically, reperfusion itself induces an additional damage 
(red line). Final infarct size (IS) is therefore dependent on two separate but 
related processes: ischemia and reperfusion.  In an ideal situation (no 
reperfusion injury), IS will only be driven by ischemic injury. Pictures on the 
right panel show representative mouse hearts after myocardial temporal 
coronary occlusion. Triphenyl-tetrazolium chloride (TTC) staining depicts the 
viable myocardium (red), while necrotic myocardium is left uncoloured 
(white). Figure adapted from Sanz-Rosa et al. (30). 
Pharmacological thrombolysis or interventional percutaneous 
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leukocytes and are the primary effectors of the immune response against 
invading pathogens and the premier cellular mediators to acute injury (31). 
These two functions rely on their ability to migrate and patrol within the blood 
vessels and tissues. Selectins and chemokines trigger endothelial integrin’s 
activation, allowing neutrophils to adhere, crawl and attach to the vessel wall 
(32) (33). Once recruited, neutrophils reorganize their 3D-structure disposing 
asymmetric polarization of membrane receptors (34) and subsequently direct 
a P-selectin glycoprotein ligand-1 (PSGL1) cluster-protruding domain into the 
lumen to scan for activated platelets present in the bloodstream. Only 
neutrophil-platelet PSGL1-dependent productive interactions thrive subsequent 
neutrophil inflammatory response and infiltration (35). When extravasated into 
the injured tissue, neutrophils enhance the release of pro-inflammatory 
cytokines and other inflammatory mediators causing deleterious effects to the 
tissue and inducing more recruitment (36) (37) (38). Consequently, those 
neutrophils unable to polarize or to transduce signals display aberrant 
inflammatory responses. 
In the context of AMI, cardiac cytokine burst induces neutrophil activation and 
rapid recruitment to the injured myocardium leading to increase myocardial 
damage in several and sequential manners (36) (39) (40). Neutrophils cause 
direct injury to endothelial cells and cardiomyocytes via production of reactive 
oxygen species (ROS), proteases, cytokines and lipids (36). In addition, in an 
inflammatory milieu, neutrophils bind to activated platelets and red blood 
cells, forming PSGL1-dependent interaction coaggregates (39). Upon 
reperfusion, these coaggregates contribute to capillaries obliteration in the 
affected vessel, precluding tissue perfusion despite blood flow restoration in 
the proximal vessels. This phenomenon is known as MVO or “No Reflow 
phenomenon” (41) (42). MVO appears in 30 to 50% of the patients with 
efficient epicardial vessel recanalization, and is a major contributor to IR 
injury, infarct size, and an independent predictor of morbidity/mortality (8) 
(43). The microcirculatory network is the interface between the epicardial 
vessel and the cardiomyocytes. No matter how efficiently and rapidly the blood 
flow is restored to the epicardial artery, if there is MVO the myocardial tissue 
irrigated distally will remain without efficient perfusion. In summary, 
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neutrophils are clearly involved in reperfusion injury, and neutrophil cellular 
dynamics (including neutrophil-platelet interactions) are an attractive 
therapeutic target for the prevention of myocardial IR injury. 
ß-Adrenergic system 
The adrenergic (or sympathetic) neuro-hormonal axis is a main regulator of 
the cardiovascular system. It particularly regulates heart function. ß-
adrenergic system activation results in and increase in heart rate and cardiac 
contractility, improvement of cardiac relaxation, decrease in venous 
capacitance, and constriction of resistance and cutaneous arteries (44) (Fig. 
3). The relevance of ADRBs is depicted by the fact that two Nobel Prizes 
(Medicine 1988 and Chemistry 2012) were awarded for ADRBs-related 
discoveries (45) (46) (47) (48). ARDBs are non-sensory G-protein–coupled 
receptors, consisting of seven trans-membrane domains, expressed on the 
surface of a wide range of target cells which primarily signal through 
heterotrimeric G-proteins once in contact with adrenergic neurotransmitters 
norepinephrine and epinephrine (49) (50). There are 3 different ADRBs 
subtypes: ADRB1, ADRB2, and ADRB3 which differ in structure, function, 
affinity states and pharmacological properties (51) (52) (53) (54) (55) (56). 
From them, ADRB1 is the predominant subtype- in the (normal, healthy) 
myocardium, representing 75% to 80% of total ADRBs density, followed by 
ADRB2, which comprises ≈15% to 18% of total cardiomyocyte ADRBs, and the 
remaining 2% to 3% is ADRB3 (under normal conditions) (44) (50). 
The ß-adrenergic system is critically involved in many inflammatory reactions 
and has been widely studied in immunity (57) (58). Particularly, both ADRB1 
and ADRB2 in humans are expressed in a wide variety of tissues including 
immune cells, as lymphocytes, macrophages, and neutrophils (59) (60). 
During ischemia, catecholamine induced-stress alters neutrophil trafficking 
(60) (61) (62) and promotes formation of neutrophil-platelet coaggregates 
(63). Moreover, extra neuronal generation of epinephrine by neutrophils 
provides amplification of the catecholamine-mediated inflammation (57). 
Despite recent advances in understanding the role of catecholamines in the 
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inflammatory response, the precise mechanism by which infarction-induced 
catecholamine release has an impact on the leukocytic-dependent innate 
immune response and contributes to further increase myocardial infarct size is 
unclear. It is known that ß-blockers inhibit inflammatory cells’ activity, 
mobilization and migration (64) (65) (66), however and besides promising 
experimental findings no clinical trial has shown positive results in the context 
of ischemia reperfusion injury. 
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ß-blockers in AMI  
In early stages of myocardial infarction, various types of stressors such as 
pain, anxiety and ischemia are activated resulting in intracellular 
catecholamine redistribution (67) and local and systemic release of 
catecholamines (68). Levels of circulating epinephrine can increase up to 10-
fold in patients suffering from AMI. This hyper sympathetic systemic 
stimulation results in malignant arrhythmias and acceleration of cell damage in 
the injured myocardium (68). ß-adrenergic antagonists (ß-blockers) are 
therefore one of the oldest and most frequently prescribed drugs used by 
cardiologists in the treatment of cardiovascular diseases. In fact, current 
clinical guidelines in the management of AMI indicate the administration of 
oral β-blockers within the first 24 hours after AMI (69) because its use 
undoubtedly reduce mortality (70). However, the ability of β-blockers to 
reduce infarct size has been a matter of intense debate.  
Figure 3. ß-adrenergic signalling & effector functions 
(a) Fight-or-flight stress responses deliver catecholamines distally into the 
tissues through the blood and locally through the nerve fibres. Agonists occupy 
ß-adrenoceptors (β-ARs) which causes the dissociation of the heterotrimeric 
G-proteins into active Gα and free Gβγ subunits which can then transduce 
intracellular signals independently of each other. ADRB1 (β1AR) and ADRB2 
(β2AR) activate Gs-protein signalling, stimulating the effector adenylate 
cyclase, which converts adenosine triphosphate (ATP) to adenosine 3′,5′-
monophosphate (cAMP), causing subsequent activation of the cAMP-dependent 
protein-kinase A (PKA). PKA is the major effector of cAMP and by 
phosphorylating a variety of substrates, ultimately induce a significant 
increase in free intracellular Ca2+ concentration, which activates several 
biochemical effector and transcriptional effectors. Lower panel summarizes the 
functional consequences from βAR stimulation in the cardiovascular system. 
(b)  Structure of the ß1-adrenergic receptor bound to ligand shown in cartoon 
representation with the intracellular side at the bottom of the figure. The 
ligand (in this case, carmoterol) is shown as a space filling model in yellow. 
The extracellular loop 2 (EL2), and transmembrane helices 1–4 (H1–H4) are 
labelled. Next, 2D and 3D illustrations of the ß1-adrenergic receptor 
antagonist, metoprolol. The oxygen (O, red), the nitrogen (N, blue). Adapted 
from Lymperopoulos et al. (44), Warne et al. (52) and Pubchem. 
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Several randomized clinical trials have contributed to understand whether 
early ß-blockers administration should be considered as a cardioprotective 
therapy against AMI. First, a subsequent analysis of the TEAHAT study 
revealed significant reduction in heart-enzyme-mediated infarction size in 
patients without ß-blockade contraindications (71). Later Van de Werf et al., 
designed a trial to study the effect of i.v. ß-blockers (atenolol) given 
concomitantly with thrombolytic therapy in patients with AMI, and found a 
neutral effect on infarct size (72). Next, in 2005, the COMMIT trial tested the 
value of adding early ß-blocker therapy in the emergency treatment 
of myocardial infarction to standard therapy against AMI. A total of 45,852 
patients with AMI who were to be re-vascularized (aspirin and thrombolysis) 
were randomized to receive early metoprolol i.v. followed by oral metoprolol or 
placebo. Despite the lack of data on infarct size, authors found a significant 
reduction in rates of re-infarction and ventricular fibrillation in patients 
receiving metoprolol (73). A more recently randomized clinical trial included 96 
patients who were randomized to receive the ultra-short-acting ADRB1-
selective blocking agent, landiolol, or placebo, showing significant 
improvement in cardiac function (Left ventricular ejection fraction, LVEF) in 
landiolol-treated patients (74). In addition, evidence from retrospective 
studies performed while PCI being the treatment of choice for a AMI, suggests 
that β-blockade treated patients presented better short-term survival and 
better outcomes (75) (76) (77). Overall, the use of different ß-blockers 
(metoprolol or atenolol), the type (oral or i.v.) and timing (early or within the 
first hours) of administration, and the different contexts of AMI therapy under 
evaluation (non-reperfused, pharmacological thrombolysis or PCI) have 
contributed to the uncertain of this promising therapy.  
Role of metoprolol on IR injury 
Metoprolol is a moderately lipophilic, ADRB1-selective antagonist, that acts 
primarily on heart and blood vessels (54). It is one of the earliest ß-blocker 
accepted for clinical use (78) and given to its like short half-life, easy i.v. 
administration and potential pleiotropic effects, metoprolol is the leading drug 
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of its class (79). Our group has focused for the last 12 years, on the role of 
metoprolol-tartrate on myocardial IR injury. Specifically, evaluating the effect 
of its pre-reperfusion (i.e. during ongoing ischemia) administration on infarct 
size. Metoprolol, in experimental models of AMI demonstrated a significant 
reduction size only when administered prior to reperfusion (80) (81). Based on 
this experimental evidence, we conducted the METOCARD-CNIC clinical trial to 
test whether early metoprolol administration was cardioprotective in patients. 
A total of 270 patients with a first anterior ST-segment elevation AMI 
undergoing percutaneous coronary intervention within 6 hours of symptoms 
onset were randomized to or not to receive i.v. metoprolol tartrate during the 
transport by ambulance or at the hospital emergency room before PCI 
revascularization. Metoprolol-treated group presented a significant infarct size 
reduction measured by CMR at 5-7 days and improved long-term cardiac 
function by a follow up cardiac CMR at 6 months (82) (83). However, the 
mechanism underlying metoprolol’s cardioprotective effect remains unclear 
(84) Identifying this mechanism could have significant implications for the 
understanding of IR injury and the development of novel infarct-limiting 
therapies. More recently, our group also participated in the EARLY BAMI trial, 
in which metoprolol administration was not associated with a significant infarct 
size reduction (85). However, the dose of metoprolol used in this trial was 
significantly less than in METOCARD-CNIC trial and it was not associated with 
a significant reduction in heart rate and blood pressure, suggesting an 
infradosing effect. 
The mechanisms by which metoprolol reduces infarct size have not been 
demonstrated and this represented the main objective of the present thesis. 
  
 Objectives 
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Pre-reperfusion administration of i.v. ADRB1-blocker is a safe strategy that 
reduces infarct size and improves long-term cardiac function. Based on this 
evidence and the relevance of inflammation on IR injury, the main hypothesis 
tested on this work is that the mechanism responsible of the protective effect 
of early (pre-reperfusion) i.v. metoprolol administration is by altering 
neutrophil dynamics, which results in a dampened inflammatory response. 
This results in reduced myocardial IR injury and, in turn, in smaller infarct 
sizes. 
The objectives set to test this working hypothesis are:  
Objective 1:   To set de myocardial IR murine model and confirm that pre-
reperfusion administration of i.v. metoprolol-tartrate cardioprotective effect in 
a murine model of IR injury.  
Objective 2:   To assess the contribution of ADRB1 blockade on the different 
heart compartments (endothelium, myocardium (cardiomyocyte) and 
hematopoietic) to cardioprotection. 
Objective 3:   To study the effect of ADRB1-selective blockade with 
metoprolol on myeloid-derived leukocyte infiltration. 
Objective 4:   To assess the effect of ADRB1 blockade on neutrophil 
function, specifically evaluating its effect on neutrophil-platelet interactions 
and neutrophil migration. 
  
 Materials and methods 
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Human cardiac magnetic resonance imaging 
The METOCARD-CNIC trial (NCT01311700) recruited patients suffering an AMI 
during hospital transit to undergo mechanical reperfusion by primary 
angioplasty. Patients were randomized to receive either i.v. metoprolol (up to 
15 mg) or no drug (control). The study design can be revised in Ibanez et al. 
(86). Patients underwent two CMR studies: 1 week and 6 months after AMI. 
Images were acquired with a 3.0 Tesla magnet (Achieva Tx®, Philips Medical 
Systems) with vector-cardiographic gating and a dedicated cardiac 32-channel 
phased-array surface coil. The extent of MVO, was measured in the 1 week 
CMR study; to detect and quantify MVO, a delayed enhancement imaging was 
performed 10 minutes after gadolinium contrast injection, using a T1-weighted 
2-D Inversion Recovery Turbo Field Echo (2D IR-TFE) sequence. Myocardial 
necrosis was defined by the extent of abnormal gadolinium enhancement, 
whereas MVO was defined as black hypo-enhanced areas within the bright-
hyper-enhanced regions. CMR analysis was undertaken by operators blinded to 
treatment allocation at CNIC. Myocardial necrosis and MVO were quantified by 
semiautomatic delineation with dedicated software (QMass MR 7.6; Medis, 
Leiden, the Netherlands). Total MVO was quantified as grams of left ventricle 
(LV). To correct for infarct size, MVO was also expressed as a % of the 
infarcted area. 
Mouse procedures  
Experimental procedures were approved by the CNIC Animal Care and Ethics 
Committee and regional authorities. Myocardial IR, thioglycolate-induced 
peritonitis, and intravital microscopy (IVM) experiments were performed with 
8-13-week-old wild-type male C57BL/6J mice. β1-adrenergic receptor (Adrb1) 
knockout (KO; Adrb1KO) mice were in a mixed background. β2-adrenergic 
receptor (Adrb2) knockout (KO; Adrb2KO) mice were in a C57BL/6J 
background.  For the bone marrow (BM) transplant experiments, Adrb1KO 
mice were backcrossed with mice expressing DsRed under the control of the β-
actin promoter to facilitate evaluation of BM engraftment. Male and female 
mice were used as donors in BM transplant procedures, but only males were 
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used in myocardial IR and thioglycolate-induced peritonitis experiments. All 
animals were randomized to receive a single i.v. injection (50 µL) of 
metoprolol-tartrate (10 mM) or vehicle (saline). Histological evaluation of 
injured myocardium in the myocardial IR model was performed in lysozyme M-
GFP+ (LysM-GFP) (87) male mice. Intravascular neutrophil and neutrophil-
platelet interactions were scored manually in the myocardium. Neutrophils 
were depleted in C57BL/6J male by i.v. injections of 50 µg anti-mouse Ly6G 
antibody 24 and 48 hours before the myocardial IR procedure (88). For in vivo 
blocking of PSGL1, 50 µg of anti-PSGL1 antibody (clone 4RA10) was i.v. 
injected 15 minutes after ischemia onset. Mice were maintained under 
pathogen-free conditions in a temperature-controlled room and a 12-hour 
light-dark cycle at the CNIC animal facilities. Chow and water were available 
ad libitum.  
Reagents  
Metoprolol-tartrate (M5391), Evans blue, triphenyltetrazolium chloride, DAPI 
(D8417-1MG), Mowiol mounting medium (81381), anti-laminin (L9393), anti-
α-actinin (A7732), Dihydrorhodamine 123 (D1054) were obtained from Sigma-
Aldrich. Dylight-650-conjugated anti-1A8 Ly6G (BE0075-1) and anti-PSGL1 
antibody (clone 4RA10) from BioXcell. Anti-CD41 (12-04-11-83) and anti-
CD115 (12-1152-83) were obtained from ebioscience. O.C.T. was obtained 
from Tissue-Tek®. Qiagen RNeasy Plus Mini Kit (74136).  Percoll Plus (17-
5445-02) and Ready-to–go RT-PCR Beads (27-9259-01) from GE Healthcare. 
CXCL1 was obtained from (453-KC-010) from R&D Systems. W-peptide 
(WKYMVM, 1799) from Tocris. Thioglycolate (BD211716) and anti-GP IIb/IIIa 
from BD Biosciences. Anti-GR1 (ab2557) was obtained from Abcam and AF-
647 (A-21472) from Molecular Probes. Anti CD45–FITC from Miltenyi Biotec, 
Germany. PC5-conjugated anti-CD14, anti-CD61 PC7 and Versalyse solution 
were obtained  from  Beckman Coulter. Cytokine  tumor  necrosis  factor  alpha
(TNFα) was obtained from R&D Systems.
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Mouse intra-carotid hemodynamic study 
Animal preparation was identical to mouse model of myocardial IR injury in 
order to evaluate metoprolol dosage under similar conditions to that of 
myocardial IR model.  
Once fully asleep, intubated and tempered in a heating pad, 5 mm of the right 
common carotid artery was dissected and exposed under aseptic conditions 
and using bluntly vessel-forceps and blood flow interrupted using several loose 
6-0 silk sutures and knots. A small incision was made between the two 
 
Figure 4. Hemodynamic effect of i.v. metoprolol on mouse 
Hemodynamic effect of a single intravenous injection (50µL) of metoprolol-
tartrate at different concentrations through the femoral vein. (a) Mean 
arterial blood pressure and (b) Heart rate (bpm) were registered through a 
left arterial carotid artery catheter. (n=3-4 per condition). Data are means ± 
s.e.m. SG, stands for salivary gland; CA, right carotid artery; CTH, catheter. 
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ligatures with a micro surgical scissor. Then a heparinized PE-tubing catheter 
connected to a pressure transducer was inserted in line with the vessel and 
then fixed with firm ligatures around the artery throughout the procedure 
(Fig. 3). Electrocardiogram, Systolic blood pressure (SBP), heart rate (HR) 
and temperature was monitored (MP36R, Biopac Systems Inc). Dose-response 
studies, consisted on 10 minutes of catheter stabilization record, followed by a 
single i.v. bolus of 50 µL of metoprolol-tartrate to each animal through the 
femoral vein (n=3/group), and 1 h continuous hemodynamic monitoring saved 
for posterior analysis of mean SBP and mean HR. 
Mouse model of myocardial IR injury  
Male 8-12-week-old mice were subjected to 45 minutes occlusion of the left 
anterior descending (LAD) coronary artery followed by 6 or 24 hours of 
reperfusion. For infarct size evaluation, reperfusion was maintained for 24 
hours. For analysis of MVO, neutrophil infiltration, and neutrophil-platelet 
interactions, reperfusion was maintained for 6 or 24 hours as indicated. The IR 
procedure was performed as previously described (89). (Fig. 5) Briefly, fully 
asleep animals were intubated and temperature controlled throughout the 
experiment at 36.5 °C to prevent hypothermic cardioprotection. Thoracotomy 
was then performed and the LAD was ligated with a nylon 8/0 monofilament 
suture for 45 min. The electrocardiogram was monitored (MP36R, Biopac 
Systems Inc.) to confirm total coronary artery occlusion (ST-segment 
elevation) throughout the 45 minutes ischemia. Ten minutes before 
reperfusion onset, mice were randomized to receive a single i.v. injection (50 
µL) of metoprolol-tartrate (10 mM) or vehicle (saline) through the femoral 
vein. Dose of metoprolol was chosen after a dose response study, which 
identified this dose as the highest dose inducing a moderate effect on heart 
rate and blood pressure (i.e. <10% variation in both parameters from pre-
dose (Fig. 4). At the end of reperfusion, the chest was closed and animals 
were kept with 100% O2 and analgesized with buprenorphine (S.C., 0.1 mg 
per kg) until the end of reperfusion. 
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Mouse infarct size quantification 
At the end of follow up, mice were re-anesthetized and re-intubated, and the 
LAD coronary artery was re-occluded by ligating the suture in the same 
position as the original infarction (89).  
 
Figure 5. Mouse model of IR injury 
Myocardial left ventricle (LV) regional ischemia is induced after stretching a 
simple knot of a ligature passed under the left anterior descending artery 
(LAD). A 2-cm piece of PE-tube (PE-T) is placed between the ligature and the 
myocardium to avoid heart sectioning and facilitate reperfusion when 
appropriate. Ten minutes before the onset of reperfusion 50 L of metoprolol 
or saline is injected through the femoral vein with an insulin gauge. After 45 
minutes of ischemia blood flow is re-established. At the end of reperfusion (6 
or 24 hours) ligature is re-streched and coronary artery re-occluded. Heart is 
then perfused with Evans blue (EB) and processed. Short-axis sections are 
then stained, weighted, incubated in triphenyl-tetrazolium chloride (TTC) and 
imaged for following analysis. Red line delineates myocardium at risk (area at 
risk, AAR), determined as the myocardium negative to EB-perfusion (i.e. lack 
of blood flow or ischemic). Blue line delineates remote myocardium (REM, 
positive-EB perfused tissue). Yellow line delineates infarcted area, determined 
after TTC incubation as the myocardium negative to TTC staining (white area; 
i.e. dead myocardium).  SUT, stands for suture; Yellow arrows indicate 
ischemic area; FA, stands for femoral artery; FV, stands for femoral vein; G, 
stands for insulin gauge. 
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Animals were then sacrificed and rapidly 1 mL of 1% (w per v) Evans Blue dye 
was infused i.v. to delineate AAR: myocardium lacking blood flow, i.e. negative 
for blue dye staining). The heart was then harvested, LV isolated, cut into 
transverse slices (5-7 1-mm thick slices per LV) and both sides imaged. 
Sections post-Evans blue staining present two different areas: one pale, 
negative for Evans blue perfusion, delineating AAR, and another blue, positive 
Evans blue, indicating remote tissue (Fig. 5). In order to differentiate 
infarcted from viable tissue, same slices were incubated in triphenyl-
tetrazolium chloride (TTC, 1 % (w per v) diluted in PBS) at 37ºC for 15 
minutes in constant shacking. The slices were then re-photographed and 
weighed. Post TTC incubation, Evans blue staining clears out and slices 
present two areas: one necrotic (pale negative to TTC staining) and one 
reddish alive (positive to TTC staining). Regions negative for Evans Blue 
staining (AAR) and for TTC (infarcted myocardium) were quantified using 
ImageJ (NIH, Bethesda, MD) by blinded observer (Fig. 5). Percentage values 
for AAR and infarcted myocardium were corrected to mg independently for 
each slice. Absolute AAR and infarct size were determined as the mg:mg ratio 
of AAR:LV and infarcted myocardium: AAR, respectively. Animals exceeding 
80% of IS were excluded assuming absence of reperfusion. 
Hearts processing for histology 
At the end of reperfusion, LysM-GFP mice were re-anesthetized, placed in a 
supine position, their ventral thoracic regions wiped with 70% alcohol, and 
euthanized by cervical dislocation. Next, 10 mL of PBS with heparin (50 U per 
mL) was gently infused through the vena cava to avoid blood clots. Hearts 
were then removed and cut into 1-mm-thick transverse sections and fixed 
with 2% PFA in PBS for 24 hours at 4 ºC. Heart slices (1 mm) designated to 
histopathological analysis of capillary obliteration were dehydrated through an 
ethanol series, cleared in xylene, embedded in paraffin wax and consequently 
sectioned (4 µm) for staining with haematoxylin and eosin (H/E). All 
immunohistochemical procedures were performed with an automated 
autostainer (Autostainer Plus®, Dako) at the CNIC Histology Unit. Images 
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were digitally scanned (Nanozoomer-RS C110730®, Hamamatsu) and 
examined with image analysis software (Tissuemorph®, Visiopharm) by 
blinded observers. Once the lesion was identified, 10 to 12 images (20x) were 
taken at random, and capillary obliteration was scored from 0 to 2, with 0 
indicating the absence of capillary obliteration and 2 indicating presence of 
obstruction in all capillaries. 
Confocal microscopy 
Sections designated for immunofluorescence staining and confocal microscopy 
were post-fixed overnight and placed in 30% sucrose for 24 hours and 
included in O.C.T. (Tissue-Tek®). Serial 4 µm coronal sections were cut on a 
freezing microtome (Leica CM1950) and stored in cryoprotective solution. 
Sections designated for evaluation of neutrophil infiltration of the injured area 
were washed in PBS for 15 minutes and incubated with DAPI (1:1000) at room 
temperature for 5 minutes, washed in PBS twice and mounted in Mowiol 
mounting medium. Images of full short-axis heart sections were acquired with 
an inverted confocal laser imaging system (Zeiss LSM7004 4-Laser) and 
reconstructed with Zeiss ZEN reprocessing software. Presence of Lysm-GFP+ 
cells analysis was performed with ImageJ (NIH, Bethesda, USA) by blinded 
observers. Values of total GFP+ surface were normalized to LV section surface. 
A second set of sections were stained with Dylight-650-conjugated anti-1A8 
Ly6G and DAPI for quantification of specific neutrophil identification and 
temporal infiltration analysis. Eight independent 40x were evaluated from 
injured myocardium from each animal, and presence of myeloid derived cells 
(LysM+), neutrophils (LysM+Ly6G+) and monocytes (LysM+Ly6Gneg) were 
identified and analysed using ImageJ by blinded observers. 4 animals were 
stained for basal quantification. Some sections were stained with anti-laminin 
to stain cell membranes (1:150) and anti-α-actinin to visualize sarcomeres in 
cardiac fibers (1:200) for detailed illustration of neutrophil infiltration in the 
injured myocardium. Images were post-processed and edited using the Imaris 
software (Bitplane AG, Switzerland) as indicated below. 
 54 
Neutrophil-platelet interactions staining in infarcted mouse heart was adapted 
from Sreeramkumar et al. (35). Briefly, OCT-embedded heart slices were cut 
into 50 µm sections, washed in PBS for 15 minutes and incubated for 20 
minutes at room temperature in blocking buffer (PBS containing 10% BSA and 
2% goat serum). For detailed visualization and characterization of the injured 
zone, cell membranes were stained with anti-laminin (1:150) and platelets 
were stained with PE-conjugated anti-CD41 (1:200). Primary and secondary 
antibodies were diluted 1:200 in blocking buffer, and incubations were 
conducted for 1 hour at room temperature. Nonspecific staining was assessed 
by omission of primary antibody. Samples were counterstained with DAPI and 
mounted in Mowiol. Images were acquired with a laser-scanning confocal 
imaging system (Leica SP8 or SP5) at the CNIC Microscopy Unit and post-
processed with Leica Las AF and Imaris software (Bitplane AG, Switzerland). 
Independent vessels (7-9) were evaluated for each animal, and intravascular 
neutrophil and neutrophil-platelet interactions were scored manually. 
Neutrophil purification and Adrb1 expression 
Adrb1 expression in circulating neutrophils was examined in blood drawn from 
wild-type or Adrb1KO mice 20 minute safter injection of heparin (50µL of 50U 
per mL). Whole blood was filtered and pooled, and polymorphonuclear 
leukocytes were purified by gradient-centrifugation (800xg, 20 min, 4 ºC) in 
65% Percoll Plus in Hanks balanced salt solution (HBSS). Cells were washed in 
PBS and residual erythrocytes were lysed using hypotonic buffer. Neutrophils 
were washed and re-suspended in HBSS. Before RNA isolation, neutrophil 
identity was confirmed by flow cytometry (anti-1A8 Ly6G) and viability 
evaluated.  
Total RNA from whole hearts, BM, and purified neutrophils samples was 
isolated with the Qiagen RNeasy Plus Mini Kit. RNA (1-2 µg) was reverse 
transcribed using Ready-to–go RT-PCR Beads (27-9259-01, GE Healthcare). 
PCR was performed with 40 cycles of 95˚C for 12s and 60˚C for 1 min. All PCR 
reactions were done in triplicate. Primers for Hprt and Adrb1 were as follows: 
mHprt_fw:5’-GAGGAGTCCTGTTGATGTTGCCAG-3’; mHprt_rv:5’-
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GGCTGGCCTATAGGCTCATAGTGC-3’; mAdrb1_fw:5’-
GTGGGTAACGTGCTGGTGAT-3’, mAdrb1_rv:5’-GAAGTCCAGAGCTCGCAGAA-3’. 
Amplicons generated in the qPCR were loaded on to an agarose gel to confirm 
single PCR products. 
Migration transwell assay  
The ability of leukocytes to migrate toward chemokine (C-X-C motif) ligand 
1 (CXCL1) was assessed using a modification of the method of Villablanca et 
al. (90) Briefly, wild-type or Adrb1KO mice were heparinized (50 µL of 50 U 
per mL, IP) and 20 minutes later blood was collected and filtered, and residual 
erythrocytes were lysed with hypotonic buffer. PBS-washed leukocytes of the 
same genotype were pooled and resuspended in RPMI containing 10% FBS 
and the appropriate treatment: saline (vehicle control), 10 µM epinephrine 
(positive control), 10 µM metoprolol-tartrate, or a combination of epinephrine 
and metoprolol. Transwell inserts (6.5 mm, 5.0 µm pore size (3421; Corning 
Costar Corporation) were pretreated with 50 µL RPMI for 20 minutes and 
placed in 24-well-plates before seeding cells (100 µL; ~1 × 105; >90% 
viability). Lower compartments (wells) were filled with 600 µL DMEM medium 
containing 0.04 ng per µL CXCL1 to induce directional movement. 
Spontaneous migration was assessed in wells lacking CXCL1. After incubation 
at 37 °C for 1.5 h, cells in the lower compartment were collected and 
neutrophils (Ly6G+ cells) were evaluated by flow cytometry. Each independent 
experiment was conducted with leukocytes pooled from 9 animals, and each of 
the 5 conditions was run with 4 replicates. Mean spontaneous migration was 
subtracted from the migration value of each well, and neutrophil migration 
was expressed as a percentage of the total number of neutrophils seeded in 
the upper chamber at the start of the experiment. For comparison between 
experiments and genotypes, migration was normalized to the mean control 
(vehicle) value. 
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Neutrophil oxidative burst assay  
Blood from wild-type or Adrb1KO mice was collected in heparinized tubes and 
distributed in 100 µL aliquots, erythrocytes were lysed with hypotonic buffer. 
After centrifugation leucocytes were first washed and then re-suspended in 
high glucose phenol red free DMEM. Cells were then incubated for 50 
minuteswith or without metoprolol-tartrate 100 µM at 37ºC. As previously 
described (91) (92), Dihydrorhodamine 123 (DHR 123, 1 µM), which converts 
to the fluorescent product rhodamine 123 (Rho 123) upon oxidation was then 
added to the medium and cells were stimulated with the chemotactic FPR 
activator-peptide, w-peptide 1µM (WKYMVM, 1799 Tocris). After 20 
minutesincubation at 37 ºC the reaction was stopped in ice and cells were 
washed in cold HBSS containing DAPI 0.1 µg per mL (D8417, Sigma). Mean 
fluorescent intensity (MFI) for Rho 123 was evaluated for neutrophils (Ly6G+ 
cells) alive (DAPIneg) by flow cytometry.  
Model of thioglycolate-induced peritonitis  
To assess the ability of metoprolol to inhibit neutrophil recruitment, we used a 
well-established thioglycolate-induced peritonitis model. Wild-type mice were 
intraperitoneally injected with 1 mL of thioglycolate and immediately 
randomized to receive a single 50 µL i.v. injection of vehicle or metoprolol-
tartrate (10 mM). Sixteen hours later, 100µL of blood from each animal was 
collected into EDTA tubes for later haematological analysis in a 
haemocytometer (Pentra 80). Next, animals were sacrificed, 2 mL PBS was 
injected intraperitoneally and distributed manually for 30 seconds to detach 
infiltrated circulatory cells. Next, another 8 mL PBS was injected to facilitate 
collection of 6 mL peritoneal exudate. Exudates were gently centrifuged, and 
cells were washed twice with PBS and incubated for 1 hour with anti-GR1 
(1:200) and PE-conjugated anti-CD115 (1:200). After washing with PBS, cells 
were incubated for 30 minutes with anti-rat 647 to detect GR1. Cell nuclei 
were stained with DAPI. All samples were analysed by flow cytometry for 
exactly 30 seconds of constant flow. Neutrophil recruitment efficiencies are 
presented as neutrophils per mL of exudate for each independent animal.  
 57 
To evaluate the role of ADRB1 in different compartments, we performed the 
same experiments in Adrb1KO mice and generated cohorts of chimeric mice by 
transplantation with BM cells from wildtype and Adrb1KO donors. Four weeks 
after BM transplantation, chimerism was evaluated by flow cytometry as the % 
of donated cells. Animals with chimerism below 85% were discarded; those 
with chimerism above 85% underwent the thioglycolate-induced peritonitis 
protocol followed by randomization to receive either i.v. vehicle or metoprolol 
(10 mM). To compare between the different chimeric groups, the mean value 
for each metoprolol-treated group was normalized to the mean for the vehicle-
treated group. 
Bone marrow transplant 
BM transplants protocols were adapted from Casanova et al. (88) Recipient 
mice from Adrb1KO or wild-type genotypes (DsRed+ or DsRed- as 
appropriate) were lethally irradiated (13Gy in 2 doses) before reconstitution 
with donor BM. Donor BM was harvested from mice of the appropriate 
genotype by flushing both tibiae and femurs into PBS containing 2 mM EDTA 
(PEB buffer). Contaminating erythrocytes were lysed with hypotonic buffer. 
Engraftment in recipient animals was assessed by flow cytometry 3-4 weeks 
after transplantation. Animals bled for engraftment evaluations were rested for 
one week before any other procedure. 
Flow cytometry 
Neutrophil purity for in vitro migration assay and Adrb1 expression analysis 
was evaluated by incubating cells with Dylight-650-conjugated anti-1A8 Ly6G 
and with DAPI to assess viability. Mouse primary blood leukocytes from 
peritonitis experiments were incubated with anti-Gr1 conjugated with AF-647 
and with PE-conjugated anti-CD115 and DAPI. Neutrophils were gated on the 
basis of Gr1-positive and CD115-negative staining in a FACS Canto-3L flow 
cytometer equipped with DIVA software (BD Biosciences). Doublet 
discrimination and viability (negative to DAPI) was assessed for every sample. 
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Data were analysed with FlowJo (Ashland) software by blinded observer. All 
experiments were conducted at the CNIC-Cellomics Unit. 
Intravital microscopy  
Intravital microscopy (IVM) of the cremaster muscle was performed after 
intrascrotal injection of TNFα (0.5 mg R&D Systems) (35), followed 
immediately by injection of a single i.v. bolus of metoprolol (10mM) or vehicle, 
and neutrophil behaviour was evaluated 3 hours after stimulus. In some 
experiments metoprolol  was injected 3 h after treatment with TNFα and 
images immediately acquired for analysis. The IVM system was built by 3i 
(Intelligent Imaging Innovations, Denver, CO) on an Axio Examiner Z.1 
workstation (Zeiss, Oberkochen, Germany) mounted on a 3-Dimensional 
Motorized Stage (Sutter Instrument, Novato, CA). This set up allows precise 
computer-controlled lateral movement between XY positions and a Z focusing 
drive for confocal acquisition. The microscope is equipped with a CoolLED pE 
widefield fluorescence LED light source system (CoolLED Ltd. UK) and a quad 
pass filter cube with a Semrock Di01-R405/488/561/635 dichroic and a FF01-
446/523/600/677 emitter. We used a plan-Apochromat 40x W NA1.0 ∞/0 
objective (Zeiss). Images were collected with a CoolSnap HQ2 camera (6.45 x 
6.45-µm pixels, 1392 x 1040pixel format; Photometrics, Tucson, AZ). For 
confocal high-speed IVM, we used laser stacks for 488, 561 and 640nm beams 
coupled with a confocal scanner (Yokogawa CSUX-A1; Yokogawa, Japan); 
images were acquired at 0.5 µm Z-intervals. Image acquisition was 
coordinated and offline data analysis facilitated with SlideBook software 
(Intelligent Imaging Innovations), run on a Dell Precision T7500 computer 
(Dell Inc., Round Rock, TX. For 3-dimensional analysis we used the 3D surface 
view function to determine the position of the CD62L+ clusters relative to the 
cell body and the lumen. Six to ten venules per mouse were analysed 210 to 
300 minutes after TNFα treatment by acquisition of fluorescence  (Cy3/561 
channels for phycoerythirn, FITC/488 channels for FITC, and Cy5/640 
channels for allophycocianin) and bright-field images with 2×2 for 2 min. For 
double staining with PE- and FITC-conjugated antibodies, acquisition was 
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facilitated in single (FITC) and quad (PE) filters in order to avoid bleed-through 
of fluorescent signals between channels. For in vivo labeling of neutrophils and 
platelets surface molecules, fluorescently labeled antibodies were injected 
intravenously (anti-CD62L-FITC, anti-Ly6G-APC, and anti-CD41-PE; 0.5-1.25 
µg per mouse). Images were post-processed and edited using the Imaris 
software (Bitplane AG, Switzerland) as indicated below. 
Analysis of blood cell interactions 
Platelets in the inflamed cremaster muscle were visualized as CD41-labelled 
cells and quantified as reported (35). Briefly, we defined the uropod of 
adherent neutrophils as the domain staining positive for CD62L, and the 
leading edge as the CD62L-negative pole forming multiple protrusions and 
showing guided movement. Six to ten venules per mouse were recorded, and 
platelet interactions with neutrophils were counted and analysed manually at 
the two distinct domains of the polarized neutrophil with the help of Slidebook 
software.  
Analysis of tracking of crawling neutrophils 
Time-lapse movies of crawling neutrophils were analysed with ImageJ, which 
includes the Manual Tracking and the Chemotaxis and Migration Tool plugins. 
For each movie, we first adjusted channel intensities and converted them into 
RGB format. Movies were rotated so that the vessels and the blood flow were 
positioned horizontally and oriented left-right. When necessary, the 
Background subtraction and Image stabilization pre-stablished plugins were 
applied to eliminate noise and reduce tissue twitching, respectively. Both 
plugins were set up with xy calibration values, which depend on the camera 
and microscope parameters, to convert pixels into linear measures, as well as 
the time interval value between movie frames (3s). Each polarized neutrophil 
(identified by a clear polarized morphology or uropod staining) was tracked 
manually for 1 minute using the Manual Tracking Plugin, which generated a 
dataset with the respective xy track coordinates. We then used the 
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Chemotaxis and Migration Tool to plot and the velocity (µm per s), 
accumulated distance (µm), euclidean distance (µm), and directionality of the 
tracks obtained. The euclidean distance is the length of the straight-line 
segment connecting the initial and finishing points, whereas the accumulated 
distance is the total length of the path covered by the cell. Directionality 
measures how straight the cell track is, and is calculated as the ratio of 
euclidean distance to accumulated distance. 
Analysis of 3D reconstructions of polarized neutrophils  
We measured the 3D features of intravascular neutrophils using Imaris 
Software (Bitplane, Oxford). From the parameters provided by the ImarisCell 
module, we selected prolate ellipticity by obtaining the lengths of the 3 semi-
axes, which correspond with the Ellipsoid axis parameters. A prolate ellipsoid 
(cigar-like shape) is one for which the polar radius is greater than the 
equatorial radius. For 3D cell reconstructions, we used the ImarisCell module 
to define the cell body. We then segmented a region of interest to enclose an 
individual cell within this region, so that the subsequent reconstruction fitted 
the real cell structure. Afterwards, the respective source channel from which 
the cells had to be computed was selected. For reconstruction analysis, we 
chose the Ly6G-APC channel as it is a membrane-bound protein that yields a 
strong signal and allows a good rendering of the actual cell morphology. 
ImarisCell module determines the cell threshold by calculating voxel (3D pixel) 
intensities from the enclosed cell and comparing them with the background 
intensity in the enclosed sub-region. To obtain the height-to-length ratios, we 
visually established the cell orientation with respect to the vessel wall surface. 
Sections of each polarized neutrophil were analysed to manually measure the 
height of the cell and maximum length (from the top view) with respect to the 
vessel wall. For this purpose, we used Imaris Section View, which shows the 
coordinates in the 3 display areas (xy top view, zy lateral view, and xz front 
view), and the Extended Crosshairs of the Section View, which in turn allows 
selection of the z-stack planes to visualize the entire cell (not just one plane or 
section) in the 3 views. A snapshot of these 3 views from a single cell was 
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taken and imported into ImageJ, where height and maximum length were 
measured from the different views after setting the capture scale. 
Human blood sampling  
Functional tests were performed in blood samples from 20 volunteers (36±6 
years, 15 men). Exclusion criteria were as follows: any antiplatelet, 
anticoagulant or anti-inflammatory drug taken within the 2 previous weeks; 
abnormal platelet or leukocyte count; or any history of abnormal bleeding, 
thrombosis, or active inflammatory disease. Written consent was obtained 
from all volunteers. Blood samples were collected into polypropylene tubes 
containing sodium citrate from an antecubital vein with a 21-gauge needle, 
discarding the first 2 mL to avoid platelet activation. Blood was collected 
between 8:00-10:00 a.m. after overnight fasting. Samples were processed 
immediately. Acute coronary syndrome (ACS) patients were recruited at our 
cathlab (both genders, age <80) from among those referred for coronary 
angiogram and subsequent percutaneous coronary intervention (PCI). 
Exclusion criteria were as follows: active treatment with β-blockers; any 
situation which might make it imprudent to administer an i.v. β-blocker; 
asthma or chronic obstructive lung disease; bradycardio (HR<55bpm); heart 
failure or valvular heart disease; atrial fibrillation requiring antiarrhythmic 
therapy; renal failure with creatinine ≥2 mg per mL; liver disease with 
bilirubin ≥2 mg per mL; acute illness of any malignancy; pregnancy or 
nursing; body mass index ≥27 kg per m2; previous severe adverse reaction to 
β-blockers; concomitant use of other antithrombotic drugs such as 
anticoagulants, dypiridamol, ticlopidine, or cilostazol; treatment before the 
intervention with GP IIb/IIIa inhibitors, or need for nonsteroidal anti-
inflammatory drugs. Written informed consent was obtained from all patients 
enrolled. Blood samples were collected from a femoral artery catheter into 
polypropylene tubes containing sodium citrate, discarding the first 2 mL. 
Samples were processed immediately.  
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Human neutrophil-platelet interactions evaluation 
Human citrated blood was diluted 1:5 in HEPES-Tyrode´s* (5mM 
hydroxyethylpiperazineethane-sulfonic acid (HEPES), 137 mM NaCl, 2.7 mM 
NaHCO3, 0.36mM NaH2PO4, 2 mM NaH2PO4, 2 mM CaCl2, 5 mM glucose, bovine 
albumin 0.2%. pH=7.4) and incubated with 0, 2, or 5 µM metoprolol for 10 
minutes. Then, 5 mL of diluted blood was incubated with 5 µM epinephrine for 
10 minutes. Unstimulated and epinephrine-stimulated samples were stained 
with PC5-conjugated anti-CD14 anti CD45–FITC and anti-CD61 PC7 for 20 
minutes at room temperature in the dark. Erythrocytes were lysed for 10 
minutes using Versalyse solution. Appropriate mouse isotype controls were 
used for each antibody. Flow cytometry analysis was performed with a Gallios 
cytometer (Beckman Coulter, Miami, Florida). Leukocytes were by CD45-FITC 
staining. Neutrophils identification was adapted from (93) (94) and performed 
by morphological parameters (side scatter) and negative staining for CD14-
PC5 but positive staining for CD45-FITC. Neutrophil-platelet conjugates were 
identified as bivariate histogram particles negative for CD14-PC5 and positive 
to CD61-PC7 (95) (96). The acquisition process was stopped after collection of 
5000 monocytes. Data are expressed as the percentage of neutrophil-platelet 
aggregates. All experiments were conducted at the Hospital Universitario 
Clínico San Carlos, Madrid. 
Human platelet aggregation assay 
Platelet aggregation was assessed using light transmittance aggregometry 
(LTA) in platelet-rich plasma by the turbidimetric method in a four-channel 
aggregometer (Chrono-Log 490 Model, Chrono-Log Corp., Havertown, 
Pennsylvania) according to standard protocols. The platelet-rich plasma (PRP) 
was obtained from citrated blood at centrifuge (800 rpm) for 10 minutes and 
platelet-poor plasma (PPP) was obtained after a second centrifugation (2500 
rpm) for 10 min. PRP will be adjusted to 250.000 per µL with autologous 
plasma. PRP was incubated with metoprolol 2 and 5 µM or saline buffer for 15 
minutes and then stimulated using epinephrine (5 µM). Light transmission was 
adjusted to 0% with PRP and to 100% with PPP for each measurement. Curves 
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were recorded during 5 minutes. and platelet aggregation was determined as 
the maximal percent change in light transmittance.  
Human platelet function evaluation 
Platelet function was determined by assessing platelet activation as surface 
expression of activated GP IIb/IIIa (Becton Dickinson) and P-Selectin using 
flow cytometry. Whole blood from healthy donors were drawn into trisodium 
citrate tubes diluted with Hepes–tyrodes-buffer (0.2% BSA) to a final volume 
of 1:8:1 (blood: Hepes–tyrodes:citrate). Diluted blood was incubated with 
metoprolol 2 µM and 5 µM or saline for 15 minutes. Following activation with 
epinephrine (5 µM) samples were incubated for 20 minutes with polyclonal 
PAC1-FITC conjugated or PE-conjugated anti-CD62P. Appropriate isotype 
controls were used in each case. Platelet activation was expressed as the 
percentage of platelets positive for antibody binding. Platelets were gated on 
the basis of light scatter and CD61 antibody expression. Activated platelets 
were defined as the percentage of expressing the activated confirmation of 
PAC1 binding and P-selectin (CD62P). Data were expressed as the percentage 
of platelets positive for antibody binding. All experiments were conducted at 
the Hospital Universitario Clínico San Carlos, Madrid. 
Statistics 
Data are represented as mean ± standard error of the mean (s.e.m.), and 
analysed using Prism software (Graph pad, Inc.) and Stata (Stata 12.0; 
StataCorp LP, College Station, TX). Comparisons between two groups were 
performed by using the unpaired two-tailed Student´s t-test or the 
nonparametric Wilcoxon-Mann–Whitney test as appropriate. Comparisons 
between more than two groups were performed by using the one-way ANOVA. 
The P-value was adjusted with the Holm Sidak’s multiple comparison test. 
Multiple linear regression analysis was used to study the influence of 
metoprolol on microvascular obstruction, adjusted for factors potentially 
affecting MVO such as sex, age, ischemia duration, diabetes, use of 
 64 
thrombectomy or glycoprotein IIb/IIIa inhibitors. Test for linear trend after 
one-way ANOVA was used to study the relationship between LVEF at 6 months 
and MVO quartiles at one week.  Power calculations were applied to obtain 
statistically significant at P-values below 0.05 significant. * p<0.05, ** 
p<0.01, *** p<0.001.  
Study approval 
All studies in patients and volunteers were approved by the ethics committee 
of Hospital Clínico San Carlos, Madrid. Written informed consent was received 
from all participants prior to inclusion in the study.  
  
 Results 
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I.v. metoprolol reduces MVO in AMI patients 
The METOCARD-CNIC trial recruited patients with an ongoing acute ST-
segment elevation AMI and randomized them to receive i.v. metoprolol or 
control before reperfusion (97). A total of 220 AMI patients underwent a CMR 
imaging exam 1 week after AMI to study the potential mechanisms underlying 
the infarct-limiting effect of metoprolol (82). MVO was defined as the absence 
of contrast wash-in inside the delayed gadolinium-enhanced area (43), and 
was quantified as grams of LV (Fig. 6). Patients treated with metoprolol 
during ongoing AMI had a 40% lower extent of MVO (Fig. 7a). This significant 
effect was maintained after adjusting for factors potentially affecting MVO by 
performing linear multiple regression analysis and including sex, age, ischemia 
duration, diabetes, and use of thrombectomy or glycoprotein IIb/IIIa inhibitors 
as covariates. To exclude the possibility that this effect simply reflected the 
reduction in total infarct size (82), MVO was further assessed as a percentage 
of the infarcted area (total late gadolinium enhanced area). Metoprolol-treated 
patients had 24% less infarct-normalized MVO than control patients (Fig. 7b). 
As expected, the extent of MVO was significantly associated with poor long-
term outcome, evaluated as chronic ventricular performance (Fig. 7c). These 
data suggest that MVO reduction might be involved in the cardioprotective 
effect of metoprolol administration in patients during ongoing AMI. 
 
Figure 6. Microvascular obstruction evaluation in patients 
(a) METOCARD-CNIC trial scheme: patients with ongoing ST-segment 
elevation acute myocardial infarction (STEMI) were recruited and randomized 
to receive metoprolol (15mg i.v. doses) or control before reperfusion. A total 
of 220 patients were evaluated for microvascular obstruction (MVO) by cardiac 
magnetic resonance (CMR) imaging one week after AMI and 202 patients for 
an additional CMR at long-term left ventricle ejection fraction (LVEF) 6 months 
after AMI for ventricular function assessment. (b) Complete CMR exams 
(short-axis covering the entire LV from base to apex). c) Representative CMR 
images, showing significant differences in one-week MVO between a control 
patient (left) and a metoprolol-treated patient (right). Lower panels show 
detailed views of the boxed images, revealing MVO (blue area, automatic 
quantification), defined as the absence of contrast wash-in inside the delayed 
gadolinium-enhanced area (red, semiautomatic quantification). Yellow 
arrowheads indicate MVO in the LV wall. 
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Intravenous metoprolol dampens neutrophilial–MVO association 
in patients 
White blood cell (WBC) and neutrophil counts during an AMI are known to be 
associated with larger infarct sizes and extensive MVO (98) (99) (100). We 
 
Figure 7. Early metoprolol reduces MVO in patients 
(a) Quantification of microvascular obstruction (MVO) in grams of left 
ventricle. (b) Quantification of MVO relative to the infarcted area (%). Dots 
represent values for individual patients: 114 in the control group (gray) vs 
106 in the metoprolol group (blue). P-value for linear trend is shown. (c) 
Long-term left ventricular ejection fraction (LVEF) evaluated by CMR 6 
months after AMI (n=202) according to quartiles of MVO extent evaluated as 
in panel a. Cardiac function was significantly smaller in patients with larger 
extent of MVO. P-value for linear trend is shown. Data are means ± s.e.m 
compared by unpaired Student’s t-test. 
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explored these associations in AMI patients from the METOCARD-CNIC trial. 
We found a significant positive correlation between absolute leukocyte count 
on admission and the extent of MVO on CMR: the higher the leukocyte count, 
the larger the extent of MVO (Fig. 8a). We further studied the association of 
the different WBC subpopulations and MVO. As expected, neutrophil count was 
significantly correlated with the extent of MVO (Fig. 8b). Conversely, there 
was no sign of association between other WBC subpopulations and MVO: 
lymphocyte, monocyte, eosinophil or platelet counts did not correlate with the 
extent of MVO (Fig. 8e). Next, we studied the effect of metoprolol on WBCs 
and on the association between these and MVO. Metoprolol treatment was not 
associated with any different in WBC count nor in any WBC subpopulation 
(Table 1). Of note, we found a significant interaction between metoprolol 
treatment and the correlation between leukocyte count and MVO: the 
significant positive correlation between neutrophil count and the extent of MVO 
was only present in control patients (that is, not receiving metoprolol); in 
patients receiving IV metoprolol before reperfusion there was no sign of 
association between total leukocyte or neutrophil counts and the extent of 
MVO (Fig. 8c and 8d). These results suggest that the administration of i.v. 
metoprolol during ongoing AMI do not affect the circulating levels of WBCs but 
modulates the impact of neutrophils on MVO.  
Population Control Median (IQR) Metoprolol Median (IQR) P-value 
Leukocyte (x103) 12.3 (10.3 – 14.7) 11.9 (9.3 – 13.7) 0.183 
Neutrophil (x103) 9.5 (7.7 – 12.4) 9.1 (6.4- 11.3) 0.098 
Lymphocyte (Abs) 1574 (1171 - 2509) 1754 (1265 - 2344) 0.164 
Monocyte (Abs) 629 (482 - 837) 632 (504 - 851) 0.5 
Eosinophil (Abs) 56 (27 - 162) 78 (35 - 168) 0.156 
Platelet (x105) 224.5 (194.5 - 259) 218 (186 – 283.5) 0.753 
 
Table 1.   White blood cell counts from METOCARD-CNIC patients 
Treatment comparison of leukocyte and subpopulations (neutrophil, 
lymphocyte, monocyte, eosinophil and platelet) count on admission in 
METOCARD-CNIC trial patients. Abs, stands for absolute count. IQR, stands for 
Interquartile range.  
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Figure 8. Metoprolol alters neutrophil counts - MVO association in 
patients  
Sensitivity analysis of the association between MVO and leukocyte and 
subpopulations count on admission from METOCARD-CNIC trial patients. 
(a,b) Association between MVO and absolute leukocyte or neutrophil count 
on admission. Grey dots represent individual values and line linear 
relationship. (c,d) Linear regression comparison between MVO and 
leukocytes and neutrophils in the subsets of METOCARD-CNIC patients 
indicating loss of correlation in the metoprolol treated group (green) as 
compared to control group (white). P’, stands for interaction P-value. (e) 
Association between MVO and rest of white blood cells subpopulations: 
Platelets, lymphocytes, eosinophils and monocytes showing no correlation in 
the extent of MVO. P stands for P-value and R, for Pearson’s correlation 
coefficient. 
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Metoprolol blunts neutrophil infiltration and capillary 
obliteration 
To identify the factors underlying the metoprolol-induced myocardial MVO 
reduction, we used the mouse model of in vivo myocardial IR injury (see Fig. 
5). Given to the metoprolol’s alteration of the association between neutrophil 
count and MVO observed in METOCARD-CNIC patients, we focused our 
attention into myeloid-derived cell population as main inflammatory players 
during in early phases of IR injury. First, we tested the infarct-limiting effect of 
metoprolol in wild-type mice. Mice were randomized to receive a single i.v. 
bolus (50 µL) of metoprolol (10 mM) or vehicle (saline) 35 minutes after 
ischemia onset (10 minutes before reperfusion) (Fig. 9a). Infarct size was 
evaluated at 24 hours reperfusion by TTC staining and normalized to area at 
risk (AAR, negative EB staining). Metoprolol-treated mice had significantly 
smaller infarcts (% of AAR) than vehicle-treated mice (Fig. 9b, 9c).  
 
Figure 9. Metoprolol reduces infarct size in mouse 
(a) Mouse model of myocardial IR. (b) Histological evaluation of left ventricle 
(LV) area at risk (AAR) and infarct size (IS) in mice subjected to IR and 
randomized to receive metoprolol (blue) or vehicle (white); NS stands for 
non-significant. n=8. (c) Representative images of LV slices showing AAR 
(negative for Evans Blue) in upper panels and extent of necrosis (triphenyl-
tetrazolium chloride (TTC)-negative area in lower panels). Data are means ± 
s.e.m. *P<0.05; determined by the nonparametric Wilcoxon–Mann–Whitney 
test for each panel. 
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Figure 10. Metoprolol reduces capillary obliteration 
(a) Mouse model of myocardial IR. (b) Representative H&E myocardial 
images at 6 h reperfusion showing disarrayed and abundant obstructed 
capillaries in the vehicle-treated sample; metoprolol-treated samples show 
cardiac injury, but no signs of MVO; scale bars, 50 m. Amplification of the 
boxes shows obstructed capillaries indicated with black arrows; black scale 
bars, 10 m. (c) Capillary obliteration quantification; n=5-6. (d) Confocal 
images from LV at 6h reperfusion onset showing massive vascular neutrophil 
migration (LysM-GFP, green) and co-aggregates with platelets (CD41, red) 
vehicle- but not in metoprolol-treated mice; scale bar, 25 m. Below, 
amplified capillary obstruction region; scale bar, 10mm. Bottom, computed 
3D reconstructions. Data are means + s.e.m. **P<0.01, determined by the 
nonparametric Wilcoxon–Mann–Whitney test for each panel. 
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Next, we examined mice carrying a GFP reporter in myeloid derived cells 
(LysM-GFP). LysM-GFP+ mice underwent the myocardial IR injury procedure 
and were randomized to receive i.v. metoprolol or vehicle. Capillary 
obliteration (a histological surrogate for MVO) and leukocyte infiltration were 
quantified at 6 hours post-reperfusion (Fig. 10 to Fig 12).  Metoprolol 
administration during ongoing AMI resulted in a significant reduction of 
capillary obliteration by circulatory cell plugins when evaluated at 6 hours 
post-reperfusion (Fig. 10a, 10b, 10c). Confocal microscopy analyses revealed 
a significant reduction in the number of myeloid cells plugins (LysM-GFP+ 
particles) and percentage of LysM-GFP+ area within the LV sections, indicating 
rapid inhibition of leukocyte recruitment and protection of lumen vessel 
patency (Fig. 10d) (See additional information, Movie 1). Temporal (6 and 
24 hours) evaluation of myeloid-derived cells infiltration into injured 
myocardium showed a maintained abrogation of neutrophil infiltration within 
the first 24 hours (Fig. 11? Fig. 12) (See additional information Movie 2) and 
a differential relative proportion of myeloid different cells (Fig 12). These 
mouse experiments confirm the clinical findings that pre-reperfusion 
metoprolol administration during ongoing AMI limits infarct size and reduces 
MVO, and further show that metoprolol reduces neutrophil infiltration, adding 
evidence to consider neutrophils as a potential target of this cardioprotective 
strategy. 
Figure 11. Metoprolol abrogates myeloid infiltration  
(a) Representative confocal microscopy images of complete left ventricle (LV) 
sections at 6 hours after reperfusion. Myeloid infiltration (LysM+, green) is 
massive within the injured myocardium of hearts from vehicle-treated mice as 
compared to those from metoprolol-treated mice. Lower panels represent 
magnifications illustrating the accumulation of myeloid cells in a vessel. (b) 
Average total positive LysM+ pixels within the complete LV section. (c) 
Average LysM+ as percentage of LV section area. (d) Mean complete LV 
sections area. (e) Representative confocal images of neutrophil infiltration 24 
h after reperfusion onset. Vehicle-treated mice show massive myocardial 
myeloid derive-neutrophil infiltration (LysM-GFP+, green), with dispersed cells 
attached to the injured cardiac fibre membranes (α-actinin, red; laminin, 
grey). (f) LysM+ total area in the left ventricle (LV) section as a %AAR; scale 
bar, 20 mm; n=5–6. Data are means ± s.e.m. *P<0.05. **P<0.01. 
Comparison was determined by the nonparametric Wilcoxon-Mann–Whitney 
test. 
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Metoprolol does not protect from AMI in the absence of 
neutrophils   
Catecholamine-stimulation of ADBRs alters neutrophil function, cytokine 
release, and neutrophil-platelet aggregate formation (63) (101) (102), 
processes associated with aggravated injury during AMI (103) (104) (105) 
(106). To decipher the role of neutrophils in the protection afforded by 
metoprolol during ongoing AMI, we evaluated the effect of the drug in the 
absence of neutrophils. Neutrohil depletion in mouse peripheral blood was 
achieved by administration of an anti-Ly6G monoclonal antibody (mAb) over 2 
days (88) (35). After neutrophil depletion, animals were subjected to 
myocardial IR, and infarct size was evaluated at 24h post-reperfusion (Fig. 
13a). Confirming earlier reports (106), neutrophil-depleted mice had smaller 
infarcts than controls. Administration of metoprolol to these mice during 
ongoing AMI did not reduce infarct size (Fig. 13b, 13c 13d). The abrogation 
of the cardioprotective effect of metoprolol confirms circulating neutrophils as 
a target of the beneficial effect associated with this pharmacological therapy. 
Figure 12. Metoprolol abrogates neutrophil infiltration 
(a) Representative confocal images of LV sections taken from injured mice 
after 6 and 24 h reperfusion onset. Myeloid infiltration (LysM-GFP+, green) 
most of which are neutrophil (Ly6G+, red) is evident in vehicle-treated mice 
and significantly attenuated in those from metoprolol treated mice; merged 
images show double positive cells (LysM+/Ly6G+, that is, neutrophils). Scale 
bar, 50 mm; n=3–5. (b,c) Myeloid-derived cell infiltration dynamics showing 
maintained attenuation in hearts from metoprolol-treated mice. n=5. (d) 
Neutrophilic proportions infiltrate dynamics. (e) Monocyte infiltration dynamics 
into the injured myocardium within the first 24 hours of reperfusion; n=5 
animals per group. (f) Percentage of monocytes (LysM+/Ly6G-), within the 
myeloid–derived population. Data are means ± s.e.m. *P<0.05; determined 
by the nonparametric Wilcoxon–Mann–Whitney test for each panel. 
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Metoprolol inhibits neutrophil migration by targeting ADRB1 
The effect of metoprolol on primary neutrophils’ function was evaluated in a 
chemokine-induced transwell migration assay and by evaluation of the 
chemotactic FPR activator-peptide, W-peptide (92), -induced ROS production 
assay (91). First, neutrophils were exposed across the transwell filter to the 
chemoattractant CXCL1 in the presence or absence of metoprolol for 1.5 
hours, and level of migration through the transwell membrane was quantified 
by flow cytometry. Metoprolol inhibited baseline and epinephrine-stimulated 
neutrophil migration toward CXCL1, reducing migration to the same level in 
both cases (Fig. 14a). Second, ROS production in vitro was measured using 
DHR-123 and W-peptide activation. ROS production was tested in metoprolol-
 
Figure 13. Neutrophil depletion abrogates metoprolol effect  
(a) Mouse model of myocardial IR. (b??) Histological evaluation of left ventricle 
(LV) area at risk (AAR) and infarct size (IS) in mice subjected to IR and 
randomized to receive metoprolol (blue) or vehicle (white); NS stands for 
non-significant. n=8. (?) Representative images of LV slices showing AAR 
(negative for Evans Blue) in upper panels and extent of necrosis TTC-
negative area in lower panels). Data are means ± s.e.m.; ns, stands for non-
significant, determined by the nonparametric Wilcoxon–Mann–Whitney test 
for each panel. 
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treated and untreated neutrophils with and without W-peptide stimulation. 
Neutrophils incubated in metoprolol presented significant decreased oxidative 
burst compared to control group (Fig. 14c, 14d). Metoprolol alone had no 
effect on ROS endogenous production. 
Metoprolol is a selective ADRB1-blocker, and ADRB1 signaling has been shown 
to mediate some of the pro-inflammatory response of monocytes (107). 
Neutrophils and monocytes are both myeloid derived cells, and we therefore 
reasoned that ADRB1 might be involved in the anti-migratory effect of 
metoprolol. Adrb1 mRNA expression in fresh and viable isolated neutrophils 
was confirmed by PCR in wild-type mice and absence in neutrophils from 
Adrb1-knockout mice (Adrb1KO) (Fig. 14e, 14f, 14g). In vitro, the -
epinephrine-mediated migration- and -W-peptide-mediated ROS production- 
inhibitory effect of metoprolol was lost in Adrb1KO neutrophils (Fig. 14a, 
14c). In addition, β2-adrenergic receptor-knockout mice (Adrb2KO) was not 
involved in the effects observed after metoprolol administration (Fig. 14b). 
Figure 14. Neutrophil function inhibition ADRB1-dependent  
(a) Metoprolol inhibits neutrophil in vitro migration through a ADRB1- 
dependent signalling. Effect of metoprolol on CXCL1-induced migration of fresh 
primary isolated neutrophils (LysM+/Ly6G+/DAPIneg) from wild-type (WT) 
and in Adrb1KO (ß1KO) mice. CXCL1-stimulated neutrophils were incubated 
with vehicle, epinephrine (10mM), metoprolol (10mM) and epinephrine 
+metoprolol; n=4 independent experiments. ns, stands for non-significant. 
(b) Neutrophil migration inhibition is independent to ADRB2 signalling. CXCL1-
induced migration fresh primary isolated neutrophils (LysM+/Ly6G+/DAPIneg) 
from WT and in Adrb2KO (ß2KO) mice, incubated with vehicle and metoprolol 
(10mM) n=5 independent experiments. ns, stands for non-significant. (c,d) 
Inhibitory effect of metoprolol on W-peptide-induced ROS production on fresh 
isolated primary neutrophils (Ly6G+) from WT or ß1KO mice. On the left, flow 
cytometry plots illustrate reduced expression of Rho-123 in metoprolol-treated 
neutrophils. On the graph, mean fluorescent intensity of Rho123 in Ly6G+ 
neutrophils after W-peptide stimulation. n=6 independent experiments; ns, 
stands for non-significant. (e, f) Purity and viability of mouse blood 
neutrophils (LysM+/Ly6G+/DAPIneg) evaluated by flow cytometry. (g) 
Agarose gel electrophoresis of PCR products, showing Adrb1 expression in 
mouse left ventricle (LV), bone marrow (BM), and blood neutrophils (Ly6G+) 
Adrb1KO (β1KO9 mice were used as a negative control Data are means ± 
s.e.m. * P<0.05; ** P<0.01 and *** P<0.001; Comparisons were performed 
using the one-way ANOVA and Holm Sidak’s post-hoc multiple comparisons 
method. 
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We next explored whether metoprolol directly inhibits the capacity of 
neutrophils to infiltrate tissues in vivo. For this, we first used a model of 
thioglycolate-induced peritonitis (Fig. 15a). Thioglycolate induces massive 
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leucocyte migration into the peritoneal cavity within the first 16 hours (Fig. 
15b), with the majority of infiltrating cells being neutrophils (Fig. 15d, 15e). 
Interestingly, a single bolus of 50 µL of Metoprolol (10 mM) sharply inhibited 
thioglycolate-induced neutrophil infiltration into the peritoneal cavity (after 16 
hours injection) of wild-type mice (Fig. 15c), but the inhibitory effect of 
metoprolol was lost in Adrb1KO mice (Fig. 15b, 15c, 15d). To better define 
the cell compartment targeted by metoprolol, we lethally irradiated Adrb1KO 
mice and restored haematopoiesis with bone marrow transplanted from wild-
type donors, generating chimeric mice expressing ADRB1 only in circulating 
cells (Fig. 15e). 4 weeks after the bone marrow procedure, transplanted 
animals presented >85% bone marrow engraftment (Fig. 15g) and were 
subjected to thioglycolate-induced peritonitis. Bone marrow transplant did not 
affect metoprolol’s effect. However, the replenishment of ADRB1 only in 
hematopoietic cells was enough to rescue the anti–leucocyte-infiltration effect 
of metoprolol (Fig. 16h). Together, these data show a direct effect of 
metoprolol on neutrophil function and demonstrate that the presence of 
ADRB1 in circulating cells is essential for it to reduce neutrophil infiltration into 
injured tissue. 
Figure 15. Metoprolol blocks neutrophil peritoneal infiltration  
(a) Metoprolol effect on thioglycolate-induced peritoneal infiltration. (b) 
Absolute leucocyte number per mL of infiltrate 16 hours after intraperitoneal 
thioglycolate injection in wild-type (WT) mice (n= 7-9) or ADRB1-knockout 
(β1KO) mice (n=5) randomized to receive either i.v. metoprolol or vehicle. (c) 
Flowcytometry plots illustrating reduced infiltration of neutrophils (CD115neg; 
GR1+) in metoprolol-treated mice; and graphs representing absolute 
neutrophils detected per mL of infiltrate at 16 hours after thioglycolate 
injection in WT mice (n=7–9) or ß1KO mice (n=5). (d)  Neutrophils as a 
percentage of the white blood cells evaluated in the infiltrate. (e) Peripheral 
blood neutrophil counts.  Metoprolol’s cardioprotective effect is dependent on 
the presence of ADRB1 on neutrophils. (f) Protocol scheme for thioglycolate-
induced peritonitis assay after bone-marrow transplants (BMT) between WT 
and ß1KO mice, evaluating the influence of the presence or absence of ADRB1 
in circulating cells. (?) Flow cytometry assessment of representative bone 
marrow transplant engraftment between 4 chimeric groups evaluated. n=10. 
(h) Effect of metoprolol on thioglycolate-induced neutrophil infiltration in the 
four BMT groups. Data are normalized to vehicle; n=4/9. and analysis 
determined by one-way ANOVA and Holm Sidak’s post-hoc multiple 
comparisons method; Data are means ± s.e.m. *P<0.05** p<0.01; *** 
p<0.001, determined by the nonparametric Wilcoxon-Mann–Whitney test for 
each panel; ns, non-significant. 
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Metoprolol cardioprotection involves hematopoietic cells´ 
ADRB1  
We next investigated the involvement of ADRB1 blockade in hematopoietic 
circulating cells in the protective effect of metoprolol in the infarcted 
myocardium. Adrb1KO mice were subjected to myocardial IR and randomized 
to receive i.v. metoprolol or vehicle during ongoing AMI (Fig. 16). Unlike the 
situation in wild-type mice, metoprolol did not limit infarct size in Adrb1KO 
animals (Fig. 16b, 16c, 16d), demonstrating the critical role of ADRB1-
blockade in the cardioprotective effect.  
To demonstrate the role of ADRB1 expressed in hematopoietic circulating cells, 
we repeated the myocardial IR protocol in the chimeras described above 
(Adrb1KO mice transplanted with wild-type bone marrow). The presence of 
ADRB1 only in hematopoietic circulating cells was sufficient to restore 
susceptibility to the cardioprotective effect of metoprolol (Fig. 16e, 16f, 16g). 
Conversely, transplant of Adrb1KO bone marrow into irradiated wild-type mice 
abrogated the protective phenotype associated with metoprolol administration 
during IR (Fig. 16h, 16i, 16j). These data confirm the involvement of ADRB1-
blockade in hematopoietic cells in the cardioprotection afforded by metoprolol 
administration during AMI.  
 
 
Figure 16. Metoprolol inhibits neutrophil ADRB1 signaling 
(a)  Protocol scheme for IR experiments in chimeric animals after BM 
transplant, evaluating the infarct-limiting effect of metoprolol in the presence 
or absence of ADRB1 in circulating cells. (b–j) Histological evaluation of left 
ventricle (LV) area at risk (AAR) and infarct size in mice subjected to IR and 
randomized to receive metoprolol (coloured bars) or vehicle (white bars) for 
each of the groups under evaluation, plus the respectively representative 
images of evans blue and TTC staining in metoprolol-treated and vehicle-
treated ß1KO and chimeras wild-type (WT) bone marrow transplanted into 
ß1KO mice and reverse transplants). Infarct size is reduced by metoprolol only 
when circulating cells express ß1-adrenergic receptor; n=9 (b,c), n=8 (e,f), 
n=5–6 (h,i). ns, stands for non-significant. Data are means ± s.e.m. 
*P<0.05; determined by the nonparametric Wilcoxon–Mann–Whitney test.   
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Metoprolol alters neutrophil dynamics in vivo 
During acute injury, neutrophils alter their morphology upon adhering to the 
activated endothelium. These shape change or polarization, permit 
intercellular interactions critical for the inflammatory response in several 
conditions, including myocardial IR (35) (108). Polarization of adhered 
neutrophils involves receptor redistribution and the assembly of a rearward 
protruding micro-domain called the uropod, and is essential for the integration 
of signals coming from the endothelium and activated platelets prior to 
infiltration (35). We were therefore interested in investigating whether 
metoprolol impaired neutrophil migration and infiltration through an effect on 
neutrophil dynamics. For this, we used bi-dimensional and 3D intravital 
microscopy (IVM) to image cremaster muscle vessels of mice treated with 
tumour necrosis factor-α (TNFα), an inflammatory model in which the vast 
majority of recruited leukocytes are neutrophils. Neutrophil behaviour was 
evaluated 3h after administration of metoprolol or vehicle (Fig. 1?a). Notably, 
metoprolol reduced neutrophil migratory velocity, accumulated crawling 
distance, and directional movement (Fig. ??b, ??c and Movie 3). 
  
  
Figure 17. Metoprolol stuns neutrophil function
??) Experimental design: wild-type (WT) mice receiving TNFα were 
randomized to receive Ι.V. metoprolol or vehicle before analysis of cremaster 
muscle vessels by 2D and 3D intravital microscopy. (b) Quantification of 
parameters related to two-dimensional intravascular motility; N=54–141 cells 
from 3 to 4 mice. (c) Representative tracks of crawling neutrophils within 
inflamed vessels. (d) 3D reconstructions of representative neutrophils within 
live vessels of saline-treated and metoprolol-treated mice (red, uropod; green, 
cell body). (e,f) Quantification of 3D parameters, indicating reduced 
elongation (prolate ellipticity) and enhanced projection of recruited neutrophils 
into the luminal space (height-to-length ratio); N=68–105 cells from 3 to 4 
mice. (g,h) Representative time-lapse images and percentage of interactions 
of platelets (CD41, red) with the polarized neutrophil uropod (CD62L, yellow) 
or leading edge (Ly6G, green); N=28–29 vessels from 3 to 4 mice. White 
arrowheads indicate interactions with the uropod and the dotted line the 
displacement of the cells during 30 s. Scale bar, 10 mm. Data are means ± 
s.e.m. *P<0.05; **P<0.01; ***P<0.001, determined by unpaired Student’s t-
test for each parameter. 
 86 
 
 
Flow
Metoprolol
0” 30” 
0” 30” 
6” 
15” 
Ve
hi
cl
e
M
et
op
ro
lo
l 
  Uropod    Neutrophil    Platelet   
Ly6G    CD62L 
 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
**
 
E
lli
pt
ic
ity  
pr
ol
at
e  
0.0 
0.5 
1.0 
1.5 *** 
R
at
io
 h
ei
gh
t /
 le
ng
th
 
Meto Vehicle 
Vehicle
Prep. Imaging 3 h
Local TNFα injection
Metoprolol
Vehicle
Endothelial plane
 
Lumen
Metoprolol Vehicle 
0.0 0.8 6  12  18
 
 
Velocity 
Directionality 
Accumulated 
distance (μm)
 
 
Eucladian 
distance (μm)
(μm per s)
***
***
***
***
24
Meto Vehicle 
a
g
b c
d e f
Vehicle
Metoprolol
0  
20  
40  
60  
80  
100
%
 in
te
ra
ct
io
ns  
* 
* 
Uropod Leading
edge
h
Vehicle
Metoprolol
5μm
10 μm
 87 
Independent-neutrophil 3D-reconstructions of live inflamed vessels showed 
that metoprolol consistently disabled the intravascular behavior of neutrophils 
without disrupting polarization within activated vessels, resulting in dramatic 
changes in cell morphology (Fig. ??d, ??e, ??f) that correlated  with  their 
abnormal crawling dynamics. These data show that metoprolol “stuns” 
neutrophils, resulting in altered dynamics and prevents the morphological 
changes needed to initiate intercellular interactions and subsequent tissue 
infiltration. 
 
 
 
Figure 18. Metoprolol prevents neutrophil–platelet interactions  
(a) Protocol scheme for evaluating the acute inhibitory effect of metoprolol 
on activated and polarized neutrophils on  wild-type (WT) and AdrbB1-
knockout (ß1KO) mice. (b) Absolute neutrophil–platelet intravascular 
interactions in WT and ß1KO mice. NS, stands for non-significant. (c) 
Temporal neutrophil–platelet interaction inhibition in WT mice 
afteradministration with i.v. metoprolol. Data are means±s.e.m. ***P<0.001, 
determined by unpaired Student’s t-test for each parameter. 
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Metoprolol blocks PSGL1-dependent neutrophil-platelet 
interactions 
Correct neutrophil polarization and organization of an extruding micro-domain 
that captures circulating platelets is required to initiate tissue-damaging 
inflammation (35). Indeed, plugs of neutrophil-platelet coaggregates in the 
microcirculation are a major contributor to MVO in AMI and in other models of 
injury (8) (35). We therefore explored the impact of metoprolol-induced 
neutrophil stunning on neutrophil-platelet interactions. Using the cremaster 
IVM model of TNFa-induced local inflammation, we evaluated the acute 
neutrophil-platelet inhibitory effect of metoprolol in polarized neutrophils (Fig. 
17 and Fig. 18) (See additional information? Movie 3). Metoprolol  i.v. 
administration effectively inhibited interactions with the uropod, but not the 
leading edge (Fig. 17g, 17h) and rapidly reduced total neutrophil-platelet 
interactions (Fig. 18a, 18b, 18c). IVM experiments in Adrb1KO mice revealed 
no differences between metoprolol-treated and vehicle-treated mice, 
implicating ADRB1 in the inhibitory effect of metoprolol on neutrophil-platelet 
interactions (Fig. 18b). 
 
 
Figure 19. Metoprolol blocks neutrophil–platelet interactions 
(a) Experimental scheme of IR model. (b) Representative confocal images 
evaluating the effect of metoprolol on the number of co-aggregates of 
neutrophils (LysM-GFP+, green) and platelets (CD41, red) in the post-
reperfused mouse myocardium. (c,d) LysM-GFP+ cells (neutrophils) attached 
to coronary vessels; N=7–9) and the numbers of interacting platelets (CD41+) 
per neutrophil in reperfused myocardium. Scale bar, 20 mm. (e) Protocol 
scheme for the IR experiment evaluating the effect of neutrophil-platelet 
blockade with anti-PSGL1 Ab (administered 15 min after ischemia onset, that 
is, 30 min before reperfusion) on the infarct-limiting effect of metoprolol 
(administered 35 min after ischemia onset, that is, 10 min before reperfusion). 
(f,g) AAR, infarct size, and representative images of Evans blue and TTC 
staining in vehicle- and metoprolol-treated mice pre-treated with anti-PSGL1 
Ab. N=5–7. ns, stands for non-significant.  Data are means ± s.e.m. *P<0.05; 
**P<0.01. Comparison was determined by the nonparametric Wilcoxon–
Mann–Whitney test.                                                           
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Based on these findings, we hypothesized that inhibition of neutrophil-platelet 
interactions underlies the inhibitory effect of metoprolol on MVO after 
myocardial IR. To test this, we first evaluated the effect of metoprolol on 
neutrophil-platelet coaggregate formation in mouse myocardial vessels after 
experimental IR. Administration of metoprolol to wild-type mice during 
ongoing AMI significantly reduced the number of neutrophils attached to the 
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vessel wall and the average number of interacting platelets per neutrophil 
(Fig. 19a, 19b, 19c, 19d). Neutrophil-platelet interactions during acute 
injury are mediated by PSGL1 and signals delivered upon these contacts 
promote subsequent neutrophil extravasation and injury to the tissue (35). 
Blockade of PSGL1 by pretreatment with PSGL1-mAB (Fig. 19e) significantly 
reduced infarct size in the myocardial IR model, and administration of 
metoprolol during ongoing AMI did not yield any further infarct-size reductions 
(Fig. 19f, 19g). These data confirm that metoprolol protects the infarcted 
myocardium by uncoupling neutrophil recruitment and polarization, thereby 
disrupting neutrophil-platelet interactions and the downstream inflammatory 
response. 
Metoprolol limits neutrophil-platelet aggregates in patients 
To investigate whether metoprolol alters neutrophil dynamics and inhibits 
neutrophil-platelet interactions in humans, whole blood drawn from healthy 
donors was incubated ex-vivo with epinephrine (5 µM) and increasing 
concentrations of metoprolol (0, 2, 5 µM). Samples were then stained, and 
neutrophil-platelet coaggregate formation was evaluated by flow cytometry 
(94) (93) (95) (96) (morphological parameters, CD14neg, CD45+, CD61+). 
Metoprolol significantly inhibited epinephrine-stimulated neutrophil-platelet 
coaggregate formation (Fig. ??a). The effect of metoprolol in vivo was 
additionally studied in patients undergoing elective coronary angioplasty for 
acute coronary syndrome. Samples were collected before and after i.v. 
administration of metoprolol (15 mg) and circulating neutrophil-platelet 
coaggregates were assessed by flow cytometry. Metoprolol administration 
significantly reduced the number of neutrophil-platelet interactions (Fig. ??b).  
To elucidate whether metoprolol was acting at the platelet level of action we 
evaluated effect of metoprolol on platelet function through platelet aggregation 
using light transmittance aggregometry (LTA) in platelet-rich plasma (Fig. 
??c) or platelet activation surface markers expression assay using flow 
cytometry (Fig. ??d, ??e). Metoprolol did not show any effect on platelet 
aggregation/activation, which together with the aforementioned effects on 
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neutrophil migration and ROS-production suggest that the effect seen on 
neutrophil-platelet coaggregates was driven by a direct effect on neutrophils. 
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Figure 20. Metoprolol inhibits neutrophil function in patients  
(a) Neutrophil–platelet formation in epinephrine-stimulated whole blood from 
healthy volunteers (n=20). Whole blood was incubated in vitro with 
epinephrine 5 mM and metoprolol (Meto) at different concentrations. (b) 
Metoprolol effect on the number of neutrophil i.v. platelet co-aggregates in 
acute coronary syndrome (ACS) patients scheduled for coronary angioplasty. 
Blood was drawn before and after metoprolol i.v. administration; n=6 ACS 
patients. Pre, before i.v. administration; Post, after i.v. administration. (c-e) 
Metoprolol on human platelet function. (c) Effect of metoprolol on maximal 
platelet aggregation on epinephrine-stimulated platelet rich plasma (PRP) from 
healthy volunteers (n=20). (d,e) Effect of metoprolol on platelet activation as 
determined by (d) surface expression of activated GP IIb/IIIa and (e) Surface 
expression of P-Selectin using flow cytometry from healthy donors (n=20). 
Data are means ± s.e.m.*P<0.05; **P<0.01, determined by one-way ANOVA 
and Holm Sidak’s post-hoc multiple comparisons method. 
 Discussion 
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Early metoprolol intravenous administration given as an adjunct to mechanical 
reperfusion during ongoing AMI is a simple, inexpensive and save 
pharmacological therapy that reduces infarct size and ameliorates post-
infarction severe cardiac dysfunction (84) (109) (110). To identify and to 
understand the mechanisms of action underlying this cardioprotective strategy 
is of great relevance since more efficient and specific protective strategies 
could be developed.  
The ability of ß-blockers, specially ADRB1-selective antagonists, to reduce IS 
was tested decades ago in several clinical trials, under the hypothesis that ß-
blockers reduce the extent of damage by a direct effect on cardiomyocytes via 
reducing oxygen consumption. However, results from early studies were 
inconclusive (8). This could be explained because most studies were 
performed in the context of non-reperfused AMI (that is, before 
pharmacological thrombolysis and primary PCI were developed). The advent of 
reperfusion as the treatment of choice for AMI changed the mode of 
myocardial death: from unrelieved ischemia to a combination of ischemic- and 
reperfusion-associated processes. This new scenario, suggested the potential 
cardioprotective effect of ß-blockers be revisited (8). A large animal study 
performed by our group in 2007, showed that metoprolol reduces IS only 
when administered before reperfusion (80) (81), suggesting that metoprolol 
might reduce infarct size by inhibiting reperfusion injury. Surprisingly, oxygen 
consumption was similar in metoprolol- and vehicle-treated pigs. Interestingly, 
IS reduction in metoprolol-treated pigs was associated with reduced 
myeloperoxidase activity in the post-ischemic myocardium 24 hours after 
reperfusion (81), which prompted us to investigate cellular mechanisms 
underlying this reperfusion-related injury-limiting effect of metoprolol on 
myocardial IR injury. Our group led the METOCARD-CNIC trial, which was the 
first trial to evaluate the ability of metoprolol to reduce IS in the context of 
angioplasty-mediated reperfused AMI (86). In this trial, early i.v. metoprolol 
administration during ongoing AMI resulted in a significant reduction of IS (82) 
(111) and of the incidence of severe ventricular dysfunction and heart failure 
readmissions (83). The mechanism of metoprolol´s protection remained 
unravelled and was the main purpose of the present dissertation. 
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Neutrophils are the most abundant inflammatory cells and ample evidence 
supports their critical implication in IR injury (27) (103) (104) (105) (106) 
(112) (113). Neutrophils exert two well described deleterious effects on the 
injured myocardium. On one side, activated neutrophils and neutrophil-platelet 
plugs contribute to microvessels occlusion preventing distal efficient tissue 
perfusion (MVO) (8). On the other, neutrophils migrate to the newly 
reperfused injured vessels, adhere to the injured endothelium and infiltrate 
the myocardium contributing to both endothelial and cardiomyocyte death 
(36) (38). This doctoral thesis confirms these associations in AMI patients: 
neutrophil count positively correlated with the extent of MVO at 7 days post- 
reperfusion in the METOCARD-CNIC trial. Although limited in number, some 
studies linked the action of metoprolol to neutrophils: reductions in post-IR 
myeloperoxidase activity in pig myocardium (81) and rat spinal cord (114), 
and inhibition of sepsis-induced inflammation in mice (115). The data obtained 
from METOCARD-CNIC trial patients MVO evaluation, is the first human 
evidence that links metoprolol with altered neutrophil behaviour in vivo and 
that shows that a positive correlation between neutrophil count and MVO can 
be altered in those patients receiving i.v. metoprolol before reperfusion. 
Although mechanism remained unknown, this result suggested altered 
neutrophil dynamics during acute injury. 
The existence of ADRBs in human leukocytes was indirectly demonstrated (38) 
(116) (117) and extensively characterized in immune cell studies (103). This 
work confirms previous results in mouse (62). Furthermore, the studies here 
developed with Adrb1KO mice provide evidence for an important role of the 
ADRB1 axis in the cardioprotective effect of metoprolol. Metoprolol effect on 
migration was absent when evaluating Adrb1KO neutrophils, and in the 
peritonitis assay, the inhibitory effect of metoprolol on neutrophil infiltration 
was lost in Adrb1KO mice. The rescue of this inhibitory effect in chimeric 
animals in which Adrb1 is expressed only in circulating cells (that is, in 
Adrb1KO animals transplanted with wild-type BM) demonstrates that the 
cellular target of metoprolol action to alter neutrophil dynamics is of 
hematopoietic origin, and rules out an involvement of other cellular 
compartments (vascular, nervous or muscular). More importantly, the 
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conclusion obtained from subjecting BM transplant mice to myocardial IR 
injury model, resulted to be in agreement: metoprolol exerts no 
cardioprotection in the absence of ADRB1 and this effect is rescued when 
ADRB1 is present only in the hematopoietic compartment. Finally, experiments 
developed in vitro on Adrb2KO mice with no significant effect exerted by 
metoprolol ruled out the involvement of ADRB2. Altogether, these results 
demonstrate the essential role of neutrophil ADRB1 blockade in the protective 
effect that metoprolol exerts against AMI, specially, against acute 
inflammatory-associated IR injury processes. In contrast to the data obtained 
and here presented, a prior study suggested that metoprolol abrogated 
neutrophil migration in vitro in an apparently ADRB1-independent manner 
(65), since metoprolol was able to inhibit neutrophil migration even in the 
presence of the β-adrenergic receptor agonist orciprenaline. The in vitro 
incubation conditions (pH, temperature and concentration) could have affected 
orciprenaline sensibility and affinity to other ADRBs and subsequently alter the 
related signalling pathways. In this doctoral thesis, genetically modified mice 
lacking ADRB1 receptor (Adrb1KO) were used to provide strong in vivo and in 
vitro data showing the indispensable role of ADRB1 in the modulation of 
neutrophil function. The absence of cardioprotective effect observed when 
using Adrb1KO, which ensures absence of ADRB1, helps clarify the essential 
role of ADRB1 in this cardioprotective therapy in vivo and in vitro. 
IR injury-associated inflammation requires neutrophils to migrate and to 
subsequently infiltrate into the injured tissue. This complex process starts 
when endothelial stress signals favour neutrophil recruitment and attachment 
to the reperfused injured capillaries. This is followed by development of 
neutrophil structural changes, characterized by lumen-oriented PSGL1 
polarized clusters protrusions, through which effective neutrophil-platelet 
interactions occur, and the consequent infiltration initiation (35). In vitro 
results presented in this dissertation confirmed previous data. First, the 
transwell migration assays confirmed the ability of metoprolol to inhibit 
migration on isolated neutrophils (65). Second, incubation of metoprolol 
inhibited endogenous, and deleterious to endothelial function, ROS production 
from neutrophils (65). This inhibitory effect on neutrophil function was 
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reinforced by the acute in vivo murine peritonitis experiments, in which a 
single metoprolol i.v. injection abrogates thioglycolate-induced neutrophil 
infiltration into the peritoneal cavity evaluated at 16 hours. Next, the IVM 
confocal imaging experiments revealed that metoprolol rapidly abrogates 
functional PSGL1 polarized clusters reducing essential neutrophil-platelet 
effective interactions. This correlated with the alteration of the essential-for-
infiltration motile and structural properties, including migratory velocity and 
directionality. In agreement with these in vivo results, in the murine 
myocardial IR injury model, metoprolol reduced the number of neutrophil-
platelet coaggregates that occlude myocardial vessels. In addition, 
metoprolol’s inability to provide additional protection after blockade of 
neutrophil-platelet interactions with the anti-PSGL1 mAB is compelling 
evidence for interference in this interaction as the mechanism underlying the 
infarct-limiting action of metoprolol during myocardial IR injury. Finally, the 
demonstration that incubation of healthy volunteers and acute coronary 
syndrome patients’ blood samples with metoprolol inhibited neutrophil-platelet 
interactions suggests that this mechanism also operates in humans. There is 
controversy on the direct effect of metoprolol on platelet aggregation. Old 
studies suggested that metoprolol was able to inhibit ADP- and epinephrine-
mediated platelet aggregation (118). However, recent studies did not show 
any anti-platelet effect of metoprolol (119). In line with the latter evidence, 
this doctoral thesis shows metoprolol to have no effect on platelet aggregation 
or in platelet activation in humans again proving strong evidence that the 
inhibitory effect of metoprolol on neutrophil-platelet aggregates is driven by a 
direct effect on activated neutrophils. In the flow cytometry studies, we 
defined a positive neutrophil–platelet interaction as CD14neg, CD45+, CD61+ 
particles. It should be noted that there are more specific neutrophil markers 
and thus our selection is a limitation of these experiments. However, given 
that all data (human and mouse) point to the same direction, we think this 
limitation did not have an impact on the conclusions obtained in these 
experiments.  
The role of neutrophils in experimental IR injury is well established; however, 
the negative results of clinical trials with anti-inflammatory therapies (e.g. 
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C5a, (120) (121) CD-18 (122)) dampened hopes for this pharmacological 
strategy (36),  and suggested that parallel mechanisms driving myocardial 
injury were at play. The demonstration that neutrophil dynamics in general 
and neutrophil-platelet interactions in particular are the target for the 
protective actions of metoprolol administered to patients during AMI reinstates 
neutrophils as a potential target for the therapeutic reduction of infarct size.  
Limitations 
The main conclusion presented in this doctoral thesis is that metoprolol 
impedes neutrophils actions upon reperfusion. We show that these phenomena 
are ADRB1-mediated. However, how the metoprolol-ADRB1 binding occurs and 
how this influences the intracellular signaling cascade within the circulation 
neutrophils is still a matter of study. A better understanding of metoprolol-
ADRBs binding and intracellular signaling would help to develop new 
pharmacological interventions directed to accurately modulate the 
inflammatory-associated processes, and thus improve prognosis of patients.  
Despite this work include studies in human cells and MVO evaluation in 
patients, the extrapolation of the experimental results to the clinic should be 
done with caution. The differences between the mouse model IR developed in 
this doctoral thesis, where an open-heart surgery is performed to pass a 
ligature around the LAD coronary artery, with the AMI in humans are not 
trivial. Nevertheless, this model is based on temporal coronary occlusion and 
has important similarities with the sequentially orchestrated leukocyte 
migration courses described in the most accurate experimental AMI models 
(22) (23)  making it the best of its class for AMI fundamental pathological 
processes study.  
Adrb1KO mice and the BM transplant procedures contributed in an invaluable 
way to elucidate the involvement of ADRB1 in hematopoietic compartment as 
crucial for metoprolol’s cardioprotective effect. However, it is worth mention 
that ADRB1 was absent in all the hematopoietic compartment, and not only in 
the circulating neutrophils. In these sense, having neutrophil-specific Adrb1KO 
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mice would have been a better tool, since it would have avoided having to 
perform BM transplants, and would have ruled out a possible indirect effect of 
other inflammatory cells.   
 Conclusions/Conclusiones 
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1. Pre-reperfusion administration of i.v. metoprolol to AMI patients is 
associated with a significant less microvascular obstruction incidence 
and extent 
2. The positive association between neutrophil counts and the 
incidence/extent of microvascular obstruction in AMI patients is blunted 
by the pre-reperfusion administration of i.v. metoprolol 
3. In a mouse model of myocardial ischemia/reperfusion, pre-reperfusion 
administration of i.v. metoprolol reduces infarct size and the extent of 
microvascular obstruction 
4. The infarct-limiting effect of metoprolol is abolished in mice lacking 
adrb1, in neutrophil-depleted mice and when neutrophils are prevented 
from interacting with platelets 
5. Pre-reperfusion administration of i.v. metoprolol inhibits deleterious 
neutrophil inflammatory responses 
6. These results identify neutrophil dynamics as a target of the 
cardioprotective effect of metoprolol against myocardial IR injury 
7. Identification of the essential role of ADRB1 in hematopoietic cells 
during acute injury and the protective role upon its modulation offers 
potential for new therapeutic strategies development 
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1. La administración previa a la reperfusión de metoprolol intravenoso en 
pacientes con IAM se asocia con una incidencia y extensión de 
obstrucción microvascular significativamente menor 
2. La asociación positiva observada entre las cuentas de neutrófilos en 
sangre y la incidencia/extensión de la obstrucción microvascular en 
pacientes con IAM es mitigada por la administración previa a la 
reperfusión de metoprolol intravenoso  
3. En un modelo isquemia/reperfusión miocárdica en ratón, el metoprolol 
intravenoso administrado previo a la reperfusión reduce el tamaño de 
infarto y la cantidad de la obstrucción microvascular 
4. El efecto limitante del infarto que ejerce el metoprolol se ve abolido en 
ratones que carecen del gen adrb1, en ratones con depleción de 
neutrófilos y cuando se bloquea la interacción de los neutrófilos con las 
plaquetas 
5. La administración previa a la reperfusión de metoprolol intravenoso 
inhibe las respuestas inflamatorias perjudiciales de los neutrófilos 
6. Estos resultados identifican la dinámica y función de los neutrófilos 
como diana del efecto cardioprotector del metoprolol contra el daño por 
reperfusión miocárdico 
7. La identificación del papel fundamental de ADRB1 en las células 
hematopoyéticas durante la lesión aguda y el papel protector sobre su 
modulación ofrece potencial para el desarrollo de nuevas estrategias 
terapéuticas 
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Additional Information 
The supplementary information that accompanies this work is available in the 
following link: https://www.nature.com/articles/ncomms14780 or in the 
attached CD-ROM. 
 
Movie 1 
MVO and neutrophil-platelet interactions in the post-reperfused myocardium. 
3D navigation of confocal microscopy samples showing MVO and neutrophil-
platelet interactions in the myocardial vessels at 6h in vehicle (top) and 
metoprolol-treated (low) mice. 
 
Movie 2 
Neutrophil infiltration in the post-reperfused myocardium. 3D navigation of 
confocal microscopy samples showing neutrophil infiltration and cardiac 
disarray in vehicle- (top) and metoprolol-treated (low) mice. Note the massive 
neutrophil infiltration in vehicle-treated mice (absent in metoprolol-treated 
mice) and the irregular shaped neutrophils in vehicle as opposed to stunned 
rounded neutrophils in metoprolol. 
 
Movie 3 
Metoprolol alters neutrophil dynamics in inflamed vessels. Intravital 
microscopy showing neutrophils (green) crawling by the vessel. Note the 
migratory velocity, accumulated crawling distance, and directional movement 
in vehicle-treated mice. Conversely stunned neutrophils from metoprolol-
treated mice show an erratic behaviour with reduced motility and altered 
platelet (red) interactions. 
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by targeting the haematopoietic compartment. Metoprolol inhibits neutrophil migration in an
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circulating platelets, resulting in erratic intravascular dynamics and blunted inﬂammation.
Depletion of neutrophils, ablation of Adrb1 in haematopoietic cells, or blockade of PSGL-1, the
receptor involved in neutrophil–platelet interactions, fully abrogated metoprolol’s infarct-
limiting effects. The association between neutrophil count and microvascular obstruction is
abolished in metoprolol-treated AMI patients. Metoprolol inhibits neutrophil–platelet
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H
eart attack (acute myocardial infarction, AMI) is one of
the principal manifestations of cardiovascular disease and
a chief contributor to mortality and morbidity worldwide.
The main determinant of poor outcome post AMI is the extent of
irreversible injury (infarct size). The mainstay of AMI treatment
is rapid reperfusion to restore blood ﬂow, which reduces
complications and improves survival. However, reperfusion itself
accelerates and exacerbates the inﬂammatory response associated
with myocardial injury1. Thus, the injury inﬂicted on the
myocardium during AMI is the result of ischaemia and
reperfusion processes, and is known as ischaemia/reperfusion
(IR) injury. The development of effective therapies to reduce
myocardial IR injury is an unmet clinical need2.
The injured myocardium is inﬁltrated by circulating neutro-
phils, and these cells are critically involved in myocardial
IR injury3–7. In an inﬂammatory milieu, neutrophils bind to
platelets and red blood cells, forming plugs7. Upon reperfusion,
these plugs are dispersed into the microcirculation, where they
form embolisms, precluding tissue perfusion despite blood ﬂow
restoration in the large coronary arteries. This phenomenon,
known as microvascular obstruction (MVO), is a major
contributor to IR injury and infarct size1. Moreover, neutrophil
inﬁltration into acutely damaged organs is dependent on their
interaction with platelets8, and these interactions are critical to
the formation of harmful co-aggregates and the initiation of
inﬂammatory-like responses before tissue inﬁltration3,8. Overall,
neutrophil dynamics (including neutrophil–platelet interactions)
are an attractive therapeutic target for the prevention of IR injury.
The intravenous (i.v.) administration of the selective
b1-adrenergic receptor (ADRB1) antagonist metoprolol has been
shown to reduce infarct size and improve long-term cardiac
function after AMI in the recent METOCARD-CNIC trial9,10.
The mechanism underlying metoprolol’s cardioprotective
effect remains unclear11. Identifying this mechanism could have
signiﬁcant implications for the understanding of IR and the
development of novel infarct-limiting therapies. The adrenergic
system is critically involved in inﬂammatory reactions12,13.
In particular, the inﬂammatory response of neutrophils
involves the de novo production and release by these cells of
catecholamines12,13. Induced catecholamine stress (as during
ischaemia) alters neutrophil trafﬁcking14–16 and promotes
formation of neutrophil–platelet co-aggregates17.
We hypothesized that pre-reperfusion i.v. metoprolol admin-
istration alters neutrophil dynamics, resulting in a dampened
inﬂammatory response, less severe reperfusion injury and smaller
infarcts. Here we show that pre-reperfusion administration of i.v.
metoprolol to AMI patients signiﬁcantly reduces the incidence of
MVO, and moreover that metoprolol inhibits deleterious
neutrophil inﬂammatory responses both in patients and in
animal models of IR. The infarct-limiting effect of metoprolol is
abolished in neutrophil-depleted mice and when neutrophils are
prevented from interacting with platelets. The beneﬁcial effects of
metoprolol are also abolished by genetic ablation of Adrb1 and
are rescued by restitution of Adrb1 expression only in
haematopoietic cells. These results identify the neutrophil
dynamics as the target of the cardioprotective effect of metoprolol
against myocardial IR injury.
Results
Intravenous metoprolol reduces MVO in AMI patients. The
METOCARD-CNIC trial recruited patients with an ongoing
acute ST-segment elevation AMI and randomized them to receive
i.v. metoprolol (15mg) or control before reperfusion18. A total of
220 AMI patients underwent a cardiac magnetic resonance
(CMR) imaging exam 1 week after AMI. To study the potential
mechanisms underlying the infarct-limiting effect of metoprolol9,
we analysed the 1-week CMR data to evaluate the extent of
MVO. MVO was deﬁned as the absence of contrast wash-in
inside the delayed gadolinium-enhanced area19, and was
quantiﬁed as grams of left ventricle (LV) (Fig. 1a,b and
Supplementary Fig 1a,b). Patients treated with metoprolol
during ongoing AMI had a 40% lower extent of MVO (Fig. 1c).
This signiﬁcant effect was maintained after adjusting for factors
potentially affecting MVO by performing linear multiple
regression analysis and including sex, age, ischaemia duration,
diabetes, and use of thrombectomy or glycoprotein IIb/IIIa
inhibitors as covariates. To exclude the possibility that this effect
simply reﬂected the reduction in total infarct size9, MVO was
further assessed as a percentage of the infarcted area (total late
gadolinium enhanced area). Metoprolol-treated patients had
24% less infarct-normalized MVO than control patients
(Fig. 1d). As expected, the extent of MVO was signiﬁcantly
associated with poor long-term outcome, evaluated as chronic
ventricular performance (Supplementary Fig. 1c). These data
suggest that MVO reduction might be involved in the
cardioprotective effect of metoprolol administration in patients
during ongoing AMI.
Intravenous metoprolol dampens neutrophilial–MVO association
in AMI. White blood cell (WBC) and neutrophil counts during
an AMI are known to be associated with larger infarct sizes and
extensive MVO20–22. We explored these associations in
AMI patients from the METOCARD-CNIC trial. We found
a signiﬁcant positive correlation between absolute leukocyte
count on admission and the extent of MVO on CMR: the higher
the leukocyte count, the larger the extent of MVO (Fig. 2a).
We further studied the association of the different WBC
subpopulations and MVO. As expected, neutrophil count was
signiﬁcantly correlated with the extent of MVO (Fig. 2b).
Conversely, there was no sign of association between other
WBC subpopulations and MVO: lymphocyte, monocyte,
eosinophil or platelet counts did not correlate with the extent
of MVO (Fig. 2e). Next, we studied the effect of metoprolol on
WBCs and on the association between these and MVO.
Metoprolol treatment was not associated with any different in
WBC count nor in any WBC subpopulation (Supplementary
Table 1). Of note, we found a signiﬁcant interaction between
metoprolol treatment and the correlation between leukocyte
count and MVO: the signiﬁcant positive correlation between
neutrophil count and the extent of MVO was only present in
control patients (that is, not receiving metoprolol); in patients
receiving i.v. metoprolol before reperfusion there was no sign of
association between total leukocyte or neutrophil counts and the
extent of MVO (Fig. 2c,d). These results suggest that the
administration of i.v. metoprolol during ongoing AMI do not
affect the circulating levels of WBCs but modulates the impact of
neutrophils on MVO.
Metoprolol blunts neutrophil inﬁltration in experimental IR.
To identify the factors underlying the metoprolol-induced
reduction in MVO within the reperfused myocardium, we
examined a mouse model of in vivo myocardial IR injury
(Fig. 3a). Given the observed modulator effect of i.v. metoprolol
in the association between neutrophil count and MVO in patients
suffering an AMI, we focused our attention into this cell
population. We ﬁrst tested the infarct-limiting effect of
metoprolol in wild-type mice by occluding the left anterior
descending (LAD) coronary artery for 45min followed by
reperfusion. Mice were randomized to receive a single i.v. bolus
(50 ml) of metoprolol (10mM) or vehicle (saline) 35min after
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ischaemia onset (10min before reperfusion). Infarct size was
evaluated at 24 h reperfusion by TTC staining and normalized to
area at risk (AAR, negative Evans blue staining). Metoprolol-
treated mice had signiﬁcantly smaller infarcts (as % of AAR) than
vehicle-treated mice (Fig. 3b–d). Next, we examined mice
carrying a GFP reporter in myeloid derived cells (LysM-GFP).
LysM-GFP mice underwent the myocardial IR procedure and
were randomized to receive i.v. metoprolol or vehicle. Capillary
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Figure 1 | Metoprolol administration during ongoing AMI reduces MVO in patients. (a) METOCARD-CNIC trial scheme: patients with ongoing
ST-segment elevation myocardial infarction (STEMI) were recruited and randomized to receive metoprolol (15mg i.v. doses) or control before reperfusion.
A total of 220 patients were evaluated for MVO by cardiac magnetic resonance (CMR) imaging 1 week after AMI and 202 patients for an additional
CMR at long-term LVEF 6 months after AMI for ventricular function assessment. (b) Representative CMR exams (short-axis covering the entire left
ventricle (LV) from base to apex), showing signiﬁcant differences in 1-week MVO between a control patient (left) and a metoprolol-treated patient (right).
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obliteration (a histological surrogate for MVO) and leukocyte
inﬁltration were quantiﬁed at 6 h post-reperfusion (Fig. 3e–m).
Metoprolol administration during ongoing AMI resulted in a
signiﬁcant reduction of capillary obliteration by circulatory cell
plugins when evaluated at 6 h post-reperfusion (Fig. 3e,f).
Confocal microscopy analyses revealed a signiﬁcant reduction in
the number of myeloid cells plugins (LysM-GFPþ particles)
and percentage of LysM-GFPþ area within the LV sections,
indicating rapid inhibition of leukocyte recruitment and protec-
tion of lumen vessel patency (Fig. 3g, Supplementary Fig. 2a–d
and Supplementary Movie 1). Temporal (6 and 24 h) evaluation
of myeloid-derived cells inﬁltration into injured myocardium
showed a persistent abrogation of neutrophil inﬁltration
(Fig. 3h–m and Supplementary Movie 2) and a differential
relative proportion of different myeloid cells in hearts from
metoprolol and vehicle-treated mice (Fig. 3j and Supplementary
Fig. 3). These mouse experiments conﬁrm the clinical ﬁndings
that pre-reperfusion metoprolol administration during ongoing
AMI limits infarct size and reduces MVO, and further show that
metoprolol reduces neutrophil inﬁltration, suggesting neutrophils
as a potential target in this cardioprotective effect.
Metoprolol does not protect from AMI in the absence of
neutrophils. Catecholamine-stimulation of bARs alters neu-
trophil function, cytokine release and neutrophil–platelet aggre-
gate formation17,23,24, processes associated with aggravated injury
during AMI (refs 25–27). To decipher the role of neutrophils in
the protection afforded by metoprolol during ongoing AMI, we
evaluated the effect of the drug in the absence of neutrophils.
Neutrophil depletion in mouse peripheral blood was achieved by
administration of an anti-Ly6G mAb over 2 days8,28. After
neutrophil depletion, animals were subjected to myocardial IR,
and infarct size was evaluated at 24 h post-reperfusion (Fig. 3n).
Conﬁrming earlier reports29, neutrophil-depleted mice had
smaller infarcts than controls. Administration of metoprolol to
these mice during ongoing AMI did not reduce infarct size
(Fig. 3o–q). The abrogation of the cardioprotective effect of
metoprolol conﬁrms circulating neutrophils as a target of the
beneﬁcial effect associated with this pharmacological therapy.
Metoprolol inhibits neutrophil migration by targeting ADRB1.
The effect of metoprolol on primary neutrophils’ function was
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evaluated in a chemokine-induced transwell migration assay
and by evaluation of the chemotactic FPR activator-peptide,
W-peptide30, -induced reactive oxygen species (ROS) production
assay31. First, neutrophils were exposed across the transwell ﬁlter
to the chemoattractant CXCL1 in the presence or absence of
metoprolol for 1.5 h, and migration through the transwell
membrane was quantiﬁed by ﬂow cytometry. Metoprolol
inhibited baseline and epinephrine-stimulated neutrophil
migration towards CXCL1, reducing migration to the same
level in both cases (Fig. 4a). Second, ROS production in vitro was
measured using DHR 123 and W-peptide activation. ROS
production was tested in metoprolol-treated and untreated
neutrophils with and without W-peptide stimulation.
Metoprolol-treated neutrophils presented signiﬁcant decreased
oxidative burst compared to the non-treated cells after
stimulation (Fig. 4b,c). Metoprolol alone had no effect on ROS
endogenous production.
Metoprolol is a selective ADRB1-blocker, and ADRB1
signalling has been shown to mediate some of the pro-inﬂam-
matory response of monocytes32. Neutrophils and monocytes
are both myeloid derived cells, and we therefore reasoned
that ADRB1 might be involved in the anti-migratory effect of
metoprolol. Adrb1 mRNA expression in fresh and viable isolated
neutrophils was conﬁrmed by PCR in wild-type mice and
absence in neutrophils from Adrb1-knockout mice (Adrb1KO)
(Supplementary Fig. 4a–c). In vitro, the -epinephrine-mediated
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migration- and -W-peptide-mediated ROS production-inhibitory
effect of metoprolol was lost in Adrb1KO neutrophils (Fig. 4a–c).
b2-adrenergic receptor-knockout mice (Adrb2KO) was not
involved in the effects observed after metoprolol administration
(Supplementary Fig. 5).
We next explored whether metoprolol directly inhibits the
capacity of neutrophils to inﬁltrate tissues in vivo. For this, we
ﬁrst used a model of thioglycolate-induced peritonitis (Fig. 4d).
Thioglycolate induces massive leucocyte migration into the
peritoneal cavity within the ﬁrst 16 h (Supplementary Fig. 6a),
with the majority of inﬁltrating cells being neutrophils (Supple-
mentary Fig. 6b–d). Metoprolol i.v. administration sharply
inhibited thioglycolate-induced neutrophil inﬁltration into the
peritoneal cavity of wild-type mice (Fig. 4e,f), but the inhibitory
effect of metoprolol was lost in Adrb1KO mice (Fig. 4f and
Supplementary Fig. 6a,b).
To better deﬁne the cell compartment targeted by metoprolol,
we lethally irradiated Adrb1KO mice and restored haematopoiesis
with bone marrow (BM) transplanted from wild-type donors,
generating chimeric mice expressing ADRB1 only in circulating
cells. At 4 weeks after irradiation, transplanted animals presented
485% BM engraftment (Supplementary Fig. 7) and were
subjected to thioglycolate-induced peritonitis. The replenishment
of ADRB1 only in haematopoietic cells was enough to rescue the
anti-leucocyte-inﬁltration effect of metoprolol (Fig. 4g). Together,
these data show a direct effect of metoprolol on neutrophil
function and demonstrate that the presence of ADRB1 in
circulating cells is essential for the ability of metoprolol to reduce
neutrophil inﬁltration into injured tissue.
IR reduction by metoprolol involves haematopoietic cells’
ADRB1. We next investigated the involvement of ADRB1
blockade in haematopoietic circulating cells in the protective
effect of metoprolol in the infarcted myocardium. Adrb1KO mice
were subjected to myocardial IR and randomized to receive i.v.
metoprolol or vehicle during ongoing AMI (Fig. 4h). Unlike the
situation in wild-type mice, metoprolol did not limit infarct size
in Adrb1KO animals (Fig. 4i–k), demonstrating the critical role of
ADRB1 blockade in the cardioprotective effect. To demonstrate
the role of ADRB1 expression in haematopoietic circulating cells,
we repeated the myocardial IR protocol in the chimeras described
above (Adrb1KO mice transplanted with wild-type BM). The
presence of ADRB1 only in haematopoietic circulating cells was
sufﬁcient to restore susceptibility to the cardioprotective effect of
metoprolol (Fig. 4l–n). Conversely, transplant of Adrb1KO
BM into irradiated wild-type mice abrogated the protective
phenotype associated with metoprolol administration during
IR (Fig. 4o–q). These data conﬁrm the involvement of ADRB1
blockade in haematopoietic cells in the cardioprotection afforded
by metoprolol administration during AMI.
Metoprolol alters neutrophil dynamics in vivo. During acute
injury, neutrophils alter their morphology upon adhering to
the activated endothelium. These shape change or polarization,
permit intercellular interactions critical for the inﬂammatory
response in several conditions, including myocardial IR
(refs 8,33). Polarization of adhered neutrophils involves receptor
redistribution and the assembly of a rearward protruding
microdomain called the uropod, and is essential for the
integration of signals coming from the endothelium and
activated platelets before inﬁltration8. We were therefore
interested in investigating whether metoprolol impaired
neutrophil migration and inﬁltration through an effect on
neutrophil dynamics. For this, we used bi-dimensional and
3D intravital microscopy (IVM) to image cremaster muscle
vessels of mice treated with tumour necrosis factor-a (TNFa), an
inﬂammatory model in which the vast majority of recruited
leukocytes are neutrophils. Neutrophil behaviour was evaluated
3 h after administration of metoprolol or vehicle (Fig. 5a).
Notably, metoprolol reduced neutrophil migratory velocity,
accumulated crawling distance and directional movement
(Fig. 5b,c and online Supplementary Movie 3). Independent-
neutrophil 3D-reconstructions of live inﬂamed vessels showed
that metoprolol consistently disabled the intravascular behaviour
of neutrophils without disrupting polarization within activated
vessels, resulting in dramatic changes in cell morphology
(Fig. 5d–f) that correlated with their abnormal crawling
dynamics. These data show that metoprolol ‘stuns’ neutrophils,
resulting in altered dynamics and prevents the morphological
changes needed to initiate intercellular interactions and
subsequent tissue inﬁltration.
Metoprolol blocks PSGL1-dependent neutrophil platelet
interactions. Correct neutrophil polarization and organization of
an extruding microdomain that captures circulating platelets is
required to initiate tissue-damaging inﬂammation8. Indeed, plugs
of neutrophil–platelet co-aggregates in the microcirculation are a
major contributor to MVO in AMI and in other models
of injury1,8. We therefore explored the impact of metoprolol-
induced neutrophil stunning on neutrophil–platelet interactions.
Figure 3 | Metoprolol reduces neutrophil inﬁltration and capillary obliteration in murine IR. (a) Mouse model of myocardial IR. (b, c) Histological
evaluation of left ventricle (LV) area at risk (AAR) and infarct size (IS) in mice subjected to IR and randomized to receive metoprolol (blue) or vehicle
(white); NS stands for non-signiﬁcant. n¼8. (d) Representative images of LV slices showing AAR (negative for Evans Blue) in upper panels and extent of
necrosis (triphenyltetrazoliumchloride (TTC)-negative area in lower panels). (e) Capillary oblliteration quantiﬁed in H&E ten random images; n¼ 5–6.
(f) Representative H&E myocardial images at 6 h reperfusion showing disarrayed and abundant obstructed capillaries in the vehicle-treated sample;
metoprolol-treated samples show injury and nuclear condensation but no signs of MVO; green scale bars, 50 mm. Detailed ampliﬁcation of the boxes show
obstructed capillaries indicated with black arrows; black scale bars, 10mm. (g) Confocal images from LV at 6 h after reperfusion onset showing massive
vascular neutrophil migration (LysM-GFP, green) and co-aggregates with platelets (CD41, red) vehicle- but not in metoprolol-treated mice; scale bar,
25mm. Next, ampliﬁed boxes indicating regions of capillary obstruction; scale bar, 10mm. Bottom yellow panels show computed 3D reconstructions.
(h,i) Myeloid-derived cell inﬁltration dynamics showing maintained attenuation in hearts from metoprolol-treated mice. n¼ 5. (j) Neutrophilic proportions
inﬁltrate dynamics. (k) Representative confocal images of LV sections taken from injured mice after 6 and 24 h reperfusion onset. Myeloid inﬁltration
(LysM-GFPþ , green) most of which are neutrophil (Ly6Gþ , red) is evident in vehicle-treated mice and signiﬁcantly attenuated in those from metoprolol-
treated mice; merged images show double positive cells (LysMþ /Ly6Gþ , that is, neutrophils). Scale bar, 50mm; n¼ 3–5. (l) Representative confocal
images of neutrophil inﬁltration 24h after reperfusion onset. Vehicle-treated mice show massive myocardial neutrophil inﬁltration (LysM-GFPþ , green),
with dispersed cells attached to the injured cardiac ﬁbre membranes (a-actinin, red; laminin, grey). (m) LysMþ total area in the LV section as a %AAR;
scale bar, 20mm; n¼ 5–6. (n–q) Effect of metoprolol on limiting-infarct size in neutrophil-depleted mice. (n) Neutrophil depletion model. (o) Myocardial
area at risk (AAR). (p) Infarct size. (q) Representative transverse ventricular slices showing AAR and infarct size Data are means±s.e.m. *Po0.05;
**Po0.01, determined by the nonparametric Wilcoxon–Mann–Whitney test for each panel.
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Using the cremaster IVM model of TNFa-induced local
inﬂammation, we evaluated the acute neutrophil–platelet
inhibitory effect of metoprolol in polarized neutrophils (Fig. 5).
Metoprolol i.v. administration effectively inhibited interactions
with the uropod, but not the leading edge (Fig. 5g,h) and
rapidly reduced total neutrophil–platelet interactions (Fig. 5i–k).
IVM experiments in Adrb1KO mice revealed no differences
between metoprolol-treated and vehicle-treated mice, implicating
ADRB1 in the inhibitory effect of metoprolol on neutrophil–
platelet interactions (Fig. 5j).
Based on these ﬁndings, we hypothesized that inhibition of
neutrophil–platelet interactions underlies the inhibitory effect of
metoprolol on MVO after myocardial IR. To test this, we
ﬁrst evaluated the effect of metoprolol on neutrophil–platelet
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co-aggregate formation in mouse myocardial vessels after
experimental IR. Administration of metoprolol to wild-type mice
during ongoing AMI signiﬁcantly reduced the number of
neutrophils attached to the vessel wall (Fig. 6a,b) and the average
number of interacting platelets per neutrophil (Fig. 6c).
Neutrophil–platelet interactions during acute injury are
mediated by PSGL1 and signals delivered upon these contacts
promote subsequent neutrophil extravasation and injury to the
tissue8. Blockade of PSGL1 by pretreatment with PSGL1-mAB
(Fig. 6e) signiﬁcantly reduced infarct size in the myocardial
IR model, and administration of metoprolol during ongoing
AMI did not yield any further infarct-size reductions (Fig. 6f,g).
These data conﬁrm that metoprolol protects the infarcted
myocardium by uncoupling neutrophil recruitment and
polarization, thereby disrupting neutrophil–platelet interactions
and the downstream inﬂammatory response.
Metoprolol limits neutrophil–platelet aggregates in patients.
To investigate whether metoprolol alters neutrophil dynamics
and inhibits neutrophil–platelet interactions in humans, whole
blood drawn from healthy donors was incubated ex vivo with
epinephrine (5 mM) and increasing concentrations of metoprolol
(0, 2, 5mM). Samples were then stained, and neutrophil–platelet
co-aggregate formation was evaluated by ﬂow cytometry34–37
(morphological parameters, CD14neg, CD45þ , CD61þ ).
Metoprolol signiﬁcantly inhibited epinephrine-stimulated
neutrophil–platelet co-aggregate formation (Fig. 7a). The effect
of metoprolol in vivo was additionally studied in patients
undergoing elective coronary angioplasty for acute coronary
syndrome (ACS). Samples were collected before and after i.v.
administration of metoprolol (15mg) and circulating neutrophil–
platelet co-aggregates were assessed by ﬂow cytometry.
Metoprolol administration signiﬁcantly reduced the number of
neutrophil–platelet interactions (Fig. 7b). To elucidate whether
metoprolol was acting at the platelet level of action we evaluated
effect of metoprolol on platelet function through platelet
aggregation using light transmittance aggregometry in platelet-
rich plasma (PRP) (Supplementary Fig. 8a) or platelet activation
surface markers expression assay using ﬂow cytometry
(Supplementary Fig. 8b,c). Metoprolol did not show any
effect on platelet aggregation/activation, which together
with the aforementioned effects on neutrophil migration and
ROS-production suggests that the effect seen on neutrophil–
platelet co-aggregates was driven by a direct effect on neutrophils.
Discussion
Early metoprolol administration during AMI, given as an adjunct
to mechanical reperfusion has been shown to reduce infarct size
and ameliorate post-infarction severe cardiac dysfunction11,38.
Deﬁning the mechanisms underlying this cardioprotection is
therefore of great medical relevance since more efﬁcient and
speciﬁc protective strategies could be identiﬁed.
The ability of ADRB1 selective blockers to reduce infarct
size was tested decades ago in several clinical trials, but the
results were inconclusive1. However, most of these early studies
were performed in the context of non-reperfused AMI. The
advent of reperfusion as the treatment of choice for AMI changed
the mode of myocardial death: from unrelieved ischaemia to a
combination of ischaemia and reperfusion processes. Therefore
the potential cardioprotective effects of ADRB1 selective blockers
needed to be revisited in light of the current evidence of IR injury
during AMI (ref. 1). The ability of metoprolol to reduce
infarct size in the context of reperfused AMI was recently
evaluated in the METOCARD-CNIC trial. In this trial, early
i.v. metoprolol administration during ongoing AMI resulted
in a signiﬁcant reduction of infarct size9,39, and also signiﬁcantly
reduced the incidence of severe ventricular dysfunction and heart
failure readmissions10. Large animal studies conducted before the
METOCARD-CNIC trial showed that metoprolol reduces infarct
size only when administered before reperfusion40,41, suggesting
that metoprolol might reduce infarct size by inhibiting
reperfusion injury. The early studies, testing the infarct-limiting
properties of metoprolol in non-reperfused AMI, were
undertaken under the hypothesis that ADRB1-blockers would
reduce the extent of damage by a direct effect on cardiomyocytes
via reducing oxygen consumption. Although our large animal
study40 did not investigate the mechanism of metoprolol-
mediated protection, it did show that oxygen consumption was
similar in metoprolol- and vehicle-treated pigs. In addition, the
infarct-size reduction in metoprolol-treated pigs was associated
with reduced myeloperoxidase activity in the post-ischaemic
myocardium 24 h after reperfusion41. These ﬁndings challenged
the idea that metoprolol could reduce cardiac damages simply by
reducing myocardial oxygen consumption directly in the heart
and prompted us to investigate the cellular mechanisms
underlying the reperfusion-related injury-limiting effect of
metoprolol during IR.
There is ample evidence supporting the critical implication of
neutrophils in IR injury4,25,27,29,42,43. Neutrophils have two
deleterious effects in this context. First, neutrophils and
neutrophil–platelet plugs occlude microvessels, preventing
efﬁcient tissue perfusion: MVO. Second, neutrophils adhering
to the newly reperfused injured vessels inﬁltrate the
myocardium1, prompting deleterious processes associated
with reperfusion25,33. Our study conﬁrms these associations in
AMI patients: neutrophil count positively correlated with the
extent of MVO as evaluated by state-of-the-art MRI 1 week after
reperfusion. There exist weak pre-existing evidence linking
the action of metoprolol to neutrophils, including reductions in
Figure 4 | Metoprolol directly inhibits neutrophil deleterious function through a ADRB1-blockade. (a) Effect of metoprolol on CXCL1-induced migration
of fresh isolated primary neutrophils (Ly6Gþ ) from WTor Adrb1-knockout (b1KO) mice. CXCL1-stimulated cells were incubated with vehicle, epinephrine
(10mM), metoprolol (10mM) and epinephrineþmetoprolol; n¼4 independent experiments. NS, stands for non-signiﬁcant. (b,c) Inhibitory effect of
metoprolol on W-peptide-induced ROS production on fresh isolated primary neutrophils (Ly6Gþ ) from WTor b1KO mice. Mean ﬂuorescent intensity of
Rho123 in Ly6Gþ neutrophils after W-peptide stimulation. n¼6 independent experiments; ﬂow cytometry plots illustrate reduced expression of Rho123 in
metoprolol-treated neutrophils. (d–f) Effect of metoprolol on limiting-thioglycolate-induced peritoneal inﬁltration on WT and b1KO mice. (e) Flow
cytometry plots illustrating reduced inﬁltration of neutrophils (CD115neg; GR1þ ) in metoprolol-treated mice. Absolute neutrophils detected per ml of
inﬁltrate at 16 h after thioglycolate injection in WTmice (n¼ 7–9) or b1KO mice (n¼ 5). (g) Effect of metoprolol on thioglycolate-induced neutrophil
inﬁltration in the four BMT groups. Protocol scheme for thioglycolate-induced peritonitis assay after bone-marrow transplants (BMT) between WT and
b1KO mice, evaluating the inﬂuence of the presence or absence of ADRB1 in circulating cells. Data are normalized to vehicle; n¼4–9. (h) Protocol scheme
for IR experiments in chimeric animals after BMT, evaluating the infarct-limiting effect of metoprolol in the presence or absence of ADRB1 in circulating cells.
(i–q) Area at risk (AAR) and infarct size, as well as representative images of Evans blue and TTC staining in metoprolol-treated and vehicle-treated b1KO
and chimeras (WT bone marrow transplanted into b1KO mice and reverse transplants). Infarct size is reduced by metoprolol only when circulating cells
express b1-adrenergic receptor; n¼ 9 (i,j), n¼ 8 (l,m), n¼ 5–6 (o,p). Data are means±s.e.m. *Po0.05; **Po0.01; ***Po0.001, determined by the
nonparametric Wilcoxon–Mann–Whitney test or using the one-way ANOVA and Holm Sidak’s post-hoc multiple comparisons method.
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post-IR myeloperoxidase activity in pig myocardium41 and rat
spinal cord44, and inhibition of sepsis-induced inﬂammation in
mice45. The data here presented from patients randomized in
a controlled clinical trial are the ﬁrst human evidence linking
metoprolol with altered neutrophil behaviour in vivo. We show
that the strong positive correlation between neutrophil count and
MVO was abolished in patients receiving i.v. metoprolol before
reperfusion. The fact that metoprolol-treated patients’ high
neutrophil count was not associated with the extent of MVO
suggests an altered neutrophil dynamics during acute injury.
Some preclinical studies have suggested an association between
metoprolol exposure and altered neutrophil dynamics41,44,45;
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however, the cellular mechanism responsible for this effect has
remained unknown. Our results from the in vitro transwell
migration assays conﬁrm previous studies showing the ability of
metoprolol to inhibit migration of isolated neutrophils46. Also,
our in vitro data conﬁrm previous studies showing that
metoprolol was able to inhibit ROS production from
neutrophils47. Our in vitro results showing migration inhibition
by metoprolol are reinforced by the acute in vivo murine
peritonitis model, in which a single metoprolol i.v. injection
abrogates neutrophil inﬁltration into the peritoneal cavity.
Furthermore, the studies with Adrb1KO mice provide evidence
for a critical involvement of the ADRB1 axis in the effects of
metoprolol. In the transwell assays, metoprolol had no effect on
the migration of Adrb1KO neutrophils, and in the peritonitis
assay, the inhibitory effect of metoprolol on neutrophil
inﬁltration was lost in Adrb1KO mice. The rescue of this
inhibitory effect in chimeric animals in which Adrb1 is expressed
only in circulating cells demonstrates that the cellular target of
metoprolol action is of haematopoietic origin, and rules out an
involvement of other compartments. Moreover, the ﬁndings in
the peritonitis model were conﬁrmed in the myocardial IR model,
with metoprolol signiﬁcantly reducing neutrophil inﬁltration into
the injured myocardium of wild-type but not Adrb1KO mice, and
rescue of the protective effect in the Adrb1KO after wild-type BM
transplant. Finally, we ruled out any involvement of ADRB2 on
the effect exerted by metoprolol. Altogether, these results
demonstrate the essential role of neutrophil ADRB1 blockade in
the protective effect of metoprolol against myocardial IR injury.
Our data are in discrepancy with a prior study suggesting
that metoprolol abrogated neutrophil migration in vitro in an
apparently ADRB1-independent manner46. In that study
authors reported that metoprolol was able to inhibit neutrophil
migration even in the presence of the b-adrenergic receptor
agonist orciprenaline, while in our study we have used a genetic
ablation toll (that is, Adrb1KO mice), which ensures the
absence of ADRB1.
Upon acute injury, neutrophils recruited to injured vessels
initiate inﬂammation by scanning for activated platelets present
in the circulation, establishing interactions with them through
PSGL1 exposed on neutrophil protrusions8. The IVM confocal
imaging analysis demonstrated that metoprolol prevents the
exposure of functional PSGL1 clusters, which are essential for
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interaction with platelets. These events correlated with alterations
in neutrophil properties essential for inﬁltration, including
migratory velocity and directionality. In agreement with
these data, in the mouse myocardial IR model, metoprolol
altered neutrophil 3D structure and reduced the numbers of
neutrophil–platelet co-aggregates that occluded myocardial
vessels. The inability of metoprolol to provide additional
protection after blockade of neutrophil–platelet interactions
with the anti-PSGL1 mAB is compelling evidence for
interference in this interaction as the mechanism underlying
the infarct-limiting action of metoprolol during myocardial IR in
mice. The demonstration that metoprolol inhibits neutrophil–
platelet interactions in healthy volunteers and ACS patients
suggests that this mechanism also operates in humans. There is
controversy on the direct effect of metoprolol on platelet
aggregation. Some studies suggested that metoprolol was
able to inhibit ADP- and epinephrine-mediated platelet
aggregation48, but recent studies did not show any anti-platelet
effect of metoprolol49. In line with the latter evidence, in our
study we found that metoprolol had no effect on platelet
aggregation or in platelet activation in healthy volunteers. These
data strongly suggest that the inhibitory effect of metoprolol on
neutrophil–platelet co-aggregates was driven by a direct effect on
neutrophils. In our ﬂow cytometry studies we deﬁned a positive
neutrophil–platelet interaction as CD14neg, CD45þ , CD61þ
particles. It should be noted that there are more speciﬁc
neutrophil markers and thus our selection is a limitation of
these experiments. However, given that all data (human and
mouse) point to the same direction, we think this limitation did
not have an impact on the conclusions obtained in these
experiments.
The role of neutrophils in experimental IR injury is well
established; however, the negative results of clinical trials with
anti-inﬂammatory therapies (for example, C5a (refs 50,51),
CD-18 (ref. 52)) dampened hopes for this pharmacological
strategy3, and suggested that parallel mechanisms driving
myocardial injury were at play. The demonstration that neutro-
phil dynamics in general and neutrophil–platelet interactions in
particular are the target for the protective actions of metoprolol
administered to patients during AMI reinstates neutrophils as
a potential target for the therapeutic reduction of infarct size.
Methods
Human cardiac magnetic resonance imaging. The METOCARD-CNIC trial
(NCT01311700) recruited patients suffering an AMI during hospital transit to
undergo mechanical reperfusion by primary angioplasty. Patients were randomized
to receive i.v. metoprolol (up to 15mg) or no drug (control). Patients underwent
two CMR studies: 1 week and 6 months after AMI. Images were acquired with
a 3.0 Tesla magnet (Achieva Tx, Philips Medical Systems) with vectorcardiographic
gating and a dedicated cardiac 32-channel phased-array surface coil. The extent of
MVO was measured in the 1-week CMR study; to detect and quantify MVO,
a delayed enhancement imaging was performed 10min after gadolinium
contrast injection, using a T1-weighted 2-D Inversion Recovery Turbo Field Echo
(2D IR-TFE) sequence. Myocardial necrosis was deﬁned by the extent of abnormal
gadolinium enhancement, whereas MVO was deﬁned as black-hypoenhanced areas
within the bright-hyperenhanced regions. CMR analysis was undertaken by
operators blinded to treatment allocation at the Centro Nacional de Investigaciones
Cardiovasculares Carlos III (CNIC). Myocardial necrosis and MVO were quanti-
ﬁed by semiautomatic delineation with dedicated software (QMass MR 7.6; Medis,
Leiden, the Netherlands). Total MVO was quantiﬁed as grams of LV. To correct for
infarct size, MVO was also expressed as a percentage of the infarcted area.
Mouse procedures. Experimental procedures were approved by the CNIC Animal
Care and Ethics Committee and regional authorities. IR, thioglycolate-induced
peritonitis and IVM experiments were performed in 8–13-week-old wild-type
male C57BL/6 mice. b1-adrenergic receptor (Adrb1) knockout (KO; Adrb1KO)
mice were in a mixed background. b2-adrenergic receptor (Adrb2) knockout
(KO; Adrb2KO) mice were in a C5BL/6 background. For the BM transplant
experiments, Adrb1KO mice were backcrossed with mice expressing DsRed under
the control of the b-actin promoter to facilitate evaluation of BM engraftment.
Male and female mice were used as donors in BM transplant procedures, but
only males were used in myocardial IR and thioglycolate-induced peritonitis
experiments. All animals were randomized to receive a single i.v. injection (50 ml)
of metoprolol-tartrate (10mM) or vehicle (saline). Histological evaluation of
injured myocardium in the myocardial IR model was performed in lysozyme
M-GFPþ (LysM-GFP)53 male mice. Intravascular neutrophil and neutrophil–
platelet interactions were scored manually in the myocardium. Neutrophils were
depleted in C57BL/6 male by i.v. injections of 50 mg anti-mouse Ly6G 24 and 48 h
before the myocardial IR procedure28. For in vivo blocking of P-selectin
glycoprotein ligand-1 (PSGL1), 50 mg of anti-PSGL1 antibody (clone 4RA10) was
i.v. injected 15min after ischaemia onset. Mice were maintained under pathogen-
free conditions in a temperature-controlled room and a 12-h light–dark cycle at the
CNIC animal facilities. Chow and water were available ad libitum.
Reagents. Metoprolol-tartrate (M5391), Evans blue, triphenyltetrazolium
chloride, DAPI (D8417-1MG), Mowiol mounting medium (81381), anti-laminin
(L9393), anti-a-actinin (A7732), dihydrorhodamine 123 (D1054) were obtained
from Sigma-Aldrich. Dylight-650-conjugated anti-1A8 Ly6G (BE0075-1) and
anti-PSGL1 antibody (clone 4RA10) from BioXcell. Anti-CD41 (12-04-11-83)
and anti-CD115 (12-1152-83) were obtained from ebioscience. O.C.T. was
obtained from Tissue-Tek. Qiagen RNeasy Plus Mini Kit (74136). Percoll Plus
(17-5445-02) and Ready-to-go RT-PCR Beads (27-9259-01) from GE Healthcare.
CXCL1 was obtained from (453-KC-010) from R&D Systems. W-peptide
(WKYMVM, 1799) from Tocris. Thioglycolate (BD211716) and anti-GP IIb/IIIa
from BD Biosciences. Anti-GR1 (ab2557) was obtained from Abcam and AF-647
(A-21472) from Molecular Probes. Anti-CD45-FITC from Miltenyi Biotec,
Germany. PC5-conjugated anti-CD14, anti-CD61 PC7 and Versalyse solution were
obtained from Beckman Coulter.
Mouse model of myocardial IR injury. Male 8–12-week-old mice were subjected
to 45min occlusion of the LAD coronary artery followed by 6 or 24 h of
reperfusion. For infarct size evaluation, reperfusion was maintained for 24 h.
For analysis of MVO, neutrophil inﬁltration and neutrophil–platelet interactions,
reperfusion was maintained for 6 or 24 h as indicated. The IR procedure was
performed as previously described54. Brieﬂy, fully asleep animals were intubated
and temperature controlled throughout the experiment at 36.5 C to prevent
hypothermic cardioprotection. Thoracotomy was then performed and the LAD was
ligated with a nylon 8/0 monoﬁlament suture for 45min. The electrocardiogram
was monitored (MP36R, Biopac Systems Inc.) to conﬁrm total coronary artery
occlusion (ST-segment elevation) throughout the 45min ischaemia. Ten minutes
before reperfusion onset, mice were randomized to receive a single i.v. injection
(50 ml) of metoprolol-tartrate (10mM) or vehicle (saline) through the femoral vein.
Dose of metoprolol was chosen after a dose response study (Supplementary Fig. 9).
At the end of reperfusion, the chest was closed and animals were kept with
100% O2 and analgesized with buprenorphine (S.C., 0.1mg per kg) until the
end of reperfusion.
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Figure 7 | Metoprolol inhibits neutrophil–platelet interactions in
patients. (a) Effect of metoprolol on neutrophil–platelet co-aggregate
formation in epinephrine-stimulated whole blood from healthy volunteers
(n¼ 20). Whole blood was incubated in vitro with epinephrine 5 mM and
metroprolol (Meto, concentrations in mM). (b) In vivo effect of metoprolol
(up to15mg i.v.) on the number of neutrophil i.v.platelet co-aggregates in
acute coronary syndrome (ACS) patients scheduled for coronary angio-
plasty. Blood was drawn before and after metoprolol i.v. administration;
n¼ 6 ACS patients. Pre, before i.v. administration; Post, after i.v. admini-
stration. Data are means±s.e.m. *Po0.05; **Po0.01, determined by
one-way ANOVA and Holm Sidak’s post-hoc multiple comparisons method.
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Mouse infarct size quantiﬁcation. At the end of follow up, mice were re-anes-
thetized and re-intubated, and the LAD coronary artery was re-occluded by ligating
the suture in the same position as the original infarction54. Animals were then
killed and rapidly 1ml of 1% (w per v) Evans Blue dye was infused i.v. to delineate
AAR: myocardium lacking blood ﬂow, that is, negative for blue dye staining.
The heart was then harvested, LV was isolated, cut into transverse slices (5–7 1-mm
thick slices per LV) and both sides were imaged. Sections post-Evans blue staining
present two different areas: one palish negative for Evans blue perfusion,
delineating AAR, and another blueish (positive Evans blue) area indicating remote
tissue. In order to differentiate infarcted from viable tissue, same slices were
incubated in triphenyltetrazolium chloride (TTC, 1% (w per v) diluted in PBS) at
37 C for 15min in constant shacking. The slices were then re-photographed and
weighed. Post TTC incubation, Evans blue staining clears out and slices present
two areas: one necrotic (palish negative to TTC staining) and one reddish alive
(positive to TTC staining). Regions negative for Evans Blue staining (AAR) and
for TTC (infarcted myocardium) were quantiﬁed using ImageJ (NIH, Bethesda,
MD, USA) by blinded observer. Percentage values for AAR and infarcted
myocardium were corrected to mg independently for each slice. Absolute AAR and
infarct size were determined as the mg:mg ratio of AAR:LV and infarcted
myocardium:AAR, respectively. Animals exceeding 80% of IS were excluded
assuming absence of reperfusion.
Hearts processing for histology. At the end of reperfusion, LysM-GFP mice were
re-anesthetized, placed in a supine position, their ventral thoracic regions wiped
with 70% alcohol and killed by cervical dislocation. Next, 10ml of PBS with
heparin (50U per ml) was gently infused through the vena cava to avoid blood
clots. Hearts were then removed and cut into 1mm-thick transverse sections and
ﬁxed with 2% PFA in PBS for 24 h at 4 C.
Heart slices (1mm) designated to histopathological analysis of capillary
obliteration were dehydrated through an ethanol series, cleared in xylene,
embedded in parafﬁn wax and consequently sectioned (4 mm) for staining with
haematoxylin and eosin. All immunohistochemical procedures were performed
with an automated autostainer (Autostainer Plus, Dako) at the CNIC Histology
Unit. Images were digitally scanned (Nanozoomer-RS C110730, Hamamatsu) and
examined with image analysis software (Tissuemorph, Visiopharm) by blinded
observers. Once the lesion was identiﬁed, 10–12 images ( 20) were taken at
random, and capillary obliteration was scored from 0 to 2, with 0 indicating the
absence of capillary obliteration and 2 indicating presence of obstruction in all
capillaries.
Confocal microscopy. Sections designated for immunoﬂuorescence staining and
confocal microscopy were post-ﬁxed overnight and placed in 30% sucrose for 24 h
and included in O.C.T. (Tissue-Tek). Serial 4 mm coronal sections were cut on
a freezing microtome (Leica CM1950) and stored in cryoprotective solution.
Sections designated for evaluation of neutrophil inﬁltration of the injured area
were washed in PBS for 15min and incubated with DAPI (1:1,000) at room
temperature for 5min, washed in PBS twice and mounted in Mowiol mounting
medium. Images of full short-axis heart sections were acquired with an inverted
confocal laser imaging system (Zeiss LSM7004 4-Laser) and reconstructed with
Zeiss ZEN reprocessing software. Presence of Lysm-GFPþ cells analysis was
performed with ImageJ (NIH) by blinded observers. Values of total GFPþ surface
were normalized to LV section surface. A second set of sections were stained
with Dylight-650-conjugated anti-1A8 Ly6G and DAPI for quantiﬁcation of
speciﬁc neutrophil identiﬁcation and temporal inﬁltration analysis. Eight
independent 40 were evaluated from injured myocardium from each animal,
and presence of myeloid derived cells (LysMþ ), neutrophils (LysMþ Ly6Gþ )
and monocytes (LysMþ Ly6Gneg) were identiﬁed and analysed using ImageJ
by blinded observers. Four animals were stained for basal quantiﬁcation. Some
sections were stained with anti-laminin to stain cell membranes (1:150) and
anti-a-actinin to visualize sarcomeres in cardiac ﬁbres (1:200) for detailed
illustration of neutrophil inﬁltration in the injured myocardium. Images were
post-processed and edited using the Imaris software (Bitplane AG, Switzerland) as
indicated below.
Neutrophil–platelet interactions staining in infarcted mouse heart was adapted
from Sreeramkumar et al.8. Brieﬂy, OCT-embedded heart slices were cut into
50mm sections, washed in PBS for 15min and incubated for 20min at room
temperature in blocking buffer (PBS containing 10% BSA and 2% goat serum).
For detailed visualization and characterization of the injured zone, cell
membranes were stained with anti-laminin (1:150) and platelets were stained
with PE-conjugated anti-CD41 (1:200). Primary and secondary antibodies were
diluted 1:200 in blocking buffer, and incubations were conducted for 1 h at room
temperature. Nonspeciﬁc staining was assessed by omission of primary antibody.
Samples were counterstained with DAPI and mounted in Mowiol. Images were
acquired with a laser-scanning confocal imaging system (Leica SP8 or SP5) at the
CNIC Microscopy Unit and post-processed with Leica Las AF and Imaris software
(Bitplane AG, Switzerland). Independent vessels (7–9) were evaluated for each
animal, and intravascular neutrophil and neutrophil–platelet interactions were
scored manually.
Neutrophil puriﬁcation and Adrb1 expression. Adrb1 expression in circulating
neutrophils was examined in blood drawn from wild-type or Adrb1KO mice
20min after injection of heparin (50 ml of 50U per ml). Whole blood was
ﬁltered and pooled, and polymorphonuclear leukocytes were puriﬁed by
gradient-centrifugation (800g, 20min, 4 C) in 65% Percoll Plus in Hanks balanced
salt solution (HBSS). Cells were washed in PBS and residual erythrocytes were
lysed using hypotonic buffer. Neutrophils were washed and resuspended in HBSS.
Before RNA isolation, neutrophil identity was conﬁrmed by ﬂow cytometry
(anti-1A8 Ly6G) and viability evaluated.
Total RNA from whole hearts, BM and puriﬁed neutrophils samples was
isolated with the Qiagen RNeasy Plus Mini Kit. RNA (1–2 mg) was reverse
transcribed using Ready-to-go RT–PCR Beads (27-9259-01, GE Healthcare).
PCR was performed with 40 cycles of 95 C for 12 s and 60 C for 1min. All PCR
reactions were done in triplicate. Primers for Hprt and Adrb1 were as follows:
mHprt_fw-50-GAGGAGTCCTGTTGATGTTGCCAG-30 , mHprt_rv-50-GGCTGG
CCTATAGGCTCATAGTGC-30 ; mAdrb1_fw-50-GTGGGTAACGTGCTG
GTGAT-30 , mAdrb1_rv-50-GAAGTCCAGAGCTCGCAGAA-30 . Amplicons
generated in the qPCR were loaded on to an agarose gel to conﬁrm single
PCR products.
Migration transwell assay. The ability of leukocytes to migrate towards
chemokine (C-X-C motif) ligand 1 (CXCL1) was assessed using a modiﬁcation of
the method of Villablanca et al.55. Brieﬂy, wild-type or Adrb1KO mice were
heparinized (50ml of 50U per ml, IP) and 20min later blood was collected and
ﬁltered, and residual erythrocytes were lysed with hypotonic buffer. PBS-washed
leukocytes of the same genotype were pooled and resuspended in RPMI containing
10% FBS and the appropriate treatment: saline (vehicle control), 10 mM
epinephrine (positive control), 10 mM metoprolol-tartrate, or a combination
of epinephrine and metoprolol. Transwell inserts (6.5mm, 5.0 mm pore size
(3421; Corning Costar Corporation)) were pretreated with 50 ml RPMI for 20min
and placed in 24-well-plates before seeding cells (100 ml; B1 105; 490%
viability). Lower compartments (wells) were ﬁlled with 600 ml DMEM medium
containing 0.04 ng per ml CXCL1 to induce directional movement. Spontaneous
migration was assessed in wells lacking CXCL1. After incubation at 37 C for 1.5 h,
cells in the lower compartment were collected and neutrophils (Ly6Gþ cells) were
evaluated by ﬂow cytometry. Each independent experiment was conducted with
leukocytes pooled from nine animals, and each of the ﬁve conditions was run with
four replicates. Mean spontaneous migration was subtracted from the migration
value of each well, and neutrophil migration was expressed as a percentage of
the total number of neutrophils seeded in the upper chamber at the start of the
experiment. For comparison between experiments and genotypes, migration was
normalized to the mean control (vehicle) value.
Neutrophil oxidative burst assay. Blood from wild-type or Adrb1KO mice was
collected in heparinized tubes and distributed in 100 ml aliquots, erythrocytes were
lysed with hypotonic buffer. After centrifugation leucocytes were ﬁrst washed and
then re-suspended in high glucose phenol red free DMEM. Cells were then
incubated for 50min with or without metoprolol-tartrate 100 mM at 37 C.
As previously described30,31, dihydrorhodamine 123 (DHR 123, 1 mM), which
converts to the ﬂuorescent product rhodamine 123 (Rho 123) upon oxidation
was then added to the medium and cells were stimulated with the chemotactic FPR
activator-peptide, w-peptide 1 mM (WKYMVM, 1799 Tocris). After 20min
incubation at 37 C the reaction was stopped in ice and cells were washed in cold
HBSS containing DAPI 0.1 mg per ml (D8417, Sigma). Mean ﬂuorescent intensity
for Rho 123 was evaluated for neutrophils (Ly6Gþ cells) alive (DAPIneg) by ﬂow
cytometry.
Model of thioglycolate-induced peritonitis. To assess the ability of metoprolol to
inhibit neutrophil recruitment, we used a well-established thioglycolate-induced
peritonitis model (see Fig. 3). Wild-type mice were intraperitoneally injected with
1ml of thioglycolate and immediately randomized to receive a single 50 ml i.v.
injection of vehicle or metoprolol-tartrate (10mM). Sixteen hours later, 100 ml of
blood from each animal was collected into EDTA tubes for later haematological
analysis in a haematocytometer (Pentra 80). Next, animals were killed, 2ml PBS
was injected intraperitoneally and distributed manually for 30 s to detach inﬁltrated
circulatory cells. Next, another 8ml PBS was injected to facilitate collection of
6ml peritoneal exudate. Exudates were gently centrifuged, and cells were washed
twice with PBS and incubated for 1 h with anti-GR1 (1:200) and PE-conjugated
anti-CD115 (1:200). After washing with PBS, cells were incubated for 30min
with anti-rat 647 to detect GR1. Cell nuclei were stained with DAPI. All samples
were analysed by ﬂow cytometry for exactly 30 s of constant ﬂow. Neutrophil
recruitment efﬁciencies are presented as neutrophils per ml of exudate for each
independent animal.
To evaluate the role of ADRB1 in different compartments, we performed the
same experiments in Adrb1KO mice and generated cohorts of chimeric mice by
transplantation with BM cells from wild-type and Adrb1KO donors. Four weeks
after BM transplantation, chimerism was evaluated by ﬂow cytometry as the
percentage of donated cells. Animals with chimerism below 85% were discarded;
those with chimerism above 85% underwent the thioglycolate-induced peritonitis
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protocol followed by randomization to receive either i.v. vehicle or metoprolol
(10mM). To compare between the different chimeric groups, the mean value for
each metoprolol-treated group was normalized to the mean for the vehicle-treated
group.
Bone marrow transplant. BM transplants protocols were adapted from
Casanova et al.28. Recipient mice from Adrb1KO or wild-type genotypes
(DsRedþ or DsRed- as appropriate) were lethally irradiated (13Gy in two doses)
before reconstitution with donor BM. Donor BM was collected from mice of the
appropriate genotype by ﬂushing both tibiae and femurs into PBS containing 2mM
EDTA (PEB buffer). Contaminating erythrocytes were lysed with hypotonic buffer.
Engraftment in recipient animals was assessed by ﬂow cytometry 3–4 weeks after
transplantation. Animals bled for engraftment evaluations were rested for 1 week
before any other procedure.
Flow cytometry. Neutrophil purity for in vitro migration assay and Adrb1
expression analysis was evaluated by incubating cells with Dylight-650-conjugated
anti-1A8 Ly6G and with DAPI to assess viability. Mouse primary blood leukocytes
from peritonitis experiments were incubated with anti-Gr1 conjugated with
AF-647 and with PE-conjugated anti-CD115 and DAPI. Neutrophils were gated on
the basis of Gr1-positive and CD115-negative staining in a FACS Canto-3L ﬂow
cytometre equipped with DIVA software (BD Biosciences). Doublet discrimination
and viability (negative to DAPI) was assessed for every sample. Data were analysed
with FlowJo (Ashland) software by blinded observer. All experiments were
conducted at the CNIC-Cellomics Unit.
Intravital microscopy. IVM of the cremaster muscle was performed after
intrascrotal injection of TNFa (0.5mg R&D Systems)8, followed immediately by
injection of a single i.v. bolus of metoprolol (10mM) or vehicle, and neutrophil
behaviour was evaluated 3 h after stimulus. In some experiments metoprolol was
injected 3 h after treatment with TNF-a and images immediately acquired for
analysis (see Fig. 4). The IVM system was built by 3i (Intelligent Imaging
Innovations, Denver, CO, USA) on an Axio Examiner Z.1 workstation
(Zeiss, Oberkochen, Germany) mounted on a 3-Dimensional Motorized Stage
(Sutter Instrument, Novato, CA, USA). This set up allows precise computer-
controlled lateral movement between XY positions and a Z focusing drive for
confocal acquisition. The microscope is equipped with a CoolLED pE wideﬁeld
ﬂuorescence LED light source system (CoolLED Ltd. UK) and a quad pass ﬁlter
cube with a Semrock Di01-R405/488/561/635 dichroic and a FF01-446/523/600/
677 emitter. We used a plan-Apochromat  40 W NA1.0N/0 objective (Zeiss).
Images were collected with a CoolSnap HQ2 camera (6.45 6.45-mm pixels,
1,392 1,040 pixel format; Photometrics, Tucson, AZ, USA). For confocal
high-speed IVM, we used laser stacks for 488, 561 and 640 nm beams coupled with
a confocal scanner (Yokogawa CSUX-A1; Yokogawa, Japan); images were acquired
at 0.5 mm Z-intervals. Image acquisition was coordinated and ofﬂine data
analysis facilitated with SlideBook software (Intelligent Imaging Innovations),
run on a Dell Precision T7500 computer (Dell Inc., Round Rock, TX, USA). For
three-dimensional analysis we used the 3D surface view function to determine the
position of the CD62Lþ clusters relative to the cell body and the lumen. Six to ten
venules per mouse were analysed 210 to 300min after TNF-a treatment by
acquisition of ﬂuorescence (Cy3/561 channels for phycoerythirn, FITC/488
channels for FITC and Cy5/640 channels for allophycocianin) and bright-ﬁeld
images with 2 2 for 2min. For double staining with PE- and FITC-conjugated
antibodies, acquisition was facilitated in single (FITC) and quad (PE) ﬁlters in
order to avoid bleed-through of ﬂuorescent signals between channels. For in vivo
labelling of neutrophils and platelets surface molecules, ﬂuorescently labelled
antibodies were injected intravenously (anti-CD62L-FITC, anti-Ly6G-APC and
anti-CD41-PE; 0.5–1.25 mg per mouse). Images were post-processed and edited
using the Imaris software (Bitplane AG, Switzerland) as indicated below.
Analysis of blood cell interactions. Platelets in the inﬂamed cremaster muscle
were visualized as CD41-labelled cells and quantiﬁed as reported8. Brieﬂy, we
deﬁned the uropod of adherent neutrophils as the domain staining positive for
CD62L, and the leading edge as the CD62L-negative pole forming multiple
protrusions and showing guided movement. Six to ten venules per mouse were
recorded, and platelet interactions with neutrophils were counted and analysed
manually at the two distinct domains of the polarized neutrophil with the help of
Slidebook software.
Analysis of tracking of crawling neutrophils. Time-lapse movies of crawling
neutrophils were analysed with ImageJ, which includes the Manual Tracking and
the Chemotaxis and Migration Tool plugins. For each movie we ﬁrst adjusted
channel intensities and converted them into RGB format. Movies were rotated so
that the vessels and the blood ﬂow were positioned horizontally and oriented
left-right. When necessary, the Background subtraction and Image stabilization
pre-stablished plugins were applied to eliminate noise and reduce tissue twitching,
respectively. Both plugins were set up with xy calibration values, which depend on
the camera and microscope parameters, to convert pixels into linear measures, as
well as the time interval value between movie frames (3 s). Each polarized
neutrophil (identiﬁed by a clear polarized morphology or uropod staining) was
tracked manually for 1min using the Manual Tracking Plugin, which generated a
data set with the respective xy track coordinates. We then used the Chemotaxis and
Migration Tool to plot and the velocity (mm per s), accumulated distance (mm),
euclidean distance (mm) and directionality of the tracks obtained. The Euclidean
distance is the length of the straight-line segment connecting the initial and
ﬁnishing points, whereas the accumulated distance is the total length of the path
covered by the cell. Directionality measures how straight the cell track is, and is
calculated as the ratio of euclidean distance to accumulated distance.
Analysis of 3D reconstructions of polarized neutrophils. We measured the 3D
features of intravascular neutrophils using Imaris Software (Bitplane, Oxford, UK).
From the parameters provided by the ImarisCell module, we selected prolate
ellipticity by obtaining the lengths of the three semi-axes, which correspond with
the Ellipsoid axis parameters. A prolate ellipsoid (cigar-like shape) is one for which
the polar radius is greater than the equatorial radius. For 3D cell reconstructions,
we used the ImarisCell module to deﬁne the cell body. We then segmented a region
of interest to enclose an individual cell within this region, so that the subsequent
reconstruction ﬁtted the real cell structure. Afterwards, the respective source
channel from which the cells had to be computed was selected. For reconstruction
analysis, we chose the Ly6G-APC channel as it is a membrane-bound protein that
yields a strong signal and allows a good rendering of the actual cell morphology.
ImarisCell module determines the cell threshold by calculating voxel (3D pixel)
intensities from the enclosed cell and comparing them with the background
intensity in the enclosed sub-region. To obtain the height-to-length ratios, we
visually established the cell orientation with respect to the vessel wall surface.
Sections of each polarized neutrophil were analysed to manually measure the
height of the cell and maximum length (from the top view) with respect to the
vessel wall. For this purpose, we used Imaris Section View, which shows the
coordinates in the three display areas (xy top view, zy lateral view and xz front
view), and the Extended Crosshairs of the Section View, which in turn allows
selection of the z-stack planes to visualize the entire cell (not just one plane or
section) in the three views. A snapshot of these three views from a single cell
was taken and imported into ImageJ, where height and maximum length were
measured from the different views after setting the capture scale.
Human blood sampling. Functional tests were performed in blood samples from
20 volunteers (36±6 years, 15 men). Exclusion criteria were as follows: any
antiplatelet, anticoagulant or anti-inﬂammatory drug taken within the 2 previous
weeks; abnormal platelet or leukocyte count; or any history of abnormal bleeding,
thrombosis, or active inﬂammatory disease. Written consent was obtained from all
volunteers. Blood samples were collected into polypropylene tubes containing
sodium citrate from an antecubital vein with a 21-gauge needle, discarding the ﬁrst
2ml to avoid platelet activation. Blood was collected between 8:00 and 10:00 after
overnight fasting. Samples were processed immediately. ACS patients were
recruited at our cath-lab (both genders, age o80) from among those referred for
coronary angiogram and subsequent percutaneous coronary intervention. Exclu-
sion criteria were as follows: active treatment with b-blockers; any situation which
might make it imprudent to administer an i.v.-b-blocker; asthma or chronic
obstructive lung disease; bradycardio (HR o55 b.p.m.); heart failure or valvular
heart disease; atrial ﬁbrillation requiring antiarrhythmic therapy; renal failure with
creatinineZ2mg per ml; liver disease with bilirubinZ2mg per ml; acute illness of
any malignancy; pregnancy or nursing; body mass index Z27 kg per m2; previous
severe adverse reaction to b-blockers; concomitant use of other antithrombotic
drugs such as anticoagulants, dypiridamol, ticlopidine or cilostazol; treatment
before the intervention with GP IIb/IIIa inhibitors, or need for nonsteroid
anti-inﬂammatory drugs. Written informed consent was obtained from all patients
enrolled. Blood samples were collected from a femoral artery catheter into
polypropylene tubes containing sodium citrate, discarding the ﬁrst 2ml. Samples
were processed immediately.
Human neutrophil–platelet interactions evaluation. Human citrated blood was
diluted 1:5 in HEPES-Tyrode’s* (5mM hydroxyethylpiperazineethane-sulfonic
acid (HEPES), 137mM NaCl, 2.7mM NaHCO3, 0.36mM NaH2PO4, 2mM
NaH2PO4, 2mM CaCl2, 5mM glucose, bovine albumin 0.2%. pH¼ 7.4) and
incubated with 0, 2 or 5 mM metoprolol for 10min. Then, 5ml of diluted blood
was incubated with 5 mM epinephrine for 10min. Unstimulated and epinephrine-
stimulated samples were stained with PC5-conjugated anti-CD14 anti CD45-FITC
and anti-CD61 PC7 for 20min at room temperature in the dark. Erythrocytes were
lysed for 10min using Versalyse solution. Appropriate mouse isotype controls were
used for each antibody. Flow cytometry analysis was performed with a Gallios
cytometer (Beckman Coulter, Miami, FL, USA). Leukocytes were by CD45-FITC
staining. Neutrophils identiﬁcation was adapted from refs 34,35 and performed by
morphological parameters (side scatter) and negative staining for CD14-PC5 but
positive staining for CD45-FITC. Neutrophil–platelet conjugates were identiﬁed as
bivariate histogram particles negative for CD14-PC5 and positive to CD61-PC7
(refs 36,37). The acquisition process was stopped after collection of 5,000
monocytes. Data are expressed as the percentage of neutrophil–platelet aggregates.
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All experiments were conducted at the Hospital Universitario Clı´nico San Carlos,
Madrid.
Human platelet function evaluation. Platelet aggregation was assessed using light
transmittance aggregometry in PRP by the turbidimetric method in a four-channel
aggregometer (Chrono-Log 490 Model, Chrono-Log Corp., Havertown, PA, USA)
according to standard protocols. The PRP was obtained from citrated blood at
centrifuge (800 r.p.m.) for 10min and platelet-poor plasma was obtained after
a second centrifugation (2,500 r.p.m.) for 10min. PRP will be adjusted to 250,000
per ml with autologous plasma. PRP was incubated with metoprolol 2 and 5 mM or
saline buffer for 15min and then stimulated using epinephrine (5 mM). Light
transmission was adjusted to 0% with PRP and to 100% with platelet-poor plasma
for each measurement. Curves were recorded during 5min and platelet aggregation
was determined as the maximal percent change in light transmittance.
Platelet function was determined by assessing platelet activation as surface
expression of activated GP IIb/IIIa (Becton Dickinson) and P-Selectin using
ﬂow cytometry. Whole blood from healthy donors were drawn into trisodium
citrate tubes diluted with Hepes-tyrodes-buffer (0.2% BSA) to a ﬁnal volume of
1:8:1 (blood: Hepes-tyrodes:citrate). Diluted blood was incubated with metoprolol
2 and 5 mM or saline for 15min. Following activation with epinephrine (5 mM)
samples were incubated for 20min with polyclonal PAC1-FITC conjugated or
PE-conjugated anti-CD62P. Appropriate isotype controls were used in each case.
Platelet activation was expressed as the percentage of platelets positive for antibody
binding. Platelets were gated on the basis of light scatter and CD61 antibody
expression. Activated platelets were deﬁned as the percentage of expressing
the activated conﬁrmation of PAC1 binding and P-selectin (CD62P). Data
were expressed as the percentage of platelets positive for antibody binding.
All experiments were conducted at the Hospital Universitario Clı´nico San Carlos,
Madrid.
Statistics. Data are represented as mean±s.e. of the mean (s.e.m.), and analysed
using Prism software (Graph pad, Inc.) and Stata (Stata 12.0; StataCorp LP,
College Station, TX, USA). Comparisons between two groups were performed
by using the unpaired two-tailed Student’s t-test or the nonparametric
Wilcoxon–Mann–Whitney test as appropriate. Comparisons between more than
two groups were performed by using the one-way ANOVA. The P-value was
adjusted with the Holm Sidak’s multiple comparison test. Multiple linear regression
analysis was used to study the inﬂuence of metoprolol on MVO, adjusted for
factors potentially affecting MVO such as sex, age, ischaemia duration, diabetes,
use of thrombectomy or glycoprotein IIb/IIIa inhibitors. Test for linear trend after
one-way ANOVA was used to study the relationship between LVEF at 6 months
and MVO quartiles at 1 week. Power calculations were applied to obtain
statistically signiﬁcant at P values below 0.05 signiﬁcant. *Po0.05, **Po0.01,
***Po0.001.
Study approval. All studies in patients and volunteers were approved by the ethics
committee of Hospital Clı´nico San Carlos, Madrid. Written informed consent was
received from all participants before inclusion in the study.
Data availability. The data that support the conclusions of this study are available
from the corresponding author on reasonable request.
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HEART MITOCHONDRIA
Imbalanced OPA1 processing and
mitochondrial fragmentation cause
heart failure in mice
Timothy Wai, Jaime García-Prieto, Michael J. Baker, Carsten Merkwirth, Paule Benit,
Pierre Rustin, Francisco Javier Rupérez, Coral Barbas, Borja Ibañez,* Thomas Langer*
INTRODUCTION:Mitochondria are essential
organelles whose form and function are in-
extricably linked. Balanced fusion and fission
events shape mitochondria to meet metabolic
demands and to ensure removal of damaged
organelles. A fragmentation of the mitochon-
drial network occurs in response to cellular
stress and is observed in a wide variety of
disease conditions, including heart failure,
neurodegenerative disorders, cancer, and obe-
sity. However, the physiological relevance of
stress-induced mitochondrial fragmentation re-
mains unclear.
RATIONALE: Proteolytic processing of the
dynamin-like guanosine triphosphatase (GTPase)
OPA1 in the inner membrane of mitochondria is
emerging as a critical regulatory step to balance
mitochondrial fusion and fission. Twomitochon-
drial proteases, OMA1 and the AAA protease
YME1L, cleaveOPA1 from long (L-OPA1) to short
(S-OPA1) forms. L-OPA1 is required for mito-
chondrial fusion, but S-OPA1 is not, although ac-
cumulationof S-OPA1 inexcess accelerates fission.
In cultured mammalian cells, stress conditions
activateOMA1,which cleavesL-OPA1and inhibits
mitochondrial fusion resulting in mitochondrial
fragmentation. In this study, we generated con-
ditional mouse models for both YME1L and
OMA1 and examined the role of OPA1 pro-
cessing and mitochondrial fragmentation in
the heart, ametabolically demanding organ that
depends critically on mitochondrial functions.
RESULTS: Deletion of Yme1l in cardiomyo-
cytes did not grossly affect mitochondrial
respiration but induced the proteolytic cleav-
age of OPA1 by the stress-activated peptidase
OMA1 and drove fragmentation of mitochon-
dria in vivo. These mice suffered from dilated
cardiomyopathy characterized bywell-established
features of heart failure that include necrotic cell
death, fibrosis and ventricular remodelling,
and a metabolic switch away from fatty acid
oxidation and toward glucose use. We dis-
covered that additional deletion of Oma1 in
cardiomyocytes prevented OPA1 processing
altogether and restored
normalmitochondrialmor-
phology and cardiac health.
On the other hand, mice
lacking YME1L in both
skeletalmuscle and cardio-
myocytes exhibited normal
cardiac function and life span despite mitochon-
drial fragmentation in cardiomyocytes. Im-
balanced OPA1 processing in skeletal muscle,
which is an insulin signaling tissue, induced
systemic glucose intolerance and prevented
cardiac glucose overload and cardiomyopathy.
We observed a similar effect on cardiac meta-
bolism upon feeding mice lacking Yme1l in
cardiomyocytes a high-fat diet, which pre-
served heart function despite mitochondrial
fragmentation.
CONCLUSION: Our work highlights the im-
portance of balanced fusion and fission of
mitochondria for cardiac function and un-
ravels an intriguing link between mitochon-
drial dynamics and cardiac metabolism in
the adult heart in vivo. Mitochondrial fusion
mediated by L-OPA1 preserves cardiac func-
tion, whereas its stress-induced processing
by OMA1 and mitochondrial fragmentation
triggers dilated cardiomyopathy and heart
failure. In contrast to previous genetic mod-
els of the mitochondrial fusion machinery,
mice lacking Yme1l in cardiomyocytes do not
show pleiotropic respiratory deficiencies and
thus provide a tool to directly assess the
physiological importance of mitochondrial dy-
namics. Preventing mitochondrial fragmen-
tation by deleting Oma1 protects against cell
death and heart failure. The identification of
OMA1 as a critical regulator of mitochondrial
morphology and cardiomyocyte survival holds
promise for translational applications in car-
diovascular medicine. Mitochondrial fragmen-
tation induces a metabolic switch from fatty
acid to glucose utilization in the heart. It turns
out that reversing this switch and restoring
normal cardiac metabolism is sufficient to
preserve heart function despite mitochondrial
fragmentation. These findings raise the in-
triguing possibility that the switch in fuel
usage that occurs in the failing adult heart
may, in fact, be maladaptive and could con-
tribute to the pathogenesis of heart failure.▪
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Critical role of balanced mitochondrial fusion and fission for cardiac metabolism and
heart function. Induced processing of the dynamin-like GTPase OPA1 in the inner membrane
by the stress-activated peptidase OMA1 leads to mitochondrial fragmentation, cardiomyopathy
and heart failure, which is characterized by a switch in fuel utilization. Heart function can be
preserved by reversing this metabolic switch without suppressing mitochondrial fragmentation.
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HEART MITOCHONDRIA
Imbalanced OPA1 processing and
mitochondrial fragmentation cause
heart failure in mice
Timothy Wai,1,2* Jaime García-Prieto,3* Michael J. Baker,1 Carsten Merkwirth,1
Paule Benit,4,5 Pierre Rustin,4,5 Francisco Javier Rupérez,6 Coral Barbas,6
Borja Ibañez,3,7† Thomas Langer1,2,8,9†
Mitochondrial morphology is shaped by fusion and division of their membranes. Here, we found
that adult myocardial function depends on balancedmitochondrial fusion and fission, maintained
by processing of the dynamin-like guanosine triphosphatase OPA1 by the mitochondrial
peptidases YME1L and OMA1. Cardiac-specific ablation of Yme1l in mice activated OMA1 and
accelerated OPA1 proteolysis, which triggered mitochondrial fragmentation and altered cardiac
metabolism.This caused dilated cardiomyopathy and heart failure. Cardiac function and
mitochondrial morphology were rescued by Oma1 deletion, which prevented OPA1 cleavage.
Feedingmice a high-fat diet or ablating Yme1l in skeletal muscle restored cardiacmetabolism and
preserved heart function without suppressing mitochondrial fragmentation.Thus, unprocessed
OPA1 is sufficient tomaintain heart function,OMA1 is a critical regulatorof cardiomyocyte survival,
and mitochondrial morphology and cardiac metabolism are intimately linked.
T
he dynamic behavior of mitochondria pre-
serves mitochondrial integrity and distri-
bution and allows mitochondrial shape
and function to be adapted to alteredphysio-
logical demands (1, 2). Disturbed mitochon-
drial dynamics is associated with a number of
neurodegenerative disorders and cardiac hyper-
trophy in mice (3, 4). Dynamin-like guanosine
triphosphatases (GTPases) mediate the fusion
and fission of mitochondrial membranes. Mito-
fusins 1 and 2 (MFN1 and MFN2) orchestrate
outer mitochondrial membrane fusion, whereas
OPA1 is required for inner mitochondrial mem-
brane fusion. Fission, on the other hand, is ex-
ecuted by dynamin-related protein 1 (DRP1), a
cytosolic protein that is recruited to the mito-
chondrial surface in response to various physio-
logical cues. This complex machinery, including
DRP1-specific receptor proteins and cytoskeletal
components, assembles at contact sites between
themitochondria and the endoplasmic reticulum,
which mark mitochondrial division sites (5, 6).
Fusion and fission ofmitochondrialmembranes
occur in a coordinated manner. Balanced cycles
of fusion and fission determine the shape, size,
and number of mitochondria, which leads to a
large variability in themorphologyofmitochondria
in different cell types. Although mitochondria
form interconnected, tubular networks in cultured
fibroblasts, they appear as distinct entities in
tissues, such as heart and skeletal muscle, that
are characterized by low fusion and fission rates
(7).Moreover, coordinatedmitochondrial dynamics
is critical for thebioenergetic functionofmitochon-
dria and is closely linked to metabolism. Changes
inmitochondrial ultrastructure anddynamics occur
in response to altered metabolic demands (8–11),
and components involved inmitochondrial fusion
are central regulators of cellularmetabolism (12).
Coordinated fusion and fission events are crucial
for mitochondrial quality-control. Fusion con-
tributes to mitochondrial maintenance, whereas
excessive fission causes mitochondrial fragmen-
tation, which allows removal of irreversibly dam-
agedmitochondria bymitophagy and is associated
with cell death (13, 14). Fragmentation of the
mitochondrial network is observed in a wide
variety of diseases.
The dynamin-like GTPaseOPA1mediatesmito-
chondrial fusion and orchestrates mitochondrial
cristae morphogenesis and resistance to apopto-
sis in response to physiological demands (15–17).
The processing of OPA1 is emerging as a central
regulatory step coordinating fusion and fission of
mitochondria (18, 19). Two peptidases in the
inner membrane, OMA1 and the i-AAA protease
YME1L, convert long OPA1 forms (L-OPA1) into
short forms (S-OPA1) (20–23). The balanced ac-
cumulation of both formsmaintains normalmito-
chondrialmorphology: Fusion depends on L-OPA1
only, whereas S-OPA1 is associated with mito-
chondrial fission (Fig. 1A) (24–26). Cellular stress,
mitochondrial dysfunction, orgenetic interventions
(such as deletion of Yme1l) can activate OMA1,
which results in the increased conversionofL-OPA1
into S-OPA1 and mitochondrial fragmentation
(25, 27–30). Loss of Yme1l in cultured fibroblasts
does not impair fusion but triggers mitochondrial
fragmentation (22, 25, 31), which can be suppressed
by deletion of Oma1 (22, 25, 31). Thus, although
OPA1 processing is dispensable for mitochon-
drial fusion per se, an increased oxidative phos-
phorylation promotes cleavage ofOPA1 by YME1L
(10). It thus appears that different stimuli modu-
late OPA1 processing by YME1L or OMA1, which
allows the coordination of mitochondrial fusion
anddivisionunder variousphysiological conditions.
In agreement with its role for stress-induced
OPA1 processing, ablation ofOma1 inmice causes
impaired thermogenesis and diet-induced obesity
andprotects against ischemickidney injury (29, 32).
Here, we generated tissue-specific mouse mod-
els for theOPA1-processing peptidases YME1L and
OMA1 and examined the role of OPA1 process-
ing in myocardial function.
Results
YME1L is essential for
embryonic development
To study the importance of balancedmitochondrial
dynamics (Fig. 1A), we generated conditional
mousemodels of the OPA1-processing peptidases
Yme1l andOma1 (fig. S1, A to D, and table S1).We
used a mouse line expressing Cre recombinase
under the control of the b-actin promoter to de-
lete Yme1l or Oma1 by Cre/loxP-mediated re-
combination in all tissues. As expected (29),
Oma1–/–micewere born at the expectedMendelian
ratio (fig. S1E). Yme1l+/–mice were viable and ex-
hibited no obvious phenotypes, but heterozygous
intercrosses did not yield viable null offspring
(Fig. 1B). We observed a generalized develop-
mental delay in Yme1l–/– embryos isolated from
embryonic day 8.5 (E8.5) to E12.5 (Fig. 1C). Hearts
from Yme1l–/– embryos isolated at E9.5 and E10.5
failed to beat properly, andwe did not recover any
null embryos after E13.5. Thus, YME1L is essential
for embryogenesis.
Cardiomyocyte-specific deletion of
Yme1l causes dilated cardiomyopathy
Wenext examined the requirement of YME1L for
the functionof theheart, ametabolicallydemanding
organ sensitive todisruptionofmitochondrial shape
(7, 33). We crossed Yme1lLoxP/LoxP mice to mice
expressing Cre recombinase specifically in cardio-
myocytes (Myh6-Cre; cYKO) (34). cYKO mice
were viable but had a significantly shortened
life span (median life span: 46 weeks) (Fig. 1, D
and E) punctuated by weight loss before their
demise (Fig. 1F), which suggested that YME1L
is required for normal heart function.
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We examined heart function from an early age
up to 40 weeks of age in cYKO mice (Fig. 2A).
Longitudinal echocardiographic (echo) analyses
(fig. S2A) revealed progressive cardiac dysfunction
(table S2), which became apparent at 20 weeks
and was characterized by hallmarks of dilated
cardiomyopathy (DCM): a reduced percentage
of LVEF (%LVEF) (Fig. 2B and fig. S2A), a dilated
left ventricular chamber (Fig. 2C), and a preserved
left ventricularmass (fig. S2B).We observedmyo-
cardial fibrosis (Fig. 2D), increased serum levels
of cardiac troponin T (Fig. 2E), and evidence of
ongoing necrotic cell death (Fig. 2, F and G) in
cYKO mice.
The failing adult heart is commonly charac-
terized by an altered metabolism where glucose
use is increased and b oxidation is decreased
(35, 36). We monitored in vivo cardiac uptake of
18fluorodeoxyglucose ([18F]FDG) in cYKOmice by
hybrid positron emission tomography–computed
tomography (PET-CT). The loss of YME1L in
cardiomyocytes caused an increase in in vivo
cardiac glucose uptake (Fig. 2, H and I) and in vitro
glycolysis rates (fig. S2C). Gas chromatography–
mass spectrometry analyses revealed increased
endogenous glucose levels and decreased lac-
tate levels in cYKO hearts, whereas the levels of
citric acid cycle intermediates were not altered
(fig. S2D) nor were the levels and use of pyr-
uvate (fig. S2E). However, we observed a global
reduction of total cardiac acylcarnitines (fig.
S2F), which indicated reduced b oxidation in
YME1L-deficient cardiomyocytes. Thus, loss of
YME1L in cardiomyocyte mitochondria can in-
duce a metabolic shift from lipid utilization to
carbohydrate utilization that is typically observed
in the failing heart (37). In conclusion, cYKOmice
develop DCM, which progresses to heart failure
and middle-aged death.
Loss of YME1L impairs mitochondrial
morphology in cardiomyocytes
To define the molecular basis of DCM in cYKO
mice, we first analyzedmitochondrial respiration.
Ex vivo cardiac respirationmeasurements revealed
no differences between resting hearts isolated
from cYKOmice and controls (Fig. 3A). Specific
activities of mitochondrial complexes II, III,
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Fig. 1. YME1L is required in the developing embryo and the adult heart.
(A) The mitochondrial proteases OMA1 and YME1L cleave L-OPA1 (a and b) at
S1 and S2, respectively, to yield S-OPA1 forms (c, d, and e). (B) No viable
Yme1l–/– mice were recovered from intercrosses of Yme1l+/– mice (0 out of
289 offspring). Chi-squared test, ****P < 0.0001. (C) Postimplantation de-
velopmental delay of Yme1l–/– embryos scaled relative to WT. Scale bar, 2 mm.
(D) Life span of cardiomyocyte-specific cYKO mice (Myh6-Cre red; median
of 46 weeks, n = 69) is reduced relative to WT littermates (green; n = 74).
Log-rank (Mantel-Cox) test, ****P < 0.0001. (E) Immunoblots of tissues
isolated from 18-week-old WT and cYKO mice. Antibodies directed against
succinate dehydrogenase subunit A (SDHA) were used to control for gel
loading. (F) Mean body weight (g) of cYKO males (red; n = 30) declines rel-
ative to WT (green; n = 30). Multiple t test, *P < 0.05, ****P < 0.0001. Data
are means ± SEM.
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and IV were increased, although we observed
onlymoderately impaired adenosine 5′-triphosphate
(ATP) synthesis by complex V in cYKO hearts (Fig.
3B) and no significant differences in the assembly
of respiratory chain complexes and supercom-
plexes (fig. S3A). Respiratory deficiencies thus
appeared unlikely to be themajor cause for DCM
in cYKO mice.
We next examined themorphology ofmitochon-
dria and performed transmission electron mi-
croscopy (TEM) of cYKO hearts (Fig. 3C). Smaller
mitochondria with normal architecture of cristae
accumulated in the absence of YME1L, which
indicated impaired mitochondrial dynamics (Fig.
3, C and D). Similar results were seen in primary
adult cardiomyocytes isolated from 8-week-old
(before DCM development) and 40-week-old
cYKO hearts (Fig. 3, E and F, and fig. S3B). Con-
sistent with our TEM data, we observed dis-
torted mitochondrial morphology in Yme1l–/–
cardiomyocytes, as seen previously in noncar-
diac cell types lacking YME1L (20, 22, 25). Loss of
YME1L in cardiomyocytes abolished formation
of S-OPA1 form d and led to the accumulation
of S-OPA1 forms c and e, which are generated
by OMA1 (Fig. 3, G and H). Moreover, the mito-
chondrial lipid transfer protein PRELID1, nor-
mally degraded by YME1L, accumulated (Fig.
3G) (38). Notably, Yme1l is specifically deleted
in cardiomyocytes and was not lost in cardiac
fibroblasts isolated from cYKO mice. However,
in vitro deletion of Yme1l in adult cardiac fibro-
blasts did recapitulate fragmentation of the
mitochondrial network (fig. S3, C and D) and
impaired OPA1 processing (fig. S3E) as observed
in Yme1l–/– cardiomyocytes. Thus, YME1L defi-
ciency in cardiomyocytes induces OPA1 process-
ing and mitochondrial fragmentation, which
raises the possibility that disturbed mitochon-
drial morphology could cause heart failure in
cYKO mice.
Deletion of Oma1 restores mitochondrial
morphology and myocardial function in
the absence of YME1L
The accumulation of OPA1 forms c and e in cardio-
myocytes lacking YME1L indicated activation
of OMA1, as previously observed in YME1L-
deficient mouse embryonic fibroblasts (MEFs)
in vitro (25). Because additional deletion ofOma1
in Yme1l–/–MEFs restores tubular mitochondria
and apoptotic resistance (25), we reasoned that
ablation ofOma1maypreserve themitochondrial
network in cardiomyocytes lacking YME1L. To
examine the role of disturbed mitochondrial
morphology in DCM and heart failure in cYKO
mice, we generated double-knockoutmice lacking
both YME1L and OMA1 specifically in cardio-
myocytes (cDKO; Myh6-Cretg/wtYme1lLoxP/LoxP
Oma1LoxP/LoxP) and monitored heart function
(Fig. 4A). In contrast to cYKOmice, cDKOmice
showed normal cardiac function and normal
exercise tolerance in treadmill tests (Fig. 4, B to
D). Myocardial fibrosis present in cYKO mice
(Fig. 2E) was absent in cDKO hearts (Fig. 4E).
Moreover, TEM analysis of cDKO hearts revealed
that mitochondrial fragmentation was largely
suppressed (Fig. 4, F and G). Similarly, mito-
chondrial morphology was restored in primary
adult cardiomyocytes isolated from cDKOmice
(Fig. 4, H and I). L-OPA1 processingwas prevented
in these cells, whereas other YME1L substrates
such as PRELID1 continued to accumulate to
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Fig. 2. Deletion of Yme1l causes dilated cardiomyopathy and heart failure. (A to C) Echocardio-
graphic evaluation of cardiac function (by M-mode) of randomized 40-week-old WT (n = 8) and cYKO (n =
8) males reveals DCM characterized by (B) reduced LVEF (****P < 0.0001) and (C) increased left
ventricular internal dimension (LVID) [d (mm), **P = 0.0154]. (D) Cardiac fibrosis in cYKO mice monitored
by trichrome and sirius red staining of heart sections [40 weeks old (40w), n = 3; scale bar, 200 mm].
(E) Increased serum levels of cardiac troponin (cTNI ng/ml) in 30-week-old cYKO mice (n = 8) relative to
WT (n = 19). Mann-Whitney test, **P = 0.0027. (F and G) Cardiomyocyte necrosis analysis of 20-week-
old cYKO (n = 4) and WT (n = 4) hearts stained with Evans Blue (EB red), wheat germ agglutinin (green),
and DAPI (blue). Individual t test, *P = 0.0286; scale bar, 50 mm. (H) PET-CTof 40-week-old cYKO (n = 8)
and WT (n = 7) animals after [18F]FDG injections. Representative images of four cYKO and four WT thoracic
scans are shown. (I) Average standardized uptake value (SUV) in WT (n = 7) and cYKO hearts (n = 8);
unpaired t test, *P = 0.0140. In graphs, data are means ± SEM.
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Fig. 3. Stress-induced OPA1 pro-
cessing in cardiomyocytes per-
turbs mitochondrial morphology.
(A) Ex vivo respiration measured
in resting hearts (n = 3 to 5) from
26- and 44-week-old WT (white
or pale gray) and cYKO (black or
dark gray) mice. Linear oxygen
uptake rates are presented as
nmol O2/min per mg (weight,
heart weight). Differences were
not significant. (B) Respiratory
chain activity measurements of
complex I to V (CI to CV) in
44-week-old hearts of WT (white)
and cYKO (black) mice. Individual
unpaired t tests (n = 3 to 5); CI
(P = 0.1442), CII (***P =
0.0003), CIII (***P = 0.0003),
CIV (**P = 0.0020), and CV
(*P = 0.0172). (C) TEM of
20-week-old WTand cYKO hearts
(thick scale bar, 500 nm; thin
scale bar, 100 nm). (D) Mito-
chondrial size was represented as
median surface area, and fre-
quency distributions of mito-
chondrial surface were calculated
from 20-week-old WT (n = 4224)
and cYKO (n = 2308) mitochon-
dria imaged by TEM. Kruskal-
Wallis test, ****P < 0.0001. Data
are median values. (E) Indirect
immunocytochemistry with anti-
bodies directed against TOMM20
(a rabbit-specific antibody) in
cardiomyocytes isolated from
WT (n = 3) and cYKO (n = 3) mice
(thin scale bar, 30 mm; thick scale
bar, 7.5 mm). 40w, 40 weeks old.
(F) Mitochondrial morphology in
WT (8w, n = 2; 40w, n = 3) and
cYKO (8w, n = 2; 40w, n = 3)
cardiomyocytes (****P < 0.0001).
Cells (>100) were counted. 8w,
8 weeks old. (G) Immunoblot
analysis of cardiomyocytes
isolated from 40-week-old mice
fed a normal chow diet (NCD)
or high-fat diet (HFD). SDHA
was used as a loading control.
(H) Quantification of OPA1
processing in hearts of WT
and cYKO mice (Fig. 3F).
(Pairwise t test, *P < 0.05,
**P < 0.01) relative to WT-NCD
controls. In graphs (B), (F),
and (H), data are means ± SEM.
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similar levels as in cardiomyocytes of cYKOmice
(Fig. 4J).
Thus, YME1L ablation in cardiomyocytes acti-
vates OMA1 and promotes OPA1 processing and
mitochondrial fragmentation, which causes DCM
and heart failure.
Loss of YME1L in skeletal muscle
preserves the function of
YME1L-deficient hearts
The results obtained from cardiomyocyte-specific
knockout mice establish an essential role of
YME1L for normal cardiac function in vivo. We
observed, to our surprise, the normal life span
of mice lacking YME1L both in cardiomyocytes
and skeletal muscle (hmYKO for heart andmuscle–
specific YME1L knockout; median life span
125weeks) (Fig. 5A, fig. S5A, and table S1). hmYKO
mice were obtained by crossing Yme1lLoxP/LoxP
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Fig. 4. Oma1 ablation restores mitochondrial morphology and protects
cYKOmice against DCMandheart failure. (A) Echocardiographic evaluation
of cardiac function (by M-mode) of 22-week-old WTand cDKOmice. (B and C)
Percentage LVEFand (C) diastolic LVID of 22-week-old WT (n = 10) and cDKO
(n = 9) mice. n.s., not significant. (D) Treadmill endurance of 20-week-old WT
(n = 10), cYKO (n = 10), and cDKO (n = 5) mice (5% incline). cYKO mice
versus WT, ****P = 0.0003; cYKO versus cDKO, ****P = 0.0001. (E) Sup-
pression of cardiac fibrosis in cDKO mice. Trichrome and sirius red staining
of heart sections of 22-week-old WTand cDKO mice (n = 3). Scale bar, 200 mm.
(F) TEM of 20-week-old cYKO and cDKO hearts (thick scale bar, 500 nm).
(G) Mitochondrial size represented as median surface area and frequency
distributions of mitochondrial surface calculated from 20-week-old cYKO
(n = 2308) and cDKO (n = 3122) mitochondria imaged by TEM. Kruskal-
Wallis test, ****P < 0.0001. Data are median values. (H) Indirect immuno-
cytochemistry with TOMM20-specific antibodies in cardiomyocytes isolated
from 22-week-old WTand cDKO mice (thin scale bar, 30 mm; thick scale bar,
7.5 mm). (I) Quantification of mitochondrial morphology from (H) (n = 3, n > 100
cells; *P = 0.0112). In (B) to (D) and (I), data are means ± SEM. (J) Immunoblot
analysis of cardiomyocytes from 22-week-old WT (n = 3) and cDKO (n = 3)
mice. SDHA was used as a loading control.
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mice to mice expressing Cre recombinase under
the control of the muscle creatine kinase (Ckmm)
promoter, which is active in cardiomyocytes and
additionally in skeletal muscle (39). Note that dif-
ferences in life span could not be explained by
differences in theefficiencyofYme1ldeletion:mRNA
(fig. S5B) and protein (fig. S5C) levels were pro-
foundly depleted in adult hearts of both cYKO
and hmYKO mice. YME1L was lost with similar
efficiencies and kinetics upon Cre recombinase–
mediated deletion of Yme1l both in postnatal
hearts of cYKO and hmYKOmice (fig. S5, D to G).
Unlike cYKO mice, however, myocardial activity
waspreserved inhmYKOmice.Weobservednormal
heart function by echocardiography and normal
cardiac uptake of [18F]FDG in these mice (Fig. 5,
B to D, and fig. S5, H and I).
We analyzed the morphology of mitochondria
in hmYKO hearts by TEM. Smaller mitochondria
accumulated in hearts of hmYKOmice as observed
in cYKO mice, which indicated mitochondrial
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Fig. 5. Deletion of Yme1l in skeletal muscle is cardioprotective. (A) Life
span of WT (green, n = 91) and hmYKO (purple, n = 75) mice are not sig-
nificantly different (n.s.) but significantly increased relative to cYKOmice (red,
n = 69; log-rank Mantel-Cox test, ****P < 0.0001). (B and C) Percentage
LVEFand diastolic LVID in 46-week-oldWT (n = 5) and hmYKO (n = 6)mice analyzed by echocardiography (fig. S5A). (D) PET-CTaverage standardized cardiac
glucose uptake in 46-week-oldWT (green, n = 8) and hmYKO (purple, n = 5)mice fed normal chow. (E) TEM of 20-week-oldWTand hmYKO hearts (thick scale
bar, 500 nm). (F) Mitochondrial size represented asmedian surface area and frequencydistributions ofmitochondrial surface calculated from20-week-oldWT
(n= 4224) (Fig. 3,C andD) and hmYKO (n= 3246)mitochondria imaged by TEM. Kruskal-Wallis test, ****P<0.0001. Data aremedian values. (G) Immunoblot
analysis of lysates from heart skeletal muscle and liver of 18-week-old hmYKOmice (n = 3), hmOKOmice (Ckmm-Cre;Oma1LoxP/LoxP, n = 3), and hmDKOmice
(Ckmm-Cre; Oma1LoxP/LoxP Yme1lLoxP/LoxP, n = 3) reveals altered OPA1 processing. (H) Intraperitoneal glucose tolerance tests in 18-week-old WT (n = 18) and
hmYKO (n = 13) mice.Two-way ANOVA (**P < 0.01, ***P < 0.001, ****P < 0.0001) relative to WTcontrols. (I) Fasting insulin levels in 20-week-old WT (n = 6)
and hmYKO (n = 7) mice. (*P = 0.0357). In (A), (C), (F), (H), and (I), data are means ± SEM.
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fragmentation (Fig. 5, E and F). These mor-
phological changes corresponded to defects in
OPA1 processing that were similar in cardiomyo-
cytes isolated fromhmYKOand cYKOmice (Figs.
3G and 5G). In both models, deletion of Yme1l in
cardiomyocytes prevented formation of S-OPA1
formd,whereas S-OPA1 forms c and e accumulated,
which was indicative of OMA1 activation (fig.
S5F). OPA1 processing was affected similarly
upon loss of YME1L in skeletalmuscle of hmYKO
mice (Fig. 5G) but normal in skeletal muscle of
cYKOmice harboring YME1L (Fig. 1E). Thus, loss
of YME1L impairs OPA1 processing and induces
mitochondrial fragmentation in cardiomyocytes
of both cYKO and hmYKO mice. Furthermore,
additional deletion of Yme1l in skeletal muscle
maintains heart function and life span without
restoring mitochondrial morphology defects in
cardiomyocytes lacking YME1L.
Mitochondrial dysfunction in skeletal muscle
is associated with impaired insulin signaling and
glucose intolerance (40–42). Thus, possible en-
docrine effects owing to the loss of YME1L in
skeletal muscle may cause metabolic alterations
in cardiomyocytes; this preserves heart function
downstream of mitochondrial deficiencies. We
thus investigated systemic glucose homeostasis
and performed intraperitoneal glucose tolerance
tests (GTT) in both hmYKOand cYKOmice (Figs.
5H and 6A). We observed glucose intolerance in
hmYKOmice but not in cYKOmice (Figs. 5H and
6A), which suggested that deletion of Yme1l in
skeletalmuscle impaired glucose homeostasis sys-
temically. Additional ablation ofOma1 in hmYKO
mice (hmDKO; table S1) prevented OPA1 pro-
cessing in both heart and skeletal muscle (Fig.
5G) and restored normal glucose tolerance (fig.
S5F). Thus, stress-induced OPA1 processing by
OMA1 in skeletal muscle impairs glucose ho-
meostasis in hmYKO mice.
Deletion of Pgc1a in skeletal muscle signifi-
cantly impairs glucose-stimulated insulin secretion,
which suggests a cytokine-mediated cross-talk
between skeletal muscle and pancreatic islets
(41). In agreementwith these findings,weobserved
lowered fasting insulin concentration in the serum
of hmYKO mice (Fig. 5I), although Yme1l was not
deleted in the pancreas of these mice. hmYKO
mice had normal fasting blood glucose (fig. S5G),
normal weight gains (fig. S5H), and body com-
position as normal lean and fat mass (fig. S5I).
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Fig. 6. Suppression
of DCM and heart
failure by dietary
intervention. (A)
Intraperitoneal glucose
tolerance tests in WT
(green, n=30; blue, n=
13) and cYKO (orange,
n = 5; red, n = 14) mice
fed HFD or NCD.
Two-way ANOVA
(*P < 0. 05, **P < 0.01,
***P < 0.001, ****P <
0.0001) relative to
WT-NCD controls.
(B) PET-CT in
30-week-old WTand
cYKO mice treated
with HFD starting at
9 weeks of age. Rep-
resentative images
of 2 cYKO and 2 WT
mice are shown.
(C) Average standard-
ized cardiac glucose
uptake in 30-week-old
WT (n = 8; blue) and
cYKO mice (n = 14;
orange) treated with
HFD starting at
9 weeks of age.
(D) Echocardiographic
M-mode images of
30-week-old WTand
cYKO mice fed with
HFDstartingat 9weeks
of age. (E and F)
Percentage LVEFand
diastolic LVID of WT
(n = 14) and cYKO
(n = 10) mice. n.s., not
significant. (G)Trichrome
and sirius red stainings
of heart sections of
40-week-old HFD-fed
WT (n = 3) and cYKO (n = 3)mice. Scale bar, 200 mm. (H) Indirect immunocytochemistry using antibodies directed against TOMM20 in cardiomyocytes isolated
from 30-week-old HFD-fedWT (n = 3) and cYKO (n = 3) mice (thin scale bar, 30 mm; thick scale bar, 7.5 mm).OPA1 processing in these cells is shown in Fig. 3G.
(I) Quantification of mitochondrial morphology from (H) (WT, n ≥ 100 cells; cYKO, n = 3; ***P = 0.001). In graphs, data are means ± SEM.
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Thus, loss of YME1L in skeletalmuscle induces
systemic glucose intolerance and lowers insulin
levels, which blunts increased cardiac glucose
uptake and alters cardiacmetabolism. Furthermore,
cell nonautonomous metabolic alleviation can
preserve cardiac function and prevent DCM and
heart failure despitemitochondrial fragmentation
in cardiomyocytes.
Feeding a high-fat diet suppresses
heart failure and restores the
life span of cYKO mice
The protective effect of systemic glucose intolerance
on the heart suggests that deleterious effects of
mitochondrial fragmentation in cardiomyocytes
can be circumvented by metabolic intervention.
To provide further support for this notion, we
subjected wild-type (WT) and cYKO mice to a
high-fat diet. This diet is commonly used to dys-
regulate systemic glucose homeostasis. It impairs
insulin signaling in target tissues and compromises
glucose-stimulated insulin secretion by pancreatic
b cells triggering obesity. Mice were fed a high-fat
diet beginning at 9 weeks of age, at a time when
cardiac functionwas normal. BothWT and cYKO
mice fed a high-fat diet gained weight significantly
more rapidly thanmice fed normal chow (fig. S6A)
and exhibited reduced glucose tolerance (Fig. 6A).
To determine whether this dietary intervention
could influence cardiacmetabolism, we examined
the cardiac uptake of [18F]FDG by PET-CT and
determined levels of endogenous glucose and acyl-
carnitine in the hearts of high fat–fed cYKOmice.
In contrast to mice fed normal chow, we did not
observe significant differences in cardiac glucose
uptake (Fig. 6, B and C) nor in the levels of endog-
enous cardiac glucose or acylcarnitine between
high fat–fed WT and cYKO mice (fig. S2, D and
F). The adjustment of the levels of these cardiac
metabolites was accompanied by restoration of
cardiac function in cYKOmice (Fig. 6, D to F, and
fig. S5B): left ventricular ejection fraction (LVEF)
and left ventricular chamber diameter values were
indistinguishable from those of high fat–fed lit-
termate controls. Treatment with the high-fat
diet also prevented cardiac fibrosis (Fig. 6G) and
suppressed differences in exercise tolerance pre-
viously observed between WT and cYKO mice
fed normal chow (fig. S6, C and D).
Similar to normally fed cYKO mice (Fig. 3, F
and G), cardiomyocytes isolated from high fat–fed
cYKOmice still contained distortedmitochondria
(Fig. 6, H and I), because the high-fat diet had not
rescued the proteolytic activity of YME1L or
OMA1-dependent, stress-induced processing of
OPA1 (Fig. 3G, H). High-fat feeding did not
markedly alter oxygen consumption or the activity
of respiratory complexes in cYKO mice (fig. S6,
E and F). Thus, the consequences of mitochon-
drial defects in cYKO mice can be metabolically
circumvented to suppress cardiomyopathy.
Discussion
In these experiments, we observed the deleterious
effects of stress-inducedOPA1processing andmito-
chondrial fragmentation on myocardial function,
which revealed an unexpected functional link
between systemic glucose homeostasis, cardiac
metabolism, andmitochondrial dynamics in vivo.
Uncleaved, fusion-active L-OPA1 is sufficient
to maintain cardiac activity. Mice lacking both
YME1L and OMA1 in cardiomyocytes exhibited
normal heart function, which demonstrates that
proteolytic cleavage ofOPA1 by YME1L andOMA1
is dispensable. The previously described, essential
role of OPA1 for normal cardiac functioning can
thus be attributed to the loss of L-OPA1 (43, 44).
L-OPA1 is sufficient to mediate mitochondrial
fusion,which serves a prosurvival function (24–26).
Mitochondrial fusion protects against mitophagy
(4, 45) and is thought to serve a repair function by
allowing content mixing and by preventing the
accumulation ofmitochondrial damage in cultured
cells (46). Although mitochondrial fusion occurs
infrequently in adult cardiomyocytes (7), it is re-
quired for cardiomyocyte differentiation and
cardiac development (7, 47–51).
Whereas L-OPA1 is sufficient to preserve cardiac
function, accumulation of S-OPA1 and unopposed
fission is deleterious for the heart. Our results
establish cardiomyocyte-specific YME1L-deficient
mice as a model for DCM and heart failure, which
culminates in middle-aged death (Fig. 7). The loss
of YME1L activates OMA1 and triggers stress-
induced OPA1 processing, which unbalances
fusion and fission of mitochondria and impairs
mitochondrial morphology in cardiomyocytes.
In the absence of YME1L, we observed the ac-
cumulation of smaller mitochondria in the heart
andmitochondrial fragmentation in cardiomyocytes
and cardiac fibroblasts in vitro. Mitochondrial
fragmentation is caused by the loss of L-OPA1
forms mediating fusion and the concomitant
accumulation of S-OPA1 forms c and e that are
generated byOMA1 and are associatedwith fission
(21, 23–26). Deletion of Oma1 restores normal
mitochondrial morphology in cardiomyocytes
lacking YME1L and myocardial activity in vivo,
which demonstrates that accelerated OPA1 pro-
cessing and mitochondrial fragmentation cause
heart failure (Fig. 7). Consistentwith a deleterious
effect of unopposed fission in theheart (7), pharma-
cological inhibition of mitochondrial fission pro-
tects against ischemia and reperfusion injury
(52). Notably, germline deletion of Oma1 does
not impair embryogenesis and is not able to sup-
press postimplantation embryonic lethality of
Yme1l–/– embryos (fig. S1F), which indicates
that stress-induced OPA1 processing is not dele-
terious for prenatal organogenesis in these mice.
Howdoes stress-inducedOPA1 processing and
mitochondrial fragmentation affect cardiac func-
tion? Mitochondria are vital for the beating heart,
and defects in mitochondrial respiration cause
cardiac dysfunction (36, 53, 54). However, we ob-
served only a minor impairment of respiratory ac-
tivities and ATP synthesis and no accumulation of
lactate in YME1L-deficient hearts, unlike other
animal models of mitochondrial cardiomyopathy
(7, 36, 51, 54). Whereas severe and lethal cardio-
myopathies manifest not long after birth in most
of thesemodels, cardiac ablation of YME1L causes
DCM and death at ~1 year of age.
Unrestrained autophagy can also cause cardio-
myocyte loss and heart failure (55), which raises
the possibility that stress-induced OPA1 processing
and the accumulation of S-OPA1 affects the auto-
phagic disposal of mitochondria. The analysis of
heart-specific DRP1 knockout mice indeed pointed
to a major role of DRP1 and fission for mitochon-
drial quality-control and autophagy in the heart
(56–58). However, autophagic marker proteins
such as p62/SQSTM1 or microtubule-associated
aad0116-8 4 DECEMBER 2015 • VOL 350 ISSUE 6265 sciencemag.org SCIENCE
Fig. 7. Unbalanced mitochondrial
dynamics in cardiomyocytes
upon loss of YME1L causes DCM
and heart failure. Unregulated
OPA1 processing by OMA1
causes metabolic alterations
triggering DCM and heart failure
in cardiomyocyte-specific Yme1l–/–
mice. Heart function is preserved
upon restoration of mitochondrial
morphology by Oma1 ablation or
without suppressing mitochondrial
morphology defects by metabolic
intervention bypassing deleterious
effects of disturbed mitochondrial
dynamics on cardiac metabolism.
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protein 1 light chain 3 did not accumulate in
YME1L-deficient heart nor weremyocardial amino
acid levels altered (fig. S7, A and B). Thus, in-
creased autophagy is unlikely to cause the loss of
cardiomyocytes in this model. In contrast, our
results suggest that stress-induced OPA1 pro-
cessing by OMA1 promotes cardiomyocyte death
in the absence of YME1L (fig. S7, C and D). We
observed increased serum levels of cardiac tro-
ponin, fibrotic remodeling, and necrotic cell death,
as well as the dysregulation of genes functionally
linked to cell death in YME1L-deficient hearts
(fig. S7, C and D). These results identify OMA1
as a critical regulator of cardiomyocyte survival
in vivo, consistent with an antiapoptotic effect of
OMA1 in cultured cells (21, 25, 29). Note that
cardiac mitochondria form normal cristae in the
absence of YME1L. Thus, cristae remodeling and
facilitated cytochrome c release does not drive
cell death in these mice, which instead is trig-
gered by the loss of L-OPA1 and the impairment
of mitochondrial fusion. In light of these obser-
vations, it is conceivable that the recently re-
ported, protective effect of OPA1 overexpression
in various mouse models for mitochondrial dis-
ease (59, 60) can be attributed to L-OPA1 alone,
which drives fusion and can support cell survival
independent of cristae morphogenesis.
Similar to previousmodels for the failing heart
(36, 61), the cardiomyocyte-specific loss of YME1L
and disturbed mitochondrial dynamics provoked
adownstreammetabolic shift from lipid to glucose
metabolism in the myocardium. We observed
reduced levels of acylcarnitine and increased
glucose uptake that indicated reinforced myo-
cardial glucose utilization, which is known to
be associated with heart failure when combined
with disturbed fatty acid metabolism (37). These
alterations occur in the absence of overt respiratory
deficiencies, which were previously observed
to enhance cardiac glucose metabolism (36, 61),
which highlights the regulatory role of mitochon-
drial dynamics in cardiac metabolism. Increasing
evidence indeed supports a close link between
energy metabolism and mitochondrial fusion
and fission in various tissues, including the central
nervous system and brown adipose tissue, and
suggests an association between mitochondrial
fission, lipid metabolism, and energy expend-
iture (62–64).
Our experiments provide strong evidence that
alterations in metabolism cause heart failure in
cYKOmice. Additional deletion ofYme1l in skeletal
muscle preserved cardiac function and normal life
span of mice lacking YME1L in cardiomyocytes
without restoring defects in mitochondrial mor-
phology (Fig. 7). This is likely due to an endocrine
effect by the skeletal muscle on glucose uptake in
the heart. Dysfunction ofmitochondria in skeletal
muscle was previously reported to affect systemic
glucose metabolism by impairing insulin secre-
tion by pancreatic b cells and glucose uptake in
target tissues (41). Similarly, we observed lowered
fasting-insulin concentrations, systemic glucose
intolerance, and normalized heart glucose uptake
inmiceuponadditional deletionofYme1l in skeletal
muscle. Loss of YME1L appears to impair insulin
signaling via its effect onmitochondrial dynamics
and stress-induced OPA1 processing by OMA1,
because we observed normal systemic glucose
homeostasis in mice lacking both OMA1 and
YME1L in skeletal muscle. These results highlight
the physiological importance of tissue cross-talk
that must be taken into consideration when ana-
lyzing tissue-specific models for mitochondrial
disease.
Further support for a critical role of disturbed
cardiomyocyte metabolism for heart failure came
from the observation that feeding a high-fat diet
preservednormal cardiac functionof cardiomyocyte-
specific YME1L knockout mice (Fig. 7). Similar to
ablation ofYme1l in skeletalmuscle, thismetabolic
intervention did not circumvent the primary
mitochondrial defects in cardiomyocytes because
the catalytic activity of YME1L, OMA1 activation,
mitochondrial morphology, and respiratory chain
profiles were unaffected by diet. However, it did
blunt downstream metabolic disruptions and
normalized cardiac glucose uptake in cardiomyocyte-
specific YME1L knockout mice, which suppressed
cell death and preserved cardiac function. Remark-
ably, feeding of cardiomyocyte-specific YME1L
knockout mice with a high-fat diet prevents
cardiomyopathy at least at early stages despite
normalweight gain of themice. Echocardiographic
analyses of failing cYKO hearts demonstrate that
these mice have reduced contractile function but
normal left ventricular mass, which suggests that
YME1L ablation does not result in a concentric
hypertrophic response, and thus cardiac dys-
function can be improved by metabolic inter-
vention. In this sense, some forms of DCM in
humans can be treated by pharmacologicalmeans
(65). Consistent with previous reports (37), high-
fat feeding of WT mice did not incite contractile
dysfunction (table S2). In contrast, feeding mice
manifesting cardiomyopathy associated with
ventricular hypertrophy a high-fat diet exacer-
bates myocardial dysfunction (66, 67). It is thus
an intriguing possibility that this metabolic in-
tervention is beneficial exclusively in the context
of DCM. Our results reveal an intimate relation
between alterations inmitochondrialmorphology
and metabolism in the heart, which may underlie
myocardial disease in humans. Metabolic inter-
ventions can preserve cardiac function even if
mitochondrial morphology is disturbed, which
opens potential avenues for therapeutic inter-
ventions in myocardial disease.
Methods
Echocardiography and PET-CT
Echocardiography and functional examination
in mice was performed as previously described
(68). All PET-CT studies were performed with a
small-animal PET-CT device. Briefly, animals were
fasted overnight, and anatomic thorax CT scan-
ning was performed 1 hour after [18F]FDG injec-
tions, followed bymetabolic PET static acquisition
for 15 min. Image analysis was performed in
prefused and prereconstructed imageswithOsirix
(AycamMedical Systems, LLC); we selectedmyo-
cardiumof thewhole left ventricle and calculated
meanmyocardial standardized uptake value (SUV
med) for each animal. See supplemental methods
for full methods description.
Incline treadmill
Treadmill experiments were conducted using a
TSE treadmill and up to six randomized mice
assessed simultaneously. Low-intensity incline (5%)
experiments began at 0.05 m/s and increasing to
0.1m/s for 60 s, 0.1 m/s for 600 s, then increasing
to 0.28m/s for 3100 s by 172-s increments. Blinded
determination of exercise exhaustionwas assessed
and plotted as a function of total distance (m).
Histology and immunochemistry
Paraffin-embedded sections (4 mm)were subjected
tohematoxylinandeosin, picrosirius red, orMasson’s
trichrome staining. Images were acquired using
a Leica SCN400 automated slide scanner at 40×.
Generation of primary cardiomyocytes
and cardiac fibroblasts
Adult cardiomyocytes were isolated by retrograde
Langerdorff perfusion with an enzymatic digestion
buffer containing trypsin and Liberase (Roche
Applied Science) (68). Primary cardiac fibroblasts
obtained during cardiomyocyte isolations were
immortalized using a plasmid encoding SV40
large T antigen and deleted for Yme1l in vitro.
See supplemental methods for full methods
description.
Transmission electron microscopy (TM)
Left ventricle samples of hearts perfused with
paraformaldehyde [2% (w/v) in phosphate-buffered
saline (PBS)] and glutaraldehyde [2% (w/v) in PBS]
hearts were fixed for 3 days in 2% (v/v) glutar-
aldehyde, 2.5% (w/v) sucrose, 3 mM CaCl2, and
100mMHEPES-KOH, pH7.4, at 4°C. After washes,
samples were fixed using reduced OsO4 [1% (w/v)
OsO4, 10mg/ml potassium ferrocyanide, 1.25% (w/v)
sucrose, and 100mM sodium cacodylate, pH 7.4]
for 1 hour on ice. After washes in water, cells
were incubated in 2% (w/v) uranyl acetate for
30 min. After dehydration with 50, 70, 90, and
100% ethanol, samples were embedded in epon
resin. Samples were observed under a transmis-
sion electron microscope (EM902; Carl Zeiss) at
an acceleration voltage of 80 kV.
Confocal fluorescence microscopy
To monitor mitochondrial morphology by im-
munofluorescence microscopy, primary cardio-
myocytes were fixed and stained with antibodies
directed against TOMM20 (rabbit-specific anti-
body 1:1000, Santa Cruz Biotechnology). Fluo-
rescently coupled secondary antibody Alexa
Fluor 568 (a goat antibody directed against a
rabbit secondary antibody) was used at 1:1000
dilution (Invitrogen). Images were acquired using
an UltraVIEW VoX spinning disc microscope
(CSU-X1; Yokogawa Corporation of America).
Quantification of mitochondrial morphology
in primary cardiomyocytes was performed by
blinded, randomized examination of z-stack images.
Cardiac necrosis was assessed by Evans Blue
diffusion as previously described (57). Paraffin-
embedded cardiac sections were stained with
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fluorescein isothoicyante–conjugated wheat germ
agglutinin (Invitrogen, W834) for 30 min before
nuclear counterstaining with 4′,6′-diamidino-
2-phenylindole (DAPI). Evans Blue–positive car-
diomyocytes fluorescence is in red. Images were
acquired using a Leica SP8 confocal microscope
at 40×.
Blood glucose and serum analyses
IntraperitonealGTTswere carried out inmice after
theywere fasted for 6hours. After determinationof
fastedbloodglucose levels, an intraperitoneal bolus
of 2 g glucose/kg body weight [20% (w/v) glucose].
Blood glucose levels were determined after 15,
30, 60, and 120 min using Contour test strips
(Bayer, Germany). Serum insulin levels were
measured fromblood collected from6hours fasted
mice, by enzyme-linked immunosorbent assays
(ELISAs), according to the manufacturer’s in-
structions (Mouse/Rat Insulin ELISA, Mouse
Leptin ELISA;Crystal Chem Inc.). Serum levels
of cardiac troponin assayed by auto-analyzer
Dimension RxL Max HM (Siemens).
Oxygen consumption measurements
Oxygen consumption of WT and cYKO hearts,
fed normal chow diet (NCD) or high-fat diet
(HFD), wasmeasured using a fluorescence-based
micro-optode that consisted of an optic fiber
equipped with an oxygen-sensitive fluorescent
terminal sensor (FireSting O2; Bionef, Paris, France)
as described previously (69). Hearts were perfused
in buffer (10 mM KH2PO4, 300 mM mannitol,
10 mM KCl, 5 mM MgCl2, 5 mM bovine serum
albumin, pH7.4), dissected,weighted, andassayedat
rest, precisely 3minaftermicewerekilledby cervical
dislocation. Oxygen uptake rates (nmol O2/min)
were adjusted relative to wet heart weight.
Respiratory chain measurements
Activity of respiratory chain complexes and citrate
synthase was spectrophotometrically assayed as
previously described (70).
Statistical analysis
Statistical analyses were performed using Prism
(GraphPad Software Inc., San Diego, CA). All
values are expressed as means ± SEM. Statistical
significance was assessed by using a two-tailed
unpaired Student’s t test or the Mann-Whitney
test for two-group comparisons. Two-way analysis
of variance (ANOVA) with Bonferroni post hoc
tests (corrected P values are given for comparison
between genotypes at specific time points) were
used to evaluatemultiple pairwise comparisons of
groups. Life span survival curves were compared
by using a log-rank Mantel-Cox test. Differences
were considered statistically significant at a value
of P < 0.05. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001.
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Abstract Selective stimulation of b3 adrenergic-receptor
(b3AR) has been shown to reduce infarct size in a mouse
model of myocardial ischemia/reperfusion. However, its
functional long-term effect and the cardioprotective
mechanisms at the level of cardiomyocytes have not been
elucidated, and the impact of b3AR stimulation has not
been evaluated in a more translational large animal model.
This study aimed at evaluating pre-perfusion administra-
tion of BRL37344 both in small and large animal models
of myocardial ischemia/reperfusion. Pre-reperfusion
administration of the b3AR agonist BRL37344 (5 lg/kg)
reduced infarct size at 2-and 24-h reperfusion in wild-type
mice. Long-term (12-weeks) left ventricular (LV) function
assessed by echocardiography and cardiac magnetic reso-
nance (CMR) was significantly improved in b3AR agonist-
treated mice. Incubation with b3AR agonist (BRL37344,
7 lmol/L) significantly reduced cell death in isolated adult
mouse cardiomyocytes during hypoxia/reoxygenation and
decreased susceptibility to deleterious opening of the
mitochondrial permeability transition pore (mPTP), via a
mechanism dependent on the Akt-NO signaling pathway.
Pre-reperfusion BRL37344 administration had no effect on
infarct size in cyclophilin-D KO mice, further implicating
mPTP in the mechanism of protection. Large-white pigs
underwent percutaneous coronary ischemia/reperfusion
and 3-T CMR at 7 and 45 days post-infarction. Pre-per-
fusion administration of BRL37344 (5 lg/kg) decreased
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infarct size and improved long-term LV contractile func-
tion. A single-dose administration of b3AR agonist before
reperfusion decreased infarct size and resulted in a con-
sistent and long-term improvement in cardiac function,
both in small and large animal models of myocardial
ischemia/reperfusion. This protection appears to be exe-
cuted through inhibition of mPTP opening in
cardiomyocytes.
Keywords b3 adrenergic receptor  Magnetic resonance
imaging  Myocardial infarction  Beta-adrenergic receptor
blocker  Ischemia/reperfusion  Mitochondrial
permeability transition pore
Introduction
Acute myocardial infarction (AMI) is a leading cause of
mortality and morbidity worldwide. Early coronary reper-
fusion has been established as the best therapeutic strategy
to limit infarct size and improve prognosis; however,
reperfusion itself induces additional damage to the myo-
cardium, known as ischemia/reperfusion injury (IRI) [20,
42, 49].
Evidence gathered over the past 40 years indicates that
myocardial injury can be attenuated by manipulation of the
response to IRI. In 1971 Braunwald et al. [38] demon-
strated that the severity of myocardial necrosis due to
coronary occlusion could be attenuated by appropriate
interventions during ischemia. Since then, multiple strate-
gies and interventions have been proposed as capable of
limiting infarct size by reducing IRI in different animal
models [5]. Despite these promising preclinical studies,
attempts to translate them to the clinic have not been
successful [23, 29, 47, 49] partly because of the lack of
studies confirming results obtained in small animals in
clinically relevant large animal models [10, 26]. The pos-
sibility of reducing the extent of cell death during an AMI
is of great importance, since infarct size is the main
determinant of post-infarction mortality [13]. Conse-
quently, there is a clear need to develop therapies for
reducing infarct size that go beyond early reperfusion.
The b3 adrenergic-receptor (b3AR) is a G-protein-cou-
pled receptor preferentially expressed in adipose tissue.
The identification of b3AR expression in the myocardium
[22] prompted suggestions that it might be a therapeutic
target in cardiovascular diseases, and b3AR-selective
stimulation has been consistently beneficial in animal
models of heart failure [12, 39]. More recently, b3AR
agonists have been shown to reduce infarct size in mice
undergoing regional myocardial ischemia/reperfusion [3].
However, it remains unknown whether b3AR stimulation
during AMI results in long-term benefits on cardiac
function and, more importantly, if this strategy is cardio-
protective in a more clinically relevant large-animal model
[28, 32]. Confirmation of an infarct-limiting effect and
long-term benefits from this new therapeutic strategy
would have a significant translational impact.
The fate of cardiomyocytes upon IRI is critically
dependent on mitochondria [21, 30, 31, 49]. Irreversible
and pathological opening of the mitochondrial permeability
transition pore (mPTP) at the onset of reperfusion is well
established as a major determinant of cardiomyocyte cell
death [19, 30, 31]. A key regulator of mPTP opening is
mitochondrial cyclophilin-D (CypD) and its pharmaco-
logical inhibition with cyclosporin-A (CsA) has been
shown to reduce infarct size both in animal models and in
clinics [4, 8, 18, 41, 48]. The effect of b3AR modulators on
cardiomyocyte mPTP opening remains to be established.
The aims of this study were (1) to analyze the effect of
pre-reperfusion b3AR agonist therapy on infarct size and
long-term myocardial performance in a mouse model of
IRI, (2) to study the cardioprotective mechanisms involved
in b3AR stimulation at the cardiomyocyte level, and (3) to
confirm the beneficial effect of b3AR agonist therapy in a
large preclinical animal model of AMI.
Materials and methods
Study design
Two sets of mice were subjected to temporal left anterior
descending (LAD) coronary artery occlusion and random-
ized to receive a single bolus of the b3AR agonist
BRL37344 or vehicle before reperfusion. In the first set,
late IRI was evaluated by quantification of infarct size at
24 h reperfusion. In a second set, serial left ventricular
(LV) function was assessed by echocardiography and high
field (7-T) cardiac magnetic resonance (CMR) at short- (1
and 4 weeks) and long-term (12 weeks) follow-up. To
confirm b3AR agonism implication, FVB/N b3AR-
knockout (KO) mice were subjected to the same myocar-
dial IRI procedure and infarct size evaluated at 24 h of
reperfusion.
To study whether the protective effect of pre-reperfusion
b3AR stimulation derives from a direct effect on cardio-
myocytes, isolated adult mouse cardiomyocytes were
subjected to simulated ischemia/reperfusion (hypoxia/
reoxygenation; H/R), and cell viability evaluated in the
presence or absence of BRL37344. The role of nitric oxide
(NO) production as an intracellular signaling mediator was
tested by co-incubation with BRL37344 and the nitric
oxide synthase (NOS) inhibitor L-NAME. In addition, the
H/R procedure was applied to adult cardiomyocytes from
mice lacking endothelial-NOS (eNOS-KO). NO signaling
Page 2 of 15 Basic Res Cardiol (2014) 109:422
123
pathway activation was evaluated by western blot in iso-
lated cardiomyocytes subjected to H/R. Susceptibility to
mPTP opening during b3AR stimulation was evaluated in
isolated cardiomyocytes in the presence of BRL37344,
saline, or the CypD inhibitor cyclosporine-A (CsA). The
implication of mPTP opening in b3AR-agonist-mediated
cardioprotection was tested in vivo in CypD-KO mice
subjected to the myocardial IRI procedure and randomized
to receive BRL37344 or vehicle before 2 h if reperfusion.
The translational impact of b3AR-agonist-mediated
cardioprotection was tested in a pig model of AMI by
60 min of percutaneous angioplasty followed by reperfu-
sion [33, 35] and randomized to receive either BRL37344
or vehicle at the onset reperfusion. Infarct size was eval-
uated by 3-T CMR at 7 days post-infarction, and LV
function was evaluated, also by CMR, at long-term follow-
up.
Mouse model of myocardial ischemia/reperfusion
injury (IRI)
Male 8- to 12-week-old mice were subjected to 45 min of
left anterior descending (LAD) coronary artery occlusion
followed by reperfusion. For infarct size evaluation,
reperfusion was maintained for 2 or 24 h; for assessment of
long-term left ventricular (LV) function, reperfusion was
maintained for 12 weeks. For the LAD procedure, mice
were intra-peritoneal anesthetized with ketamine (60 mg/
kg), xylacine (20 mg/kg), and atropine (9 mg/kg). Once
deeply asleep, and under direct visualization of the trachea,
animals were orally intubated using a blunted 22G cannula
and mechanically ventilated throughout the entire proce-
dure (SAR-830. CWE Inc.). Temperature was controlled
(BAT-12, Physitemp Instruments) and kept constant at
37 C with a heated operating table (V500VStat, Peco
Services) to prevent hypothermic cardioprotection [2]. As
previously described by Gomez et al. [24], a nylon 8/0
monofilament suture was passed beneath the LAD
approximately 2 mm below the tip of the left atrium
appendage. After stabilization for 5 min, regional ischemia
was induced by tightening a simple snare to stop coronary
blood flow. A short segment of PE-10 tubing was placed
between the tissue and the suture to minimize damage and
allow for complete reperfusion after the ischemic period.
Successful LAD occlusion was confirmed by ST-segment
elevation on ECG (MP36R, Biopac Systems Inc.) and the
appearance of myocardial pallor. During ischemia, the
thorax was covered with parafilm to prevent dehydration.
Anesthetic mixture was injected intra-peritoneally when
needed. Five minutes before the onset of reperfusion, mice
were randomized to receive a single bolus injection (50 lL,
with an insulin syringe) of the b3AR agonist BRL37344
(5 lg/kg) or saline into the femoral vein. The BRL37344
dose was selected on the basis of dose–response studies
performed before the initiation of the IRI procedure (data
not shown). The thoraxes of animals designated for infarct-
size evaluation at 24 h reperfusion were closed with a 6/0
silk thread, and animals were recovered with 100 % O2 and
analgesized with buprenorphine (S.C., 0.1 mg/kg) until the
end of the procedure. Animals designated to early IRI
evaluation (2 h reperfusion) were maintained completely
asleep and under mechanical ventilation until the end of the
procedure.
Infarct size quantification
Mice reperfused for 24 h were briefly re-anesthetized at the
end of the reperfusion period, and were then intubated and
the LAD re-occluded by ligating the suture in the same
position as the original infarction. Animals were then killed
and 1 mL of 1 % (w/v) Evans Blue dye infused i.v. to
delineate the Area at Risk (AAR: myocardium lacking
blood flow, i.e. negative to blue dye staining). The heart
was then excised, the left ventricle (LV) was isolated and
cut into seven 1-mm-thick transverse slices, and pictures
were taken from both sides. In order to differentiate
infarcted from viable tissue, slices were incubated in tri-
phenyltetrazolium chloride (TTC, 1 % (w/v) diluted in
PBS) at 37 C for 15 min. The slices were then re-photo-
graphed and weighed. Regions negative for Evans Blue
staining (AAR) and negative for TTC (infarcted myocar-
dium) were calculated by a blinded observer using the
computer-assisted planimetry function in ImageJ 6.0 (NIH,
Bethesda, MD). Infarct size for each slice was calculated as
the average percentage of infarcted myocardium from both
sides of each section. Following a previously described
method [9], percentile values for AAR and IS were cor-
rected to mg independently for each slice. Finally, absolute
infarct size was determined as the ratio
P
mg of IS/
P
mg
of AAR. This methodology takes into account individual
AAR variability [11]. The full set of LV images is shown in
supplemental Fig. 2.
Echocardiography functional examination in mice
Echocardiographic evaluations to determine cardiac vol-
ume and LV contractility were performed by an experi-
enced observer blinded to the study allocation in mice at 1,
4 and 12 weeks post-infarction. Mice were anesthetized by
inhalation of isoflurane/oxygen and examined with a
30-MHz transthoracic echocardiography probe and a Vevo
2100 ultrasound system (VisualSonics, Toronto, Canada).
From short-axis and long-axis B-mode views, end-systolic
and end-diastolic LV volumes and LV ejection fraction
(LVEF) were calculated using the area-length method [16].
LV regional function was evaluated in a 13-segment model
Basic Res Cardiol (2014) 109:422 Page 3 of 15
123
(basal, middle and apical segments of the septum, anterior,
lateral, postero-inferior walls and the apex) and scored as
follows: normal (0), hypo/akinesis (1), dyskinesis/aneu-
rysm (2). A segmental LV wall motion score was defined
as the sum of the individual segment scores in each animal.
High field CMR protocol in mice
Myocardial volumes and function were assessed by CMR
12 weeks post-AMI. Mice were anesthetized by inhalation
of isoflurane/oxygen (5 %/95 %) and examined with a 7-T
field preclinical CMR system (BioSpec 70/20 USR, Bruker
BioSpin) with a maximum gradient of 750 mT/m. A vol-
ume resonator (72 mm inner diameter) operating in quad-
rature mode was used for excitation and a four-element
phased array surface mouse heart coil (Rapid Biomedical)
was used for signal reception. After standard cardiac lo-
calizers, cine images were acquired using fast low-angle
shot (Intragate-FLASH) sequences in 6–7 short-axis planes
to cover the whole LV with a field of view (FOV) of
2.7 9 3 cm, a 1-mm slice thickness without gaps, TE
2.4 ms, TR 8 ms, cardiac phases 10, and matrix of
256 9 256 pixels. Cine images were reconstructed using
retrospective ECG-gating performed with IntraGate, which
is included in the CMR Paravision Bruker software. ECG
and breathing rhythm were monitored with a CMR-com-
patible system for small animals (Model 1025, S.A.
Instruments, Inc., New York, USA).
Isolation of adult mouse cardiomyocytes
The protocol for mouse adult cardiomyocyte isolation was
adapted from several studies [36, 44, 50]. Briefly, 10- to
12-week-old C57BL/6J WT or eNOS-KO mice were hep-
arinized (50 USP units) and anesthetized with a mixture of
ketamine (140 mg/kg), xylazine (33 mg/kg), and atropine
(9 mg/kg). Once pedal pinch reflexes were completely
inhibited, animals were placed in a supine position, ventral
thoracic regions were wiped with 70 % alcohol, and ani-
mals were euthanized. The heart was quickly removed,
cannulated through the ascending aorta, and mounted on a
modified Langendorff perfusion apparatus. The heart was
then retrogradely perfused (3 mL/min) for 5 min at room
temperature (RT) with pre-filtered Ca2?-free Perfusion-
Buffer [NaCl (113 mmol/L); KCl (4.7 mmol/L); KH2PO4
(0.6 mmol/L); Na2HPO4 (0.6 mmol/L); MgSO47H2O
(1.2 mmol/L); NaHCO3 (12 mmol/L); KHCO3 (10 mmol/
L); Phenol Red (0.032 mmol/L); HEPES-Na salt
(0.922 mmol/L); taurine (30 mmol/L); glucose (5.5 mmol/
L); 2,3-butanedione-monoxime (10 mmol/L), pH 7.4].
Enzymatic digestion was performed with digestion-buffer
[perfusion-buffer with LiberaseTM (0.2 mg/mL), Trypsin
2.5 % (5.5 mmol/L); DNase (5 9 10-3 U/mL) and CaCl2
(12.5 lmol/L)] for 20 min at 37 C. At the end of enzy-
matic digestion, both ventricles were isolated and gently
disaggregated in 5 mL of Digestion Buffer. The resulting
cell suspension was filtered through a 100-lm sterile mesh
(SEFAR-Nitex) and transferred for enzymatic inactivation
to a tube with 10 mL of stopping-buffer-1 [perfusion-buf-
fer supplemented with fetal bovine serum (FBS, 10 % v/v)
and CaCl2 (12.5 lmol/L)]. After gravity sedimentation for
20 min, cardiomyocytes were resuspended in stopping-
buffer-2 containing lower FBS (5 % v/v) for another
20 min. Cardiomyocyte Ca2?-reintroduction was per-
formed in stopping-buffer-2 with five progressively
increased CaCl2 concentrations (62 lmol/L, 112 lmol/L,
212 lmol/L, 500 lmol/L and 1 mmol/L). Cells were
resuspended and allowed to decant for 10 min in each step,
contributing to the purification of the cardiomyocyte sus-
pension. The homogeneous suspension of rod-shaped
cardiomyocytes was then resuspended in M199 supple-
mented with Earle’s salts and L-glutamine, penicillin–
streptomycin (1 %), insulin–transferin–selenium-A (0.19),
bovine serum albumin (BSA, 2 g/L), blebbistatin
(25 lmol/L) and FBS (5 %). Cells were plated in single
drops onto 22-mm2 glass coverslips precoated with 200 lL
of mouse laminin (10 mg/mL) in phosphate-buffered saline
(PBS) for 1 h.
Hypoxia/reoxygenation in adult mouse cardiomyocytes
Prior to being subjected to induced hypoxia/reoxygenation,
plated isolated adult mouse cardiomyocytes were washed
and stabilized for 30 min at 37 C with normoxic-buffer
(NB) [NaCl (113 mmol/L); KCl (4.7 mmol/L); KH2PO4
(0.6 mmol/L); Na2HPO4 (0.6 mmol/L); MgSO47H2O
(1.2 mmol/L); NaHCO3 (12 mmol/L); KHCO3 (10 mmol/
L); HEPES-Na Salt (0.922 mmol/L); Glucose (10 mmol/
L); CaCl2 (1 mmol/L) and pH 7.4]. Hoechst 33342 (H42,
1 lg/mL) was added for cell recognition, and propidium
iodide (PI, 1 lg/mL) was added to evaluate cell viability.
Simulated ischemia was induced at 1 % O2 by placing cells
in a H35 Hypoxystation chamber (Don Whitley Scientific
Limited, UK) in ischemic-buffer (IB), in which glucose
and HEPES were replaced with lactate-Na (10 mmol/L)
and PIPES (10 mmol/L), at pH 6.8 for 30 min (IB was pre-
equilibrated at 1 % O2 for 2 h prior to use). After the
hypoxia incubation, IB was replaced with NB for 1 h to
simulate reperfusion. Duplicate wells were randomized to
receive (1) control: NaCl (0.9 %), (2) insulin as positive
control (2 nmol/L), (3) BRL37344 (7 lmol/L), or (4) NG-
nitro-L-arginine methyl ester (L-NAME (10 lmol/L).
Fluorescent images were acquired with a Nikon Time-lapse
confocal microscope after 15, 30, 45 and 60 min of
reoxygenation. An average of 350 rod-shaped cells/well
from 6 independent experiments was analyzed by a blinded
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observer using ImageJ 6.0 (NIH, Bethesda, MD, USA).
Cell death, indicated by internalization of red fluorescence
(Red, PI positive) was expressed as a percentage of the
total number of cardiomyocytes at each point (Blue, H42
positive) and normalized to saline treatment.
Western blot
For protein isolation, cardiomyocytes were maintained in
suspension in 1 mL of IB for 30 min at 1 % O2 in a H35
Hypoxystation chamber (Don Whitley Scientific Limited,
UK) followed by 15 min of simulated reoxygention in NB
in the CO2 incubator. Cardiomyocytes were spun down and
proteins isolated in RIPA lysis buffer (150 mmol/L NaCl,
1.0 % IGEPAL, 0.5 % sodium deoxycholate, 0.1 % SDS,
50 mmol/L Tris, pH 8.0) supplemented with protease/
phosphatase inhibitors. After quantification (Pierce BCA
Protein Assay Kit) 30 lg of protein was loaded on 10 and
7 % SDS polyacrylamide gels. After electrophoresis, pro-
teins were transferred to a polyvinylidene fluoride (PVDF)
membrane. Primary antibodies specific for total Akt and
phospho-Akt (Ser473) (Cell Signaling Technology, USA)
were incubated with the PVDF membranes overnight in
Tris Buffered Saline containing 0.1 % Tween and 5 %
bovine serum albumin. After HRP-secondary antibody
incubation blots were developed by chemiluminescence
using Luminata Forte substrate (Millipore, USA). Densi-
tometry of bands was analyzed with ImageJ 6.0 (NIH,
Bethesda, MD, USA). The ratio between the phospho-
specific and total protein densitometry signals was
calculated.
Induction and detection of mPTP opening
To determine the effect of beta-3-adrenoceptor stimulation
on the susceptibility to mPTP opening, we used a well-
characterized model that simulates the deleterious effect of
mitochondrial reactive oxygen species (ROS) production
upon reperfusion [6, 15, 17]. Maintained confocal laser-
stimulation of the fluorescent mitotraker tetramethyl-rho-
damine methyl ester (TMRM) produces ROS within the
mitochondria, which results in mPTP opening as indicated
by mitochondrial membrane depolarization [51]. Suscep-
tibility to mPTP opening was defined as the time taken to
induce mitochondrial membrane depolarization, visualized
as dequenching of TMRM fluorescence upon its translo-
cation to the cytoplasm. Isolated adult cardiomyocytes,
freshly plated on laminin-precoated (10 mg/mL) cover-
slips, were loaded with TMRM (3 lmol/L) in Hank’s
buffered saline solution (1.2 mmol/L CaCl2, 15 min at
37 C). Before induction and detection of mPTP opening,
cardiomyocytes were randomly assigned to the following
treatment groups and loaded for 10 min with (1) vehicle
control: DMSO (0.02 %) ? NaCl (0.9 %); (2) CsA posi-
tive control (0.4 lmol/L); (3) BRL37344 (7 lmol/L); (4)
Both treatments in combination (CsA ? BRL37344). An
average of 200 rod-shaped cells was analyzed per group in
9 different experiments. Cells were monitored with a Leica
confocal microscope (SP5), and images were acquired at
2.63-s intervals with simultaneous excitation at 543 nm.
The gain was adjusted to achieve maximum signal intensity
without saturation. All time values were normalized against
the mean time for cardiomyocytes maintained in vehicle.
Pig model of AMI
A re-perfused anterior wall AMI was experimentally
induced in 3-month-old castrated male Large-white pigs
bred at the CNIC’s farm. The protocol for AMI induction is
detailed elsewhere [33, 35]. In brief, anesthesia was induced
by intramuscular injection of ketamine (15 mg/kg), xyla-
zine (2 mg/kg), and midazolam (0.5 mg/kg). buprenorphine
(0.03 mg/kg) was used as an analgesic during the inter-
vention. All animals were intubated and mechanically
ventilated with oxygen (fraction of inspired O2, 28 %) and
anesthesia was maintained by intravenous administration of
midazolam (0.2 mg/kg/h). A continuous infusion of amio-
darone (300 mg, 150 mg/h) was maintained during the
procedure in all pigs as prophylaxis for malignant ventric-
ular arrhythmias. The LAD immediately distal to the origin
of the first diagonal branch was occluded for 60 min with an
angioplasty balloon inserted via the percutaneous femoral
route. Animals were allocated 1:1 by a restricted randomi-
zation (Efron’s biased coin randomization) to receive the
b3AR agonist (BRL37344, 5 lg/kg) or vehicle via marginal
vein of the ear 5 min before reperfusion. The treatment
(BRL37344 or vehicle) was prepared in non-labeled
syringes before the AMI induction and administered by
operators blinded to the randomization. After balloon
deflation, a coronary angiogram was obtained to confirm
appropriate coronary reperfusion. Animals were recovered
thereafter and cared by dedicated veterinarians and tech-
nicians at the CNIC Comparative Medicine Unit.
CMR protocol in pigs
Cardiac magnetic resonance studies were performed 7 and
45 days after AMI to assess infarct size and LV perfor-
mance. Pigs were anesthetized by intramuscular injection
of ketamine, xylacine and midazolam as described above,
and anesthesia was maintained by continuous intravenous
infusion of midazolam. All studies were performed using a
Philips 3-T Achieva Tx whole body scanner (Philips
Medical Systems, Best, The Netherlands) equipped with a
32-element cardiac phased-array surface coil. Images were
acquired with the use of ECG gating by operators blinded
Basic Res Cardiol (2014) 109:422 Page 5 of 15
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to the study arm. Segmented cine steady-state free pre-
cession (SSFP) was performed to acquire 11–13 contiguous
short-axis slices covering the heart from the base to the
apex to evaluate global and regional LV motion (FOV of
280 9 280 mm; slice thickness of 8 mm without gap; TR
2.8 ms; TE 1.4 ms, flip angle 45; cardiac phases 25; voxel
size 1.8 9 1.8 mm; 3 NEX). Edema imaging (for AAR
quantification) was performed with a T2-weighted, triple
inversion-recovery fast spin-echo (T2W-STIR) sequence
(FOV of 280 9 280; 11–13 short-axis slices with thickness
of 8 mm and no gap; TR 2–3 heartbeats; TE 80 ms; voxel
size 1.4 9 1.4 mm; STIR delay 210 ms; trigger delay
longest; echo-train length 16; 2 NEX). A coil sensitivity
correction algorithm for all T2W images was implemented
in the scan acquisition. Finally, late gadolinium enhance-
ment imaging was performed 15 min after the adminis-
tration of 0.2 mmol/kg gadopentate dimeglumine using an
inversion-recovery fast gradient-echo sequence to
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Fig. 1 Long-term
cardioprotective effect in mice
subjected to ischemia/
reperfusion after pre-reperfusion
administration of the b3AR
agonist BRL37344. a AAR
(%LV) and IS (%AAR) in
C57BL/6J WT mice subjected
to myocardial IRI and treated
with the b3AR agonist
BRL37344 (BRL, 5 lg/kg) or
vehicle before reperfusion.
b Representative histological
images of 1-mm-thick
transverse ventricular slices of
mice treated with BRL37344 or
vehicle. Upper images show the
AAR (negative for Evans Blue
staining). Lower images show
the extent of necrosis (paler
area) in the same sections after
incubation in TTC. c LVEF
evaluated by serial
echocardiography at 1, 4 and
12 weeks post-infarction in
mice treated with BRL37344 or
vehicle before reperfusion.
d Representative short-axis
echocardiography images at
mid-ventricular level,
illustrating left-ventricular
contractility defects (red
arrows). e LVEF evaluated by
serial CMR at 12 weeks post-
infarction in mice treated with
BRL37344 or vehicle before
reperfusion. f Representative
short-axis CMR images at mid-
ventricular level, illustrating LV
contractility defects (red
arrows). LV motion videos
obtained by echocardiography
and CMR are available in
Supplemental material online.
Data are presented as
mean ± SEM. *p \ 0.05
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determine MI size (FOV of 280 9 280 mm; 11–13 short-
axis slices with a thickness of 8 mm and no gap; TR
5.6 ms; TE 2.8 ms; voxel size 1.6 9 1.6 mm; time interval
optimized to null normal myocardium; trigger delay lon-
gest; bandwidth, 304 Hz per pixel; 2 NEX).
CMR data analysis
All CMR images were analyzed using dedicated software
(QMass MR v.7.6, Medis, Leiden, The Netherlands). Images
were analyzed by two experienced observers with vast
experience in CMR analysis and blinded to the study allo-
cation. The analysis protocol has been detailed elsewhere
[34]. In brief, LV cardiac borders were traced in each cine
image to obtain LV end-diastolic volume (LVEDV), end-
systolic volume (LVESV) and LVEF. LV volumes normal-
ized to the body surface area were calculated with Brody’s
formula [37]. The left ventricle was divided into 16 segments
based on the American Heart Association (AHA) segmented
model. Fractional wall systolic thickening was quantified
from endocardial and epicardial tracings using a centerline
analysis and expressed as the mean of the segmental thick-
enings. A wall systolic thickening index was calculated in
each animal as the number of segments of LV with fractional
wall systolic thickening higher than 30 % [40]. The area of
myocardium AAR was defined as the extent of the LV
demonstrating high signal intensity on T2W-STIR images
[1]. Infarct size (necrosis) was quantified from the extent of
abnormal delayed gadolinium enhancement. AAR and
necrosis were identified as hyperintense regions, defined as
[50 % of the peak myocardial signal intensity (full width
half maximum) with manual adjustment when needed. If
present, a central hypointense core within the area of
increased signal was included in the T2W-STIR or late
gadolinium enhancement analysis. As described above,
infarct size was expressed as a percentage of the AAR. In
addition, three short-axis slices (basal, mid-cavity and api-
cal) from the SSFP sequence of each animal were selected for
deformation analysis using CMR-based feature tracking
[45]. Circumferential strain was assessed with ad hoc soft-
ware (2D Cardiac Performance Analysis MR, TomTec
Imaging System, Germany). Endocardial borders were
manually drawn in all analyzed slices and then the automatic
computation was triggered. Finally, the global circumfer-
ential strain (GCS) in each animal was calculated as the
median of all segmental circumferential strains.
All animal studies conducted at the CNIC were approved
by the local ethics committee, and all animal procedures
conformed to EU Directive 2010/63EU and Recommen-
dation 2007/526/EC regarding the protection of animals
used for experimental and other scientific purposes,
enforced in Spanish law under Real Decreto 1201/2005.
Procedures carried out at the Hatter Cardiovascular Institute
(UCL) were conducted in accordance with the UK National
Institute of Health Guidelines for the Care and Use of
Laboratory Animals. Authors had full access to and take full
responsibility for the integrity of the data. All authors have
read and agree to the manuscript as written.
Drugs
Reagents were purchased from Sigma-Aldrich Co. LLC.,
Thermo Fisher Scientific Inc., and Tocris Bioscience.
Statistical analysis
The distribution of continuous variables was analyzed with
graphical methods. For normally distributed variables,
results are expressed as mean (SD) and compared either by
Table 1 Echocardiography-derived parameters from the mouse
model of myocardial IRI
Follow-up post-I/R Vehicle
(n = 9)
BRL37344
(n = 11)
p value
1-week echo
HR (bpm) 457 (58) 456 (54) 0.956
LVEDV (lL) 53.3 (13.2) 51.5 (15.7) 0.787
LVESV (lL) 30.9 (14.6) 24.9 (11.3) 0.312
LVEF (%) 44.2 (13.8) 52.7 (11.3) 0.148
SV (lL) 22.4 (6.3) 26.6 (8.8) 0.244
CO (mL/min) 10.2 (2.8) 12.0 (4.0) 0.264
SWMS 2.0 [2.5] 2.0 [2.0] 0.583
4-week echo
HR (bpm) 506 (55) 474 (46) 0.171
LVEDV (lL) 66.9 (19.4) 54.7 (9.4) 0.111
LVESV (lL) 45.9 (18.4) 33.4 (8.8) 0.090
LVEF (%) 33.0 (10.7) 39.6 (10.7) 0.188
SV (lL) 21.0 (5.4) 21.2 (4.8) 0.920
CO (mL/min) 10.5 (2.3) 10.1 (2.4) 0.686
SWMS 3.0 [2.0] 2.0 [2.0] 0.073
12-week echo
HR (bpm) 487 (40) 505 (52) 0.417
LVEDV (lL) 75.4 (22.4) 61.2 (12.4) 0.089
LVESV (lL) 54.4 (18.5) 35.9 (10.7) 0.012
LVEF (%) 28.4 (5.7) 41.7 (8.5) 0.001
SV (lL) 20.9 (5.1) 25.3 (6.2) 0.108
CO (mL/min) 10.2 (2.6) 12.7 (3.4) 0.080
SWMS 3.0 [0.5] 1.0 [1.0] 0.005
Bold values indicate statistical significance according to the pre-
specified threshold of significance (p \ 0.05). For a more detailed
information, the actual p values are provided
Values are expressed as mean (SD) or median [IQR] as appropriate
CO cardiac output, HR heart rate, I/R ischemia/reperfusion, LVEDV
LV end-diastolic volume, LVEF LV ejection fraction, LVESV LV
end-systolic volume, SV stroke volume, SWMS segmental LV wall
motion score
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Student’s unpaired t test (with Welch’s correction when
appropriate) or one-way ANOVA. When repeated mea-
surements were performed, two-way repeated-measures
ANOVA were applied followed by Bonferroni correction
for post hoc analysis. Non-normal data are reported as
median (IQR) and compared by Mann–Whitney U test.
Differences were considered statistically significant at
p value \0.05 (two-tailed).
Results
Pre-reperfusion administration with b3AR agonist
reduces infarct size and improves long-term cardiac
function in mice
Administration of the b3AR agonist BRL37344 before
reperfusion induced a significant reduction in infarct size
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Fig. 2 b3 adrenergic receptor
stimulation protects isolated
cardiomyocytes against
hypoxia/reoxygenation through
NO-dependent signaling.
Isolated adult mouse
cardiomyocytes were subjected
to 30-min hypoxia followed by
reoxygenation in the presence of
vehicle (0.9 % NaCl),
BRL37344 (BRL, 7 lM),
L-NAME (10 lM) or insulin
(2 nM; positive control).
a Representative fluorescent
microscopical images of
isolated cardiomyocytes before
H/R during (1) normoxia:
showing PI-negative rod-shaped
fresh cardiomyocytes and (2)
reoxygenation: showing a high
% of PI-positive
hypercontracted rounded cells.
b BRL37344 (BRL) treatment
significantly reduces cell death
while co-incubation with
L-NAME abrogates the
protective effect, detected as the
% of PI-positive cells. Data are
mean ± SEM of % PI scores in
images taken at 15 min intervals
up to 1 h. Groups were
compared by two-way repeated
measures ANOVA with the
Bonferroni correction for post
hoc analysis. c Percentage of
cell death in adult
cardiomyocytes isolated from
eNOS-KO mice and subjected
to H/R with or without
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The protective effect of
BRL37344 is abrogated in the
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(27.1 (13.0) % of area at risk (AAR) in b3AR-treated mice
vs. 41.1 (10.7) % with vehicle; p = 0.025) (Fig. 1a). AAR
was similar in both groups. Consistent with the reduced
infarct size, pre-reperfusion BRL37344 led to a long-term
improvement in LV contractile function, as assessed by
echocardiography at sequential follow-up evaluations
(Fig. 1c; Table 1). Similarly, CMR evaluation revealed
that LV ejection fraction (LVEF) was significantly higher
in BRL37344-treated mice than controls after 12 weeks
(46.5 (6.3) vs. 37.7 (6.0) %; p = 0.004; Fig 1e; Table 1).
The cardioprotection afforded by BRL37344 administra-
tion was absent in b3AR-KO mice: (31.5 (9.5) % of AAR
vs. 24.1 (6.7) %; p = 0.112; Supplemental Fig 1). Echo-
cardiographic and CMR videos are available in the sup-
plemental material online.
Selective b3AR stimulation with BRL37344 increases
survival of isolated adult cardiomyocytes undergoing
hypoxia/reoxygenation (H/R)
Isolated adult cardiomyocytes from WT mice were sub-
jected to simulated ischemia/reperfusion in the presence
of BRL37344 or saline. Analysis of PI exclusion showed
significant reduction of cell death in the presence of
BRL37344. Co-incubation with the NOS inhibitor
L-NAME abrogated the cardioprotection shown by
BRL37344 (Fig. 2a). When we repeated the procedure in
eNOS-KO cardiomyocytes no differences were found
between BRL37344-treated and non-treated cells. These
results confirm the key role of NO in the protection
exerted by b3AR-selective stimulation (Fig. 2c). Due to
the importance of Akt in cardioprotection [27], we
assessed the activation of AKT by western blot. Densi-
tometric analysis showed a significant increase of Akt
phosphorylation at serine 473 in BRL37344-treated cells
(Fig. 2d).
The cardioprotective effect of b3AR-selective
stimulation involves mPTP
To determine whether selective b3AR stimulation has a
direct pharmacological effect on mPTP, TMRM-preloaded
adult cardiomyocytes were incubated with BRL37344,
saline, or CsA, alone or in combination, and subjected to
oxidative-stress-induced mPTP opening. BRL37344 treat-
ment delayed the time to mPTP opening by 1.26 (0.67)-
fold compared with vehicle values (p \ 0.001; Fig. 3c).
Interestingly, combined treatment with BRL37344 and
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TMRM-preloaded adult cardiomyocytes subjected to laser-mediated
oxidative stress. a Time-lapse confocal images showing progressive
loss of mitochondrial membrane potential after induction of oxidative
stress by sustained confocal laser scanning. Arrows indicate sites of
incipient mPTP opening and consequent dequenching of the dye in
the cytoplasm. b Detailed view of mitochondrial membrane depolar-
ization: mPTP opening triggers rapid TMRM release from mitochon-
dria, resulting in locally increased fluorescence intensity due to dye
dequenching. mPTP opening proceeds in a wave across the cell in a
polarized manner and of the phenomenon of cardiomyocyte hyper-
contractility, caused by mitochondrial membrane depolarization after
sustained exposure to oxidative stress. c Normalized mean values of
the time to mPTP opening in cardiomyocytes after addition of vehicle
(DMSO, 0.02 %), cyclosporine-A (positive control; CsA, 0.4 lM),
BRL37344 (BRL, 7 lM) and BRL ? CsA. n independent experi-
ments, with 150–200 cells analyzed per treatment. Data are presented
as mean ± SEM. *p \ 0.05
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CsA did not further delay mPTP opening compared with
each treatment independently.
To confirm the implication of mPTP in b3AR-mediated
cardioprotection in vivo, we tested the effect of pre-
reperfusion BRL37344 on early IRI in WT and CypD KO
mice. In WT mice, b3AR stimulation significantly reduced
infarct size at 2 h reperfusion (28.1 (12.3) % of AAR vs.
45.8 (12.1) % in vehicle-treated mice; p = 0.020; Fig. 4b).
Consistent with the in vitro cardiomyocyte experiments,
b3AR stimulation did not reduce infarct size in animals
lacking mitochondrial CypD (30.9 (14.7) % vs. 30.0
(7.9) % of AAR in BRL37344- and vehicle-treated CypD
KO mice, respectively; p = 0.884; Fig. 4b).
Pre-reperfusion b3AR agonist administration reduces
infarct size and improves long-term cardiac function
in a swine model of myocardial I/R
Acute myocardial infarction was induced in Large-white
pigs (40.1 (6.2) kg) by percutaneous angioplasty (60 min
balloon-mediated LAD coronary occlusion) followed by
reperfusion. No pigs died during AMI induction, but seven
died within the first week after infarction and, therefore,
did not undergo day-7 CMR (3 allocated to BRL37344 and
4 to vehicle). Two pigs (one per treatment group) died
suddenly before completing the day 45 CMR. Final num-
bers of animals are noted in the figures.
Pre-reperfusion administration of BRL37344 provoked a
transient increase in heart rate compared with vehicle (10.0
(9.5) vs. -1.2 (2.3) change from baseline bpm; p = 0.013);
heart rate returned to baseline after 10 min. Conversely,
pre-reperfusion BRL37344 had no significant effect on
mean blood pressure (-0.13 (7.4) vs. -0.83 (2.8) mmHg;
p = 0.78). Full data in Supplemental Table 1.
On day 7 CMR, infarct size was significantly smaller in
the b3AR-agonist-treated group (80.0 (21.4) % of AAR,
vs. 93.5 (16.8) % in vehicle-treated pigs; p = 0.044;
Fig. 5a). Consistent with this, BRL37344-treated pigs had
improved LV contractile performance on day 45 CMR:
pigs receiving BRL37344 showed a better regional myo-
cardial contractile function than pigs treated with vehicle,
as evidenced by higher fractional systolic thickening (45.4
(5.8) % vs. 36.4 (9.0) %; p = 0.032; Table 2) and systolic
thickening index (11.0 (1.0) vs. 9.0 (2.0) segments;
p = 0.026; Fig. 5c). BRL37344-treated pigs also showed a
trend on day 45 CMR toward a higher LVEF (41.4 (6.3) %
vs. 37.0 (4.6) %; p = 0.119; Fig. 5b). Finally, myocardial
deformation analyses showed that pigs receiving the b3AR
agonist had a better global circumferential strain (-20.1
(1.7) vs. -17.0 (2.8) %; p = 0.018; Fig. 5e). Full CMR is
presented in Table 2.
Discussion
This study presents the first evidence for long-term ben-
efits from pre-reperfusion IV administration of a b3AR-
selective agonist in AMI. In a mouse model, these
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beneficial effects are evident both at very early (2 h
reperfusion) and late (24 h reperfusion) stages of IRI and
in isolated cardiomyocytes. Analysis with CMR shows
that b3AR agonism with BRL37344 limits infarct size
and improves cardiac function several weeks post AMI in
mice and pigs. This cardioprotective effect is mediated by
a delay in mPTP opening dependent on the Akt-NO sig-
naling pathway. To our knowledge, this is the first dem-
onstration of reduced IRI and associated long-term
functional benefits after a single i.v. administration of a
b3AR agonist in a clinically relevant large animal model
of AMI.
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Fig. 5 Pre-reperfusion
treatment of the b3AR agonist
BRL37344 reduces infarct size
and exerts a long-term
beneficial effect in a pig model
of AMI. a Infarct size (%AAR)
assessed by CMR at 7 days
post-infarction in large-white
pigs. BRL stands for BRL37344
(5 lg/kg). b Evolution of LVEF
in vehicle- and BRL37344-
treated pigs, assessed by CMR
at 7 and 45 days post-infarction;
LVEF tends to improve in
BRL37344-treated pigs while it
tends to worsen in vehicle-
treated pigs. c LV systolic wall
thickening index assessed by
CMR at long-term follow-up.
d Representative short-axis
CMR images at the same level
of the LV, showing the extent of
area at risk (AAR: hyper-intense
area in T2-weighted CMR
sequence), myocardial necrosis
[delayed enhancement (DE)
after gadolinium injection], and
the merged view of both in one
animal receiving pre-
reperfusion BRL37344 and in
another receiving vehicle.
e Global circumferential strain
assessed by CMR-based feature
tracking. f Representative
segmental circumferential strain
images evaluated by CMR-
based feature tracking in a pig
receiving pre-reperfusion b3AR
agonist treatment. Data are
presented as mean ± SEM.
*p \ 0.05
Basic Res Cardiol (2014) 109:422 Page 11 of 15
123
b3AR agonist administration before reperfusion
reduces infarct size, resulting in a long-term beneficial
effect
b3AR-selective stimulation has recently been proposed as
a new therapy for several myocardial diseases [3, 12, 39].
Aragon et al. [3] recently demonstrated a reduction in
infarct size (evaluated 24 h after IRI) when a b3AR agonist
was administered before reperfusion but reported no
improvement in cardiac function after b3AR agonist
treatment in mice assessed by echocardiography at short-
term follow-up (1 week), raising doubts about whether
evidence of cardioprotection from histological evaluation
translates to functional benefits. Our present data confirm
the beneficial pre-reperfusion b3AR agonist administration
effect when evaluated at early stages (2 h reperfusion),
suggesting that the cardioprotection afforded by this ther-
apy takes place within the first minutes of reperfusion.
Similar to Aragon’s results, our data show that LV function
1 week after AMI did not differ significantly between
b3AR-agonist- and vehicle-treated animals. However, the
longer follow-up period in our study allowed us to dem-
onstrate a clear association of the infarct-limiting effects of
pre-reperfusion b3AR-agonist treatment with improved
cardiac function shown by both echocardiography and
CMR. The most likely reason for the late appearance of
improved cardiac function is that at early stages the sal-
vaged myocardium is in a stunned, non-contractile, state
and that full contractile recovery is, therefore, seen only
after longer follow-up. This interpretation is supported by
the gradual recovery of segmental LV wall motion scores
after 1-week follow-up in b3AR-agonist-treated mice
(Table 1). These results thus highlight the importance of
long-term follow-up for evaluation of the functional ben-
efits of a cardioprotective intervention.
It is noteworthy that infarcts in b3AR KO mice appear
to be smaller than those in wild-type mice. A similar
effect is apparent in previous works by other groups [3]. In
this regard, it should be noted that the b3AR KO mice
used here were in the FVB/N genetic background, which
has been reported to confer innate cardioprotection against
IRI [25]. Another potential explanation for this effect
could be that the absence of b3AR results in a redistri-
bution of the other two types of bAR. If bAR redistribu-
tion would result in an upregulation of b2AR, this might
explain the spontaneous protection of these mice, since
signaling via b2AR during IRI has been shown to reduce
infarct size [7], and its upregulation by gene therapy
results in an incremental protective cardiac phenotype
[43]. However, this alternative protective scenario in
b3AR KO mice is speculative since the actual redistribu-
tion of b1AR and b2AR in the absence of b3AR has not
been studied in the heart.
Cardiomyocyte b3AR-Akt-eNOS-NO-mPTP signaling
pathway is implicated in the cardioprotection afforded
by b3AR-selective stimulation
Previous studies into the protective effect of b3AR-selec-
tive stimulation in cardiac diseases [3, 14, 39] did not
address whether the mechanism involves an action in
cardiomyocytes [28]. In our analysis, b3AR-selective
stimulation significantly increased the viability of isolated
adult cardiomyocytes in response to hypoxia/reoxygena-
tion, indicating that the cardioprotection associated with
b3AR-agonist stimulation occurs in the early phases of IRI
through an effect at the cardiomyocyte level. We further
demonstrate that serine 473 phosphorylation of Akt and
NO-dependent signaling are both critical mediators of this
protection.
Moreover, BRL37344 significantly delays the opening
of the mPTP, which plays a central role in cardiomyocyte
death upon IRI [4, 18]. Interestingly, the co-incubation of
cardiomyocytes with BRL37344 and a known inhibitor of
mPTP opening, CsA, did not significantly increase the
delay in mPTP opening, suggesting that the two agents act
on the same cardioprotective pathway. Finally, we have
documented that b3AR stimulation had no additional
infarct-limiting effect in CypD-KO mice [4], which have
been shown to be protected against IRI [4, 6], again sug-
gesting action on the same pathway. Although CypD KO
mice are strongly protected against IRI, further reductions
in infarct size in these animals can be obtained with
Table 2 CMR-derived parameters from the large animal (pig) model
of AMI
Vehicle BRL37344 p value
7-day CMR n = 10 n = 9
LVEDV (mL/m2) 129.1 (18.2) 120.9 (18.4) 0.344
LVESV (mL/m2) 78.0 (15.3) 72.4 (15.6) 0.440
LVEF (%) 39.8 (6.3) 40.6 (4.8) 0.766
AAR (% LV) 28.2 (5.2) 29.0 (4.2) 0.718
Infarct size (% AAR) 93.5 [16.8] 80.0 [21.4] 0.044
45-day CMR n = 9 n = 8
LVEDV (mL/m2) 147.6 (26.6) 139.3 (20.4) 0.487
LVESV (mL/m2) 93.3 (19.8) 82.3 (19.3) 0.269
LVEF (%) 37.0 (4.6) 41.4 (6.3) 0.119
SWT (%) 36.4 (9.0) 45.4 (5.8) 0.032
SWT index 9.0 [2.0] 11.0 [1.0] 0.026
GCS (%) -17.0 (2.8) -20.1 (1.7) 0.018
Values are expressed as mean (SD) or median [IQR] as appropriate
AAR area at risk, GCS global circumferential strain, LVEDV LV end-
diastolic volume, LVESV LV end-systolic volume, SWT systolic wall
thickening
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protective strategies affecting targets other than the mPTP
[6]. Altogether, these data indicate that the protection
exerted by b3AR selective stimulation involves the mPTP.
Pre-reperfusion b3AR agonist administration provides
cardioprotection in a preclinical large animal model
of AMI
A key finding of the present study is that pre-reperfusion
b3AR-agonist administration reduces infarct size and
improves long-term cardiac function in a more translational
large animal (pig) model of AMI. Several novel therapies
have demonstrated beneficial effects in preclinical studies
but subsequently failed in the clinical arena. This poor
translation between preclinical findings and clinical studies
is in part due to the absence of randomized studies showing
robust beneficial outcomes in large-animal models [46].
The pig model was selected because of its anatomical and
physiological similarities to humans. To mimic a potential
clinical scenario, we administered BRL37344 before cor-
onary reperfusion and quantified infarct size by CMR,
assessing the myocardial AAR to better define the protec-
tive effect of the intervention.
Taken together, our results show that a single i.v.
administration of a b3AR agonist before reperfusion pro-
vides a powerful and highly translational cardioprotective
therapy for AMI, and this beneficial effect is translated into
long-term improvement in cardiac contractile function. In
addition, we show that b3AR selective stimulation during
IRI is associated with an increase in Akt phosphorylation
and bioavailability of NO and ultimately in inhibition of
lethal mitochondrial collapse upon restoration of blood
flow (see Fig. 6).
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Background—The effect of β-blockers on infarct size when used in conjunction with primary percutaneous coronary 
intervention is unknown. We hypothesize that metoprolol reduces infarct size when administered early (intravenously 
before reperfusion).
Methods and Results—Patients with Killip class II or less anterior ST-segment–elevation myocardial infarction (STEMI) 
undergoing percutaneous coronary intervention within 6 hours of symptoms onset were randomized to receive intravenous 
metoprolol (n=131) or not (control, n=139) before reperfusion. All patients without contraindications received oral metoprolol 
within 24 hours. The predefined primary end point was infarct size on magnetic resonance imaging performed 5 to 7 days after 
STEMI. Magnetic resonance imaging was performed in 220 patients (81%). Mean±SD infarct size by magnetic resonance 
imaging was smaller after intravenous metoprolol compared with control (25.6±15.3 versus 32.0±22.2 g; adjusted difference, 
−6.52; 95% confidence interval, −11.39 to −1.78; P=0.012). In patients with pre–percutaneous coronary intervention 
Thrombolysis in Myocardial Infarction grade 0 to 1 flow, the adjusted treatment difference in infarct size was −8.13 (95% 
confidence interval, −13.10 to −3.16; P=0.0024). Infarct size estimated by peak and area under the curve creatine kinase 
release was measured in all study populations and was significantly reduced by intravenous metoprolol. Left ventricular 
ejection fraction was higher in the intravenous metoprolol group (adjusted difference, 2.67%; 95% confidence interval, 
0.09–5.21; P=0.045). The composite of death, malignant ventricular arrhythmia, cardiogenic shock, atrioventricular block, 
and reinfarction at 24 hours in the intravenous metoprolol and control groups was 7.1% and 12.3%, respectively (P=0.21).
Conclusions—In patients with anterior Killip class II or less ST-segment–elevation myocardial infarction undergoing 
primary percutaneous coronary intervention, early intravenous metoprolol before reperfusion reduced infarct size and 
increased left ventricular ejection fraction with no excess of adverse events during the first 24 hours after STEMI.
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Timely reperfusion by primary percutaneous coronary intervention (PCI) is the best therapeutic strategy for 
ST-segment–elevation myocardial infarction (STEMI),1,2 
and its widespread use has significantly reduced mortality.3 
However, STEMI survivors are at high risk of recurrent car-
diovascular events such as congestive heart failure, arrhyth-
mia, and sudden death. A major determinant of postinfarction 
mortality and morbidity is the extent of myocardial necrosis 
after STEMI4; therefore, strategies to limit infarct size (car-
dioprotection during STEMI) are important. Several mechani-
cal and pharmacological interventions have been proposed as 
potential cardioprotective therapies,5 but their use in clinical 
practice has been limited.
Editorial see p 1487   
Clinical Perspective on p 1503
The potential of β-blockers to limit myocardial necrosis was 
proposed long ago,6 but their cardioprotective capacity dur-
ing STEMI has been disputed.7 Most analyses of the infarct- 
limiting effects of β-blockers were done in the prereperfusion 
era and yielded conflicting results.8–11 Data on the cardiopro-
tective effect of β-blockers during thrombolytic reperfusion are 
scarce, with just 1 randomized12 and 1 nonrandomized13 study, 
with contradictory results. In the era of primary PCI as the treat-
ment of choice for STEMI, no randomized trials aiming to test 
the infarct-limiting effect of β-blockers have been published.
Data from large-animal models of acute myocardial infarc-
tion show that the β1-selective blocker metoprolol is able 
to markedly reduce infarct size but only when administered 
intravenously before reperfusion.14,15 Current clinical guide-
lines for STEMI recommend the initiation of oral β-blockers 
within 24 hours after infarction for patients with no contrain-
dications1,2; very early intravenous β-blockade, although per-
mitted, is not mandatory.
We aimed to determine whether early pre-reperfusion 
intravenous β-blocker administration reduces infarct size in 
STEMI patients treated by primary PCI by performing a mul-
ticenter, randomized, controlled, clinical trial.
Methods
The design of the study has previously been published.16 The Effect 
of Metoprolol in Cardioprotection During an Acute Myocardial 
Infarction (METOCARD-CNIC) trial was a multicenter, random-
ized, parallel-group, single-blinded (to outcome evaluators) clini-
cal trial in STEMI patients comparing pre-reperfusion intravenous 
metoprolol and no pre-reperfusion metoprolol (control). The pri-
mary hypothesis of the trial was that anterior STEMI patients receiv-
ing early intravenous metoprolol before reperfusion would have a 
reduced infarct size compared with control subjects. All patients 
received oral metoprolol within 24 hours after reperfusion, as rec-
ommended by current clinical guidelines.1,2
The study was approved by the ethics committees and institutional 
review boards at each participating center. All eligible patients gave 
written informed consent.
Patient Selection and Randomization
Patients eligible for enrollment were 18 to 80 years of age and 
showed symptoms consistent with STEMI for >30 minutes and ST 
elevation ≥2 mm in ≥2 contiguous leads in V1 through V5 with an 
anticipated time of symptom onset to reperfusion of ≤6 hours. To 
ensure that all patients underwent reperfusion within 6 hours from 
symptom onset, the inclusion criterion was ≤4.5 hours from symptom 
onset to randomization.16 Exclusion criteria were Killip class III to IV 
acute myocardial infarction, systolic blood pressure persistently <120 
mm Hg, PR interval >240 milliseconds (or type II–III atrioventricular 
block), heart rate persistently <60 bpm, or active treatment with any 
β-blocker agent.
To avoid a potential selection bias, randomization was done after 
informed consent was signed by the patient.
Patients randomized to intravenous metoprolol received up to three 
5-mg boluses of metoprolol tartrate 2 minutes apart.17 Patients were 
identified and randomized either out of hospital by the participating 
emergency medical services or on arrival at any of the 7 participat-
ing hospitals (in 4 regions across Spain). Patients randomized to the 
intravenous metoprolol group in the out-of-hospital setting received 
intravenous metoprolol during transfer to the PCI center.
Apart from intravenous metoprolol, patients were treated accord-
ing to clinical guidelines. Thrombus aspiration and use of glycopro-
tein IIb/IIIa during PCI were recommended. All patients except those 
who developed contraindications received oral metoprolol tartrate 
during hospitalization. The first oral dose was scheduled for 12 to 24 
hours after infarction, in line with clinical guidelines.1,2
Randomization was stratified by time from symptom onset to 
enrollment (<1.5 versus ≥1.5 hours), diabetes mellitus status, sex, 
and age (<60 versus ≥60 years). Patients were randomized 1:1 by 
telephone with a block size of 4 within strata. The randomization 
center was located at the SUMMA112 emergency medical services 
headquarters and was run around the clock by trained nurses.
Magnetic resonance imaging (MRI) was scheduled for 5 to 7 days 
after infarction. Patients on long-term β-blocker treatment, with 
a history of previous acute myocardial infarction, or with no final 
diagnosis of acute myocardial infarction (no enzymatic evidence of 
infarction) were excluded from the primary analysis according to the 
protocol and thus did not undergo MRI.16
End Points
The primary end point was infarct size by MRI (extent of myo-
cardial necrosis quantified by delayed gadolinium enhancement). 
Prespecified efficacy secondary end points were the extent of 
myocardial salvage on MRI, infarct size quantified by MRI in the 
subgroup of patients with a pre-PCI Thrombolysis in Myocardial 
Infarction (TIMI) grade 0 to 1 flow, and infarct size estimated by 
peak and area under the curve (AUC; 72 hours) release of creatine 
kinase (CK). The major prespecified safety secondary end point was 
the incidence of major adverse cardiac events, defined as a compos-
ite of death, malignant ventricular arrhythmias, advanced atrioven-
tricular block, cardiogenic shock, and reinfarction during the first 
24 hours after STEMI.
MRI and angiography were evaluated at independent core labora-
tories; end-point events were adjudicated by an independent clinical 
events committee. All were blinded to treatment group.
MRI Performance and Analysis
A detailed description of the MRI protocol and methods for analysis 
is reported elsewhere.16 Analyses were undertaken by the core labora-
tory at Centro Nacional de Investigaciones Cardiovasculares Carlos 
III (CNIC). Data were quantified with dedicated software (QMass 
MR 7.5; Medis, Leiden, the Netherlands). Left ventricular (LV) 
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01311700. EUDRACT number: 
2010-019939-35.  (Circulation. 2013;128:1495-1503.)
Key Words: adrenergic beta-antagonist ◼ infarction ◼ magnetic resonance imaging ◼ metoprolol  
◼ myocardial infarction ◼ percutaneous coronary intervention ◼ reperfusion injury
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volume, LV mass, LV ejection fraction (LVEF), and the extent of 
edema and necrosis were determined. Myocardial necrosis (grams of 
LV tissue) was defined by the extent of abnormal delayed gadolinium 
enhancement, whereas myocardium at risk (grams of LV tissue) was 
defined by the extent of edema (high signal intensity on T2-weighted 
short T1 inversion-recovery images).18,19 Myocardial salvage was 
defined as the difference between myocardium at risk and myocardial 
necrosis normalized to myocardium at risk.18,19
Statistical Methods
The study was powered for detect a relative reduction in infarct 
size of 20% in patients receiving intravenous metoprolol. This 
required 220 evaluable patients to provide 90% power (2-sided 
α=0.05). Sample size calculation was based on a previous MRI-
based study reporting mean infarct size and dispersion in anterior 
STEMI patients.20 To compensate for ≈20% patients not undergo-
ing MRI,16 we planned to recruit ≈275 patients. All randomized 
patients, including those not undergoing MRI, were analyzed for 
clinical end points.
All efficacy analyses were performed according to the intention-
to-treat principle. For quantitative variables, data are expressed as 
mean±SD and compared by parametric methods. Nonnormal data are 
reported as medians with first and third quartiles and were compared 
by nonparametric methods (Wilcoxon rank-sum test). For categorical 
data, percentages were compared by use of exact methods. Because 
the variance of peak and AUC CK release data tends to be propor-
tional to the mean, a square-root transformation was used.
MRI data were analyzed by linear regression models, with treat-
ment effect estimates (and 95% confidence intervals [CIs]) presented 
both without and with adjustment for the 4 stratification variables.
To confirm that the analysis based on MRI-quantified infarct size 
was not influenced by selection bias, a sensitivity analysis was per-
formed comparing the estimated difference between treatments for 
peak and AUC CK release between the overall study population and 
the subset undergoing MRI. All analyses were conducted with the R 
2.14.1 statistical language.
Results
Study Population
Between November 2010 and October 2012, 270 patients were 
randomized to receive intravenous metoprolol pre-reperfusion 
(n=139) or no metoprolol pre-reperfusion (n=131, control sub-
jects). One hundred forty-seven patients (55%) were random-
ized out of hospital during ambulance transfer to the PCI center. 
Four patients (2 in each group) withdrew consent. Twenty-four 
patients (9%) were not scheduled for MRI because of errone-
ous recruitment criteria (n=14) or no enzymatic evidence of 
infarction (n=10). Of patients scheduled for MRI, 22 (9%) 
did not undergo MRI because of poor clinical status (n=7), 
claustrophobia (n=12), or technical problems with the mag-
net (n=3). Patients with poor clinical status not undergoing 
MRI included 4 patients in the intravenous metoprolol group 
(2 patients with refractory heart failure, 1 patient with cardiac 
rupture, and 1 patient with massive hemoptysis) compared 
with 3 patients in the control group (2 patients with refractory 
heart failure and 1 patient with aortic dissection). Thus, 220 
patients (106 receiving intravenous metoprolol and 114 con-
trol subjects) had MRI data available for primary analysis. A 
CONSORT (Consolidated Standards of Reporting Trials) flow 
diagram is shown in Figure 1. Baseline characteristics of the 
study population are presented in Table 1.
Figure 1. Diagram of patients flow in the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-
CNIC) trial. Patients with no ECG criteria exclusions included the following. Three patients (all 3 allocated to intravenous metoprolol pre-
reperfusion) who had no ST-segment elevation ≥2 mm. These patients had no enzymatic evidence of infarction and had a final diagnosis 
of unspecific chest pain. Two patients (1 in each study group) had ST-segment elevation only in leads II, III, and aVF. One patient 
(allocated to intravenous metoprolol pre-reperfusion) had junction rhythm. AMI indicates acute myocardial infarction; and MRI, magnetic 
resonance imaging.
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Metoprolol Administration
Of the 139 patients allocated to pre-reperfusion intrave-
nous metoprolol, 138 (99%) received at least one 5-mg 
metoprolol intravenous bolus (82% received 2 boluses and 
67% received 3 boluses). The same pattern was found for 
the subset randomized in the out-of-hospital environment. 
Intravenous metoprolol was administered at a median of 10 
minutes (quartiles 1 and 3, 7 and 19 minutes) after STEMI 
diagnosis. Oral metoprolol was initiated within 24 hours 
after STEMI in 96% and 92% of patients in the intravenous 
metoprolol and control groups, with mean±SD initiation 
times of 15.7±10.6 and 15.9±8.7 hours after reperfusion, 
respectively.
Two patients allocated to the control group erroneously 
received pre-reperfusion intravenous metoprolol. These 
patients were included in the control group for the intention-
to-treat analyses and in the intravenous metoprolol group for 
the safety analysis of major adverse cardiac events. Similarly, 
1 patient allocated to intravenous metoprolol did not receive 
any owing to a vagal reaction and was included in the intrave-
nous metoprolol group for primary analysis and in the control 
group for the analysis of major adverse cardiac events.
Table 1. Baseline Characteristics of the Patients*
All Patients (n=270) Patients Undergoing MRI (n=220)
Intravenous Metoprolol 
(n=139)
Control  
(n=131)
Intravenous Metoprolol 
(n=106)
Control  
(n=114)
Age, y 58.7±12.7 58.2±10.8 58.4±12.4 58.7±10.6
Male sex, n (%) 119 (85.6) 114 (87) 92 (86.8) 99 (86.8)
Body mass index, kg/m2 27.6±3.7 27.9±3.9 27.5±3.5 27.8±3.9
Hypertension, n (%) 54 (40.3) 54 (42.2) 38 (36.5) 48 (42.1)
Smoking, n (%)
  Current smoker 71 (53) 69 (53.9) 56 (53.8) 59 (51.8)
  Ex-smoker (0–10 y before) 14 (10.4) 14 (10.9) 12 (11.5) 12 (10.5)
Dyslipidemia, n (%) 53 (39.8) 51 (40.2) 43 (41.3) 47 (41.2)
Diabetes mellitus, n (%) 31 (23.3) 24 (18.8) 21 (20.2) 22 (19.3)
Ischemia duration, min† 197±61 187±66 198±62 187±67
Killip class at recruitment, n (%)
  I 128 (92.1) 114 (87.0) 98 (92.5) 100 (87.7)
  II 11 (7.9) 17 (13.0) 8 (7.5) 13 (11.4)
Infarct artery lesion location, n (%)
  Proximal LAD 37 (26.6) 38 (29.0) 29 (27.4) 34 (29.8)
  Mid LAD 76 (54.7) 71 (54.2) 62 (58.5) 67 (58.8)
  Distal LAD 11 (7.9) 11 (8.4) 11 (10.4) 9 (7.9)
  Diagonal 3 (2.2) 1 (0.8) 2 (1.9) 1 (0.9)
  Left main 1 (0.7) 1 (0.8) 0 (0) 0 (0)
  Other 11 (7.9) 9 (6.9) 2 (1.9) 3 (2.6)
TIMI grade 0–1 flow before PCI, n (%) 104 (76.5) 101 (77.1) 86 (81.1) 92 (80.7)
Successful PCI, n (%)‡ 128 (94.1) 125 (95.4) 106 (100) 111 (97.4)
SBP at recruitment, mm Hg 143±19 142±19 142±18 142±19
HR at recruitment, bpm 82±14 82±14 82±13 82±14
SBP after intravenous metoprolol, mm Hg 129±20 NA 128±18 NA
HR after intravenous metoprolol, bpm 69±12 NA 68±12 NA
Treatment at the time of PCI, n (%)
  Heparin 123 (95.3) 119 (96) 102 (96.2) 108 (96.4)
  Aspirin 127 (98.4) 121 (97.6) 105 (99.1) 109 (97.3)
  Thienopyridine 126 (97.7) 121 (97.6) 104 (98.1) 110 (98.2)
  Thrombus aspiration 108 (82.4) 100 (80.6) 91 (85.8) 92 (82.1)
  GP IIb/IIIa during PCI 92 (70.2) 99 (79.8) 76 (71.7) 90 (80.4)
There were no significant differences in any of the baseline characteristics. GP indicates glycoprotein; HR, heart rate; LAD, 
left anterior descending coronary artery; MRI, magnetic resonance imaging; NA, not applicable; PCI, percutaneous coronary 
intervention; SBP, systolic blood pressure; and TIMI, Thrombolysis in Myocardial Infarction.
*Plus-minus values are mean±SD. 
†Ischemia duration means time from symptom onset to reperfusion. 
‡Successful PCI was defined as TIMI grade 2 to 3 flow after PCI. 
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Effect on Infarct Size
MRI data are presented in Table 2. Mean±SD infarct size in 
the intravenous metoprolol group (primary end point) was 
25.6±15.3 versus 32.0±22.2 g in the control group (adjusted 
treatment effect, −6.52; 95% CI, −11.39 to −1.78; P=0.012). 
Myocardial salvage (see Methods) in the intravenous metopro-
lol group was 34.9±22.3% versus 27.7±23.7% in the control 
group (adjusted treatment effect, 7.20%; 95% CI, 0.78–13.48; 
P=0.024). Infarct size in the subset of patients with a pre-PCI 
TIMI grade 0 to 1 flow (prespecified secondary end point) was 
26.7±15.0 g in intravenous metoprolol patients versus 34.4±20.0 
in the control group (adjusted treatment effect, −8.13; 95% CI, 
−13.10 to −3.16; P=0.0024). In the subset of patients with a 
pre-PCI TIMI grade 2 to 3 flow (patent artery), infarct size 
was 20.7±16.4 g in the intravenous metoprolol group versus 
22.2±28.3 g in the control group (P=0.6). Infarct size distribu-
tions in the 2 predefined study groups are illustrated in Figure 2.
Infarct size was also estimated in all study population by 
peak and AUC CK release as prespecified secondary end 
points. Pre-reperfusion intravenous metoprolol administra-
tion significantly reduced infarct size estimated by peak and 
AUC CK release. Peak CK in the intravenous metoprolol 
group was 2397±214 versus 3176±254 IU/L in the control 
group (adjusted treatment effect, −740; 95% CI, −1361 to 
−120; P=0.019). The AUC CK in the intravenous metopro-
lol group was 49 427±4013 versus 62 953±4634 IU/L in the 
control group (adjusted treatment effect, −12 825; 95% CI, 
−24 346 to −1305; P=0.029). Similar results were obtained 
in the subset of patients undergoing MRI. These findings are 
shown in Figure 3.
Pre-reperfusion administration of intravenous metopro-
lol significantly increased LVEF on MRI (46.1±9.3% ver-
sus 43.4±10.4%; adjusted treatment effect, 2.67; 95% CI, 
0.09–5.21; P=0.045). In the subset of patients with a TIMI 
grade 0 to 1 flow before primary PCI, LVEF was 45.1±8.9% 
in the intravenous metoprolol group versus 41.0±9.5% in 
the control group (adjusted treatment effect, 4.13; 95% CI, 
1.34–6.85; P=0.0031).
Safety Data
The prespecified safety end point was the incidence of major 
adverse cardiac events within 24 hours after STEMI in all 
patients (entire study population). Prereperfusion administra-
tion of intravenous metoprolol did not increase the incidence 
of major adverse cardiac events: There were 10 events (7.1%) 
in the prereperfusion intravenous metoprolol group and 16 
Figure 2. Effect of early pre-reperfusion intravenous metoprolol 
administration on infarct size evaluated by magnetic resonance 
imaging (MRI) 5 to 7 days after infarction. A and B, Infarct size 
assessed by delayed gadolinium enhancement in all patients 
undergoing MRI (A) and in the subset of patients with TIMI grade 
0 to 1 flow before primary percutaneous coronary intervention 
(PCI) (B). Red lines represent mean±SEM. Circles are individual 
patient data. TIMI indicates Thrombolysis in Myocardial Infarction.
Table 2. Magnetic Resonance Imaging Data (5 to 7 Days After Infarction)
Patients Undergoing MRI (n=220)
Intravenous Metoprolol 
(n=106) Control (n=114) Unadjusted
Adjusting for Stratification  
Variables
Mean (SD) Mean (SD) Difference (95% CI) P Value Difference (95% CI) P Value
LVEDV, mL 169.0 (33.0) 172.6 (39.4) −3.64 (−13.14 to 5.84) 0.46 −4.37 (−13.22 to 4.41) 0.33
LVESV, mL 91.9 (26.7) 99.6 (34.8) −7.70 (−15.92 to 0.41) 0.063 −7.85 (−15.70 to −0.09) 0.047
LV mass, g 108.8 (24.7) 112.5 (26.3) −3.72 (−10.29 to 2.84) 0.28 −4.08 (−10.06 to 1.89) 0.2
Myocardium at risk, g 37.6 (17.1) 40.9 (20.0) −3.30 (−8.19 to 1.44) 0.19 −3.44 (−8.29 to 1.26) 0.16
Infarcted myocardium, g* 25.6 (15.3) 32.0 (22.2) −6.43 (−11.46 to −1.67) 0.013 −6.52 (−11.39 to −1.78) 0.012
Infarcted myocardium, % LV 21.2 (11.5) 25.1 (13.9) −3.85 (−7.28 to −0.51) 0.029 −3.77 (−7.17 to −0.46) 0.032
Salvage index: (MAR−IM)/MAR, %† 34.9 (22.3) 27.7 (23.7) 7.17 (0.80 to 13.30) 0.028 7.20 (0.78 to 13.48) 0.024
LVEF, % 46.1 (9.3) 43.4 (10.4) 2.74 (0.13 to 5.35) 0.039 2.67 (0.09 to 5.21) 0.045
Infarcted myocardium in pre-PCI 
TIMI grade 0–1 flow, g‡
26.7 (15.0) 34.4 (20.0) −7.72 (−12.82 to −2.85) 0.004 −8.13 (−13.10 to −3.16) 0.002
Infarcted myocardium in pre-PCI 
TIMI grade 0–1 flow, % LV
21.9 (11.1) 26.7 (13.0) −4.77 (−8.21 to −1.25) 0.011 −4.91 (−8.40 to −1.35) 0.0078
CI indicates confidence interval; IM, infarcted myocardium; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left 
ventricular end-systolic volume; MAR, myocardium at risk; MRI, magnetic resonance imaging; PCI, percutaneous coronary intervention; and TIMI, Thrombolysis in 
Myocardial Infarction.
*Primary end point.
†Prespecified secondary end point.
‡Prespecified secondary end point in 178 patients (86 receiving intravenous metoprolol and 92 control subjects).
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events (12.3%) in the control group (P=0.21). Adverse cardiac 
events are presented in Table 3.
Discussion
This study shows that early administration of intravenous 
metoprolol before reperfusion reduces infarct size and 
increases LVEF in anterior STEMI patients undergoing pri-
mary PCI. It also appears safe and does not increase the inci-
dence of cardiac events during admission.
Our objective was to determine whether intravenous meto-
prolol reduced infarct size in STEMI patients treated accord-
ing to current clinical guidelines,1,2 including glycoprotein IIb/
IIIa and thrombus aspiration, 2 widely applied interventions 
with potential infarct-limiting effects.21,22
Infarct size was evaluated by 3 different methods: total 
myocardial necrosis by MRI (the gold standard), relative 
myocardial necrosis by MRI (normalized to myocardium 
at risk), and biomarker (CK) release. All 3 methodologies 
provided evidence of a significant and consistent reduction 
in infarct size resulting from pre-reperfusion intravenous 
metoprolol administration. LVEF 1 week after STEMI was 
significantly increased by intravenous metoprolol, as evalu-
ated by highly accurate MRI technology. Because reduced 
LVEF is a strong predictor of postinfarction mortality, this 
finding adds to the clinical value of pre-reperfusion intrave-
nous metoprolol administration.
β-Blockers are a first-line treatment in secondary preven-
tion after acute myocardial infarction with a clear reduction 
in mortality.23 Current guidelines recommend oral β-blockade 
within 24 hours after STEMI1,2 but with no emphasis on early 
intravenous initiation before reperfusion. Previous studies of 
β-blocker effects on infarct size had inconclusive results7 but 
were conducted before reperfusion became the standard treat-
ment for STEMI. Recent studies in large animals indicate that 
metoprolol can reduce infarct size14 if administered before 
reperfusion15 and may reduce reperfusion injury.24 We there-
fore hypothesized that the conflicting findings on the cardio-
protective capacity of β-blockers in STEMI reflect the facts 
that very few clinical studies have been performed in the reper-
fusion era and that no studies testing the ability of β-blockers 
to reduce infarct size have been done in the era of primary 
PCI as the treatment of choice for STEMI. Van de Werf et al12 
Table 3. Adverse Cardiac Events
Intravenous Metoprolol 
(n=140), n (%)
Control  
(n=130),  
n (%)
MACE at 24 h 10 (7.1) 16 (12.3)
Death 0 (0) 1 (0.8)
Malignant ventricular arrhythmia 5 (3.6) 10 (7.7)
Advanced AV block 1 (0.7) 2 (1.5)
Cardiogenic shock 6 (4.3) 7 (5.4)
Reinfarction 0 (0) 0 (0)
Death during admission 3 (2.1) 3 (2.3)
Killip class III or greater during 
admission
11 (7.9) 9 (6.9)
Reinfarction during admission 1 (0.7)* 0 (0)
AV indicates atrioventricular; and MACE, major adverse cardiac events 
(composite of death, malignant ventricular arrhythmias [ventricular fibrillation/
sustained ventricular tachycardia], advanced AV block, cardiogenic shock, and 
reinfarction). 
*Periprocedural infarction during percutaneous coronary intervention to a 
nonculprit coronary artery 4 days after index ST-segment–elevation myocardial 
infarction.
Figure 3. Effect of early pre-reperfusion intravenous metoprolol 
administration on infarct size estimated by peak and area 
under the curve (AUC) creatine kinase (CK) release. A and B, 
Back-transformed mean±SEM of peak CK release in patients 
undergoing magnetic resonance imaging (MRI; A) and in the 
entire study population (B). Nontransformed median of peak CK 
release in patients undergoing MRI was 2600 IU/L (quartiles 1 
and 3, 1306 and 4272 IU/L) in the intravenous metoprolol group 
vs 3700 IU/L (quartiles 1 and 3, 1311 and 5626 IU/L) in the 
control group (P=0.040). Nontransformed median of peak CK 
release in the entire study population was 2217 IU/L (quartiles 1 
and 3, 877 and 4151 IU/L) in the intravenous metoprolol group 
vs 3558 IU/L (quartiles 1 and 3, 1118 and 5593 IU/L) in the 
control group (P=0.011). C and D, AUC CK release in patients 
undergoing MRI (C) and in the entire study population (D). Data 
are presented as back-transformed mean±SEM for each time 
point of serum CK determination. Nontransformed median AUC 
CK release in patients undergoing MRI was 49 984 IU/L (quartiles 
1 and 3, 28 279 and 76 748 IU/L) in the intravenous metoprolol 
group vs 65 966 IU/L (quartiles 1 and 3, 28 837 and 10 9329 IU/L) 
in the control group (P=0.042). Nontransformed median AUC CK 
release in the entire study population was 47 030 IU/L (quartiles 
1 and 3, 23 869 and 78 453 IU/L) in the intravenous metoprolol 
group vs 63 656 IU/L (quartiles 1 and 3, 27 988 and 108 686 IU/L) 
in the control group (P=0.025).
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randomized STEMI patients undergoing thrombolysis to 
receive prethrombolysis atenolol or placebo. Contrasting with 
our results, they found no reduction in infarct size by intrave-
nous β-blocker administration. The reason for this disparity 
is unknown; however, a possible explanation is that ischemia/
reperfusion injury differs between patients treated by throm-
bolysis and primary PCI and that cardioprotective strategies in 
patients treated by PCI (abrupt coronary opening) do not work 
in patients treated by thrombolysis (gradual coronary open-
ing). Another potential explanation is that not all β-blockers 
have the same cardioprotective effect. In this regard, the non-
randomized TEAHAT (Thrombolysis Early in Acute Heart 
Attack) study found a significant infarct size reduction in 
STEMI patients undergoing thrombolysis and receiving early 
intravenous metoprolol.13 It is also likely to be significant that, 
in contrast to our trial, only 33% of STEMIs in the Van de Werf 
et al12 study were of anterior location and that reperfusion was 
never achieved in 25% of the study population. Finally, infarct 
size in our study was evaluated by MRI and was estimated by 
biomarker release by van de Werf et al.
In the era of primary PCI, a few retrospective studies25–27 
and 1 small randomized trial28 have evaluated the effect of 
pre-PCI β-blocker administration on clinical events. Despite 
none of these studies being designed to detect differences in 
infarct size, the clinical benefits observed by prereperfusion 
β-blockade in all of them are in agreement with our results.
It is our hypothesis that metoprolol reduces infarct size by 
ameliorating reperfusion injury.24 For that reason, a prespeci-
fied secondary end point was infarct size in the subgroup of 
patients with a pre-PCI occluded artery. Infarct size in the 
subgroup of patients with pre-PCI TIMI grade 0 of 1 flow 
was reduced to a larger extent than in the entire study popu-
lation (Table 2), supporting our hypothesis. In agreement 
with this idea, infarct size was not reduced in the subgroup 
of patients with pre-PCI TIMI grade 2 to 3 flow; however, 
the small number of patients with an open artery precludes a 
definite statement.
The results of the Clopidogrel and Metoprolol in Myocardial 
Infarction Trial (COMMIT) trial29 are the main reason why 
clinical practice guidelines do not emphasize early intra-
venous β-blocker initiation in STEMI.1 In this trial, STEMI 
patients undergoing thrombolysis were randomized to early 
intravenous followed by oral metoprolol or matching pla-
cebo. The COMMIT trial did not report data on infarct size 
but showed significantly reduced rates of reinfarction and ven-
tricular fibrillation in response to early intravenous metoprolol; 
however, this benefit came at the cost of excess cardiogenic 
shock, resulting in a net neutral effect on mortality.29 Although 
patients in COMMIT presented late (mean time from symp-
tom onset to thrombolysis, 10.3 hours), mortality was lower 
in Killip class I and II patients receiving intravenous metopro-
lol. Conversely, total mortality was increased by intravenous 
metoprolol in Killip class III patients.29 In addition, metopro-
lol increased mortality in patients with systolic blood pressure 
<120 mm Hg. These results reinforce the contraindications 
for intravenous β-blocker therapy in patients with overt heart 
failure, and these patients have been systematically excluded 
from other β-blocker trials. In contrast to the COMMIT trial, 
we randomized patients presenting early (within 6 hours 
of STEMI onset), used PCI as the reperfusion strategy, and 
excluded patients with Killip class III or greater at first medical 
contact. In METOCARD-CNIC, the number of patients who 
progressed to Killip class grade III to IV during admission was 
similar in both treatment groups (7.9% for intravenous meto-
prolol versus 6.9% for control). Patients with Killip class III to 
IV STEMI potentially have larger infarctions. Given that we 
excluded these types of patients (for safety reasons), we might 
have underestimated infarct size in our population and poten-
tially diluted the benefits of this cardioprotective strategy.
A possible limitation of our trial is that 19% of the recruited 
patients population did not undergo MRI for primary end-point 
evaluation. This attrition rate was as we projected16 and is sim-
ilar to those in other STEMI trials using MRI.21,30 Moreover, 
we analyzed infarct size by peak and AUC CK release in the 
entire study population to see if the loss of recruited patients 
introduced a selection bias, and this proved compatible with 
the MRI findings. A significant reduction in infarct size was 
observed in patients allocated to intravenous metoprolol 
before reperfusion in the entire population. Another limitation 
is that 22 patients scheduled for MRI were withdrawn from 
the imaging study for various reasons. However, this rate of 
withdrawal from scheduled MRI is compatible with previous 
experience16 and is lower than in other trials performing MRI 
early after STEMI.21,30,31
As shown in Figure 1, there was a significant difference 
in the proportion of no MRI performance between groups 
(higher in the intravenous metoprolol group). This was 
observed despite the fact that the evaluation of the qualifying 
criteria for MRI performance was done blinded to treatment 
allocation or other variables that might influence the outcome. 
In this regard, a sensitivity analysis showed that the estimated 
difference between treatments for CK release in all study 
population and in the subset of patients undergoing MRI was 
similar, ruling out a selection bias.
METOCARD-CNIC was a prospective, randomized, open, 
blinded end-point (PROBE) trial. Evaluators of all outcomes 
were nonetheless blinded to treatment allocation. Although 
evidence suggests that PROBE trials yield results similar 
to double-blinded trials,32 we cannot completely rule out an 
influence of this design on the study results.
Infarct size is a major determinant of postinfarction mortal-
ity, so limiting the extent of myocardial necrosis in STEMI is 
a major therapeutic target.33 Huge resources have been dedi-
cated to exploring novel therapies that might reduce infarct 
size but so far with little success.34 Here, we show that an 
inexpensive medication already approved for STEMI treat-
ment (intravenous metoprolol) can significantly reduce infarct 
size simply by being administered before reperfusion. Further 
evidence is needed to assess potential longer-term clinical 
benefits in a larger clinical trial.
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CLINICAL PERSPECTIvE
The capacity of β-blockers to reduce infarct size was evaluated extensively in the prereperfusion era with controversial results. 
In the context of reperfusion as the treatment of choice for ST-segment–elevation myocardial infarction (STEMI), this has 
been poorly investigated. Experimental data suggest that the β-blocker metoprolol is able to reduce infarct size only when 
administered intravenously before reperfusion. Here, we present the results of the Effect of Metoprolol in Cardioprotection 
During an Acute Myocardial Infarction (METOCARD-CNIC) trial, the first randomized, clinical trial prospectively evaluat-
ing the effect of early intravenous β-blockade on infarct size in conjunction with primary angioplasty. A total of 270 patients 
with anterior STEMI (Killip class II or less) revascularized within 6 hours after symptom onset were randomized to receive 
intravenous metoprolol or not before reperfusion. All patients received oral metoprolol according to clinical guidelines (first 
dose, 12–24 hours after infarction). Infarct size, evaluated by magnetic resonance imaging and creatine kinase release, was 
significantly reduced in the intravenous metoprolol group with no excess side effects. Left ventricular ejection fraction was 
higher in the intravenous metoprolol group. This cardioprotective effect appeared to be restricted to patients with a prean-
gioplasty Thrombolysis in Myocardial Infarction grade 0 to 1 flow. Here, we show that an inexpensive medication already 
approved in the context of STEMI can significantly reduce infarct size just by administering it intravenously before reperfu-
sion in patients with no contraindications. Given the important role of final infarct size as a main determinant of long-term 
mortality in STEMI survivors, the possibility of applying inexpensive strategies available to a wide proportion of STEMI 
patients is of clinical value.
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Long-Term Benefit of Early Pre-Reperfusion
Metoprolol Administration in Patients With
Acute Myocardial Infarction
Results From the METOCARD-CNIC Trial
(Effect of Metoprolol in Cardioprotection During an
Acute Myocardial Infarction)
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Objectives The goal of this trial was to study the long-term effects of intravenous (IV) metoprolol administration before
reperfusion on left ventricular (LV) function and clinical events.
Background Early IV metoprolol during ST-segment elevation myocardial infarction (STEMI) has been shown to reduce infarct size
when used in conjunction with primary percutaneous coronary intervention (pPCI).
Methods The METOCARD-CNIC (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction) trial recruited
270 patients with Killip class !II anterior STEMI presenting early after symptom onset (<6 h) and randomized them
to pre-reperfusion IV metoprolol or control group. Long-term magnetic resonance imaging (MRI) was performed on
202 patients (101 per group) 6 months after STEMI. Patients had a minimal 12-month clinical follow-up.
Results Left ventricular ejection fraction (LVEF) at the 6 months MRI was higher after IV metoprolol (48.7 " 9.9% vs.
45.0 " 11.7% in control subjects; adjusted treatment effect 3.49%; 95% conﬁdence interval [CI]: 0.44% to 6.55%;
p ¼ 0.025). The occurrence of severely depressed LVEF (!35%) at 6 months was signiﬁcantly lower in patients
treated with IV metoprolol (11% vs. 27%, p ¼ 0.006). The proportion of patients fulﬁlling Class I indications for
an implantable cardioverter-deﬁbrillator (ICD) was signiﬁcantly lower in the IV metoprolol group (7% vs. 20%,
p ¼ 0.012). At a median follow-up of 2 years, occurrence of the pre-speciﬁed composite of death, heart failure
admission, reinfarction, and malignant arrhythmias was 10.8% in the IV metoprolol group versus 18.3% in the
control group, adjusted hazard ratio (HR): 0.55; 95% CI: 0.26 to 1.04; p ¼ 0.065. Heart failure admission was
signiﬁcantly lower in the IV metoprolol group (HR: 0.32; 95% CI: 0.015 to 0.95; p ¼ 0.046).
Conclusions In patients with anterior Killip class !II STEMI undergoing pPCI, early IV metoprolol before reperfusion resulted
in higher long-term LVEF, reduced incidence of severe LV systolic dysfunction and ICD indications, and fewer
heart failure admissions. (Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The
METOCARD-CNIC Trial; NCT01311700) (J Am Coll Cardiol 2014;63:2356–62) ª 2014 by the American College
of Cardiology Foundation
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ST-segment elevation myocardial infarction (STEMI) is a
major contributor to mortality and morbidity worldwide (1–3).
Beyond the high mortality rate in the acute phase, STEMI
survivors are at high risk of recurrent events such as congestive
heart failure, arrhythmia, or sudden death. Post-infarction
patients with severely depressed left ventricular ejection frac-
tion (LVEF) are at the highest risk of long-term adverse out-
comes. Pharmacological and nonpharmacological (implantable
cardioverter-deﬁbrillator [ICD]) interventions have greatly
reduced long-term mortality rates in these patients (4,5).
However, the implementation of such strategies represents a
huge economic burden that precludes its universal application.
There is, therefore, a need for additional low-cost therapies to
prevent severe post-infarction left ventricular (LV) dysfunction.
The size of the infarct after a STEMI has been revealed as
the main determinant of adverse post-infarction outcomes
(6). Therapies able to reduce infarct size are therefore ur-
gently sought under the hypothesis that smaller infarctions
will result in better long-term heart performance and that
this will translate into fewer adverse clinical events (7,8).
Early intervention with intravenous (IV) metoprolol
before reperfusion (METOCARD-CNIC [Effect of Meto-
prolol in Cardioprotection During an Acute Myocardial
Infarction] trial) was recently shown to signiﬁcantly reduce
infarct size as evaluated by magnetic resonance imaging
(MRI) 1 week post-infarction (9). Here, we present the pre-
speciﬁed evaluation on long-term LVEF (primary MRI
measurement) and the effect on clinical endpoints of the
METOCARD-CNIC trial.
Methods
Study population. The design of the study has been
previously published (10). METOCARD-CNIC was a
multicenter randomized clinical trial in which STEMI pa-
tients undergoing primary percutaneous coronary interven-
tion (pPCI) were randomized to receive IV metoprolol
or control group (no metoprolol) before reperfusion.
Between November 2010 and October 2012, 270 patients
were randomized to IV metoprolol pre-reperfusion (n ¼
139) or control group (n ¼ 131). Inclusion criteria were
patient age 18 to 80 years, Killip
class !II anterior STEMI, and
anticipated symptom onset-to-
reperfusion time !6 h. Exclusion
criteria were systolic blood pres-
sure persistently <120 mm Hg,
atrioventricular block, heart rate
<60 beats/min, prior infarction,
or active treatment with b-
blockers. Patients randomized to
IV metoprolol received up to 3
5-mg boluses of metoprolol
tartrate. Fifty-ﬁve percent of the
study group was recruited and
treated during ambulance trans-
fer to the hospital. Apart from IV
metoprolol pre-reperfusion (or
control group), all patients re-
ceived state-of-the-art treatment
according to clinical guidelines,
including long-term oral treatment with b-blockers (ﬁrst
dose within 24 h after admission) in all patients with no
contraindication. All patients were treated by local physi-
cians who were blinded to treatment allocation and were
responsible for all clinical actions.
The primary readout of the trial (infarct size evaluated by
MRI performed 1 week post-infarction) was available in 220
patients. The results of the 1-week MRI have been reported
(9): administration of pre-reperfusion IV metoprolol resul-
ted in signiﬁcantly smaller (by 20%) infarcts and with no
excessive side effects.
The study was approved by the ethics committees and
institutional review boards at each participating center, and
all eligible patients gave written informed consent.
Long-term MRI data. The protocol included a follow-up
MRI 6 months after infarction in all patients except for
those who showed no evidence of infarction on baseline
MRI (no detectable gadolinium delayed enhancement). The
detailed MRI protocol and methods for analysis have been
reported (10). Analyses were undertaken by the Centro
Nacional de Investigaciones Cardiovasculares Carlos III
(CNIC) imaging core laboratory by expert researchers
blinded to treatment arm. Data were quantiﬁed using
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dedicated software (QMass MR version 7.5, Medis, Leiden,
the Netherlands). At 6-month MRI follow-up, LV volume,
LV mass, LVEF, and the extent of myocardial necrosis
(grams of LV tissue on delayed gadolinium enhancement
images) were determined.
A post-hoc comparison was performed of the between-
group frequencies of long-term LV reduced ejection frac-
tion according to established cutoffs for clinical relevance
(30%, 35%, and 40%) (4).
Evaluation of the indication for ICD implantation.
Given the clinical, social, and economic implications of post-
infarction ICD implantation, we performed a post-hoc
analysis of the rate of ICD indication between study
groups. ICD indication was deﬁned according to Class I
recommendations in current clinical guidelines (4,5): chronic
LVEF !30% or chronic LVEF 30% to 35% in patients
in New York Heart Association functional class II or III.
Clinical endpoints. The pre-speciﬁed clinical endpoint was
the composite of death, readmission because of heart failure,
reinfarction, and malignant ventricular arrhythmias (10).
Clinical follow-up was performed by telephone interview and
access to hospital reports. Once a potential event was detec-
ted, an independent clinical events committee blinded to the
treatment arm reviewed the primary source data and adjudi-
cated the event according to the pre-established protocol.
Statistical methods. The distribution of the continuous
variables was analyzed using graphical methods. For quan-
titative variables, data are expressed as mean " SD and
compared by parametric methods. For categorical data,
percents were compared using exact methods. MRI data
were analyzed between treatment groups by linear regression
models. LVEF was categorized by cutoffs of clinical sig-
niﬁcance, as described in the preceding text. To evaluate
between-group trends, an ordinal regression was performed,
and the proportional odds assumption was then checked.
The survival distributions during follow-up of patients with
and without IV metoprolol treatment were estimated by the
Kaplan-Meier method, followed by the Cox proportional
hazards regression model. The proportional hazards
assumption was conﬁrmed by inspection of Schoenfeld
residuals. Finally, as a pre-speciﬁed outcome, the treatment
effect on the incidence of 1-year follow-up major adverse
cardiac events (MACE) was evaluated by logistic regression.
Treatment effect estimates of all regression models (and 95%
conﬁdence intervals [CIs]) are presented both without and
with adjustment for the 4 stratiﬁcation variables used in
the randomization: time from symptom onset to enrollment
(<1.5 h vs. $1.5 h), diabetes mellitus status, sex, and age
(<60 years vs. $60 years).
Differences were considered statistically signiﬁcant at a
p value <0.05 (2-tailed).
All statistical tests were performed with IBM SPSS Sta-
tistics software, v.20.0 (SPSS, IBM, Armonk, New York)
and Stata 12 (Stata Statistical Software: Release 12, 2011,
StataCorp, College Station, Texas).
Results
Long-term MRI data. MRI was scheduled 6 months
after STEMI in all 220 patients undergoing 1-week MRI
except for those with no evidence of infarction in the ﬁrst MRI
study (3 IV metoprolol, 6 control subjects). Nine additional
patients did not undergo follow-up MRI for the following
causes: 1 death (control group), 1 disabling stroke (control
group), 1 technical problem with the MRI (IV metoprolol
group), 1 emigration (IV metoprolol group), and 5 refusals to
undergo follow-up MRI (3 IV metoprolol, 2 control subjects).
Thus, a total of 202 patients underwent 6-month MRI
(101 IV metoprolol and 101 control subjects). Long-term
medication with known beneﬁcial effects on LV remodeling
was similar in both groups of patients (Online Table 1).
MRI data are presented in Table 1. Pre-reperfusion
administration of IV metoprolol resulted in a signiﬁcantly
higher long-term mean LVEF on 6-month MRI (48.7 "
9.9% vs. 45.0 " 11.7% in control patients; adjusted treat-
ment effect 3.49; 95% CI: 0.44% to 6.55%; p ¼ 0.025)
(Fig. 1). LV end-systolic volume was signiﬁcantly lower in
patients treated with pre-reperfusion IV metoprolol (98.1 "
36.0 ml vs. 112.0 " 45.0 ml; adjusted treatment
effect %13.25; 95% CI: %24.47 to %2.03; p ¼ 0.021). The
LVEF values from the 1-week study (9) correlated tightly
with the 6-month values regardless of treatment group
(Online Fig. 1). Long-term extension of scar tissue was
15.7 " 10.4 g in the IV metoprolol group versus 18.6 " 11.3
Table 1 MRI Data (6 Months After Infarction)
IV Metoprolol Group
(n ¼ 101)
Control Group
(n ¼ 101)
Unadjusted
Adjusted
for Stratiﬁcation Variables
Difference (95% CI) p Value Difference (95% CI) p Value
LVEDV, ml 187.0 " 38.8 197.6 " 45.7 %10.62 (%22.45 to 1.22) 0.078 %10.34 (%21.73 to %1.05) 0.075
LVESV, ml 98.2 " 36.1 112.0 " 45.0 %13.87 (%25.22 to %2.51) 0.017 %13.25 (%24.47 to %2.03) 0.021
LV mass, g 84.6 " 17.4 86.8 " 18.1 %2.20 (%7.15 to 2.75) 0.38 %2.09 (%6.81 to 2.63) 0.38
Infarcted myocardium, g 15.7 " 10.5 18.6 " 11.3 %2.89 (%6.02 to 0.24) 0.070 %2.58 (%5.69 to 0.53) 0.10
Infarcted myocardium, % LV 15.7 " 9.6 18.3 " 9.8 %2.52 (%5.29 to 0.26) 0.075 %2.30 (%5.09 to 0.49) 0.11
LVEF, % 48.7 " 10.0 45.0 " 11.7 3.67 (0.64 to 6.71) 0.018 3.49 (0.44 to 6.55) 0.025
Values are mean " SD unless otherwise indicated.
CI ¼ conﬁdence interval; IV ¼ intravenous; LV ¼ left ventricle; LVEDV ¼ left ventricular end-diastolic volume; LVEF ¼ left ventricular ejection fraction; LVESV ¼ left ventricular end-systolic volume;
MRI ¼ magnetic resonance imaging.
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g in the control group (treatment effect %2.89; 95%
CI: %6.02 to 0.24; p ¼ 0.070).
LVEF depression and ICD indications according to
clinical guidelines. The numbers of patients in each
treatment group according to clinically relevant LVEF cut-
offs are illustrated in Figure 2A. The proportion of patients
with depressed LVEF at 6 months was signiﬁcantly lower
in the IV metoprolol group (e.g., 11% vs. 27% with
LVEF !35%, p ¼ 0.006), and the treatment groups also
differed in the distribution of patients by LVEF category.
Treatment allocation to IV metoprolol was associated with
being in a higher LVEF category (common odds ratio 1.84;
95% CI: 1.11 to 3.07; p ¼ 0.019).
The 6-month MRI data were analyzed for formal indi-
cation for ICD implantation according to current clinical
guidelines (4,5) (Fig. 2B). Pre-reperfusion metoprolol
administration resulted in a signiﬁcant reduction of patients
with ICD Class I recommendation (7% vs. 20% in the
control patients, a risk difference of 12.7% [95% CI: 3.2% to
22.3%]; p ¼ 0.012; adjusted odds ratio 0.32; 95% CI: 0.13
to 0.81; p ¼ 0.016). The number needed to treat to avoid
1 ICD indication was 8 (95% CI: 4.5 to 31; p ¼ 0.015).
Clinical follow-up. Median follow-up was 2 years after
STEMI, with all patients but 6 lost to follow-up having a
minimum of 12 months follow-up. The incidence of the
pre-speciﬁed MACE endpoint (composite of death, heart
failure admission, reinfarction, and malignant arrhythmia)
and its individual components by treatment group are
summarized in Table 2. There were fewer numerical MACE
events after pre-reperfusion IV metoprolol administration:
10.8% versus 18.3% in control group (adjusted hazard ratio
[HR]: 0.55; 95% CI: 0.26 to 1.04; p ¼ 0.065). This was
mainly driven by a lower rate of readmission because of heart
failure (2.2% in the IV metoprolol group vs. 6.9% in the
control group; HR: 0.32; 95% CI: 0.015 to 0.95; p¼ 0.046).
Kaplan-Meier curves are shown in Figure 3.
Discussion
This pre-speciﬁed follow-up of the METOCARD-CNIC
trial shows that patients receiving pre-reperfusion IV
metoprolol have a signiﬁcantly higher long-term mean
LVEF compared with control groups and are protected
Figure 1 LVEF on MRI 6 Months After Infarction
Left ventricular ejection fraction (LVEF) in patients undergoing magnetic resonance
imaging (MRI) 6 months after infarction. Boxplots represent mean ("SEM).
Circles are individual patient data. i.v. ¼ intravenous.
Figure 2 Follow-Up LVEF Categories and Indications for ICD According to Treatment Allocation
(A) Distribution of patients according to LVEF categories. Fisher exact test p ¼ 0.026 and linear-by-linear association test p ¼ 0.006. (B) Rate of formal indication
(Class I recommendation in clinical guidelines) for ICD; see text. Fisher exact test p ¼ 0.012. NYHA ¼ New York Heart Association; other abbreviations as in Figure 1.
JACC Vol. 63, No. 22, 2014 Pizarro et al.
June 10, 2014:2356–62 Long-Term Effect of Early Metoprolol in STEMI
2359
Downloaded From: https://content.onlinejacc.org/ on 06/11/2014
against long-term LVEF depression. These effects were
accompanied by a trend towards reduced hard clinical end-
points. To the best of our knowledge, this is the ﬁrst
demonstration of a pharmacological cardioprotective strategy
used in conjunction with pPCI resulting in sustained ben-
eﬁts on overall LVEF and in a signiﬁcant reduction of cases
of chronic severe LV systolic dysfunction.
The design of the METOCARD-CNIC trial included a
6 months MRI study for the evaluation of the effect of the
therapy on long-term validated prognostic parameters.
MRI is the gold standard for the evaluation of heart
anatomy and function (11). In the 6 months MRI, we
found that besides a higher LVEF, patients in the IV
metoprolol group had signiﬁcantly smaller LV end-systolic
volumes, another well-established post-infarction prog-
nostic parameter (12). We previously reported a signiﬁ-
cantly higher LVEF in the IV metoprolol group in the
1-week post-infarction MRI study (9). As presented, the
LVEF values from the 1-week study correlated tightly with
the follow-up values in both groups of treatment,
supporting the conclusion that the long-term beneﬁts of
pre-reperfusion IV metoprolol are a consequence of the
short-term beneﬁcial effects detected at 1 week post-
infarction. In order to determine whether the attrition of
patients between the 1-week and 6-month MRI studies
could have biased the results reported here, we evaluated
the 1-week MRI LVEF in those patients who underwent
the ﬁrst scan, but not the 6-month follow-up (n ¼ 18):
median (ﬁrst and third quartile) LVEF values were 53.0%
(45.5% to 59.0%) in the IV metoprolol group versus 52.5%
(46.8% to 62.0%) in the control group, excluding the
possibility of selection bias introduced by patient attrition
between 1-week and follow-up MRIs.
The long-term beneﬁcial effects of pre-reperfusion IV
metoprolol on LVEF were associated with a nonsigniﬁcant
trend toward reduced hard clinical endpoints. The main
limitation for the interpretation of this ﬁnding is that our
trial was not powered to detect differences in clinical events.
Other small trials testing the effect of cardioprotective
strategies in STEMI have reported a signiﬁcant reduction in
long-term events despite being underpowered. In the
CONDI (Remote Ischemic Conditioning in Primary PCI)
trial, Sloth et al. (13) found that remote ischemic condi-
tioning in STEMI seemed to improve long-term clinical
outcomes. Their minimum follow-up was 3 years, whereas
ours was 12months. In fact, the survival curves in theCONDI
trial showed a clear divergence after 2 years of follow-up. In a
different study, Stone et al. (14) found that intracoronary
abciximab in anterior STEMI resulted in a signiﬁcant events
reduction in the non–pre-speciﬁed time range (30 days to
12 months) post-infarction. Given the strong trend towards
events reduction found in our trial, it is plausible that longer
follow-up will reveal statistically signiﬁcant differences.
Similarly, non–pre-speciﬁed analyses of our study showed
Table 2 Clinical Events
IV Metoprolol Control p Value
MACE 15 (10.8) 24 (18.3) 0.065
Death 6 (4.3) 6 (4.6) 0.92
Cardiac death 3 (2.2) 5 (3.8)
Noncardiac death 3 (2.2) 1 (0.8)
Heart failure admission 3 (2.2) 9 (6.9) 0.046
ICD implantation 2 (1.4) 7 (5.3)
Decompensation 1 (0.7) 3 (2.3)
Re-AMI 1 (0.7) 3 (2.3) 0.15
Malignant ventricular arrhythmia 5 (3.6) 10 (7.7) 0.18
Values are n (%). MACE was the composite of all-cause death, heart failure admission (internal
cardioverter deﬁbrillator [ICD] implantation or clinical decompensation), reinfarction, and malignant
ventricular arrhythmias (ventricular ﬁbrillation/sustained ventricular tachycardia). Values were
adjusted for randomization of variables.
AMI ¼ acute myocardial infarction; IV ¼ intravenous; MACE ¼ major adverse cardiac event(s).
Figure 3 Follow-Up Clinical Endpoints
(A) Kaplan-Meier curves illustrating cumulative incidence of the pre-speciﬁed composite of death, admission as a result of heart failure (HF), reinfarction, or malignant
ventricular arrhythmias. (B) Kaplan-Meier curves showing the cumulative incidence of readmission as a result of heart failure. CI ¼ conﬁdence interval; HR ¼ hazard ratio;
i.v. ¼ intravenous; MACE ¼ major adverse cardiac events.
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statistical signiﬁcance (heart failure admission HR: 0.32;
p ¼ 0.046). However, we feel that these non-powered or
non–pre-speciﬁed analyses are of limited value even when
statistical signiﬁcance is shown.We believe that our data form
a sufﬁcient basis for a larger STEMI clinical trial of early IV
metoprolol powered for clinical events reduction.
The implementation of reperfusion strategies over the past
decades has signiﬁcantly reduced the acute mortality associ-
ated with STEMI (15). However, a high proportion of sur-
vivors remain at high risk of future cardiovascular events
throughout life, including sudden death and repetitive epi-
sodes of heart failure. Long-term post-infarction LV systolic
function is a major predictor of these clinical events; indeed,
LVEF remains the principal objective parameter used for the
indication for post-infarction heart failure therapies (4,5).
Extensive clinical research has led to chronic heart failure
interventions (pharmacological and device-based) that reduce
long-term mortality in STEMI survivors with low LVEF
(4,5). Nonetheless, the implementation of these strategies
comes at a high socioeconomic cost (16,17). The enormous
economic burden for health services is the main factor pre-
venting universal implementation of these new heart failure
therapies (18,19), and most countries in development cannot
afford them (20), despite having implemented reperfusion
strategies for STEMI. Even in advanced economies, eco-
nomic considerations prevent universal use of the most
expensive therapies (ICD and cardiac resynchronization de-
vices) (21,22). The present trial demonstrates that adminis-
tration of a low-cost therapy (<2V in Spain, <$3 in the
United States) results in higher long-term LVEF. Although
the observed 3.7-point absolute difference in mean LVEF
could be judged as small, the much lower number of patients
with severely depressed LVEF in the treatment group is more
clinically relevant, and would translate into a greater socio-
economic impact. Furthermore, the number of patients
with a formal indication for ICD implantation according to
clinical guidelines was two-thirds less among the IV meto-
prolol patients. Overall, the rate of actual ICD implantation
among cases with a formal indication was 33% (9 of 27,
Table 2). This rate of ICD implantation is in agreement with
other dedicated studies (rate between 30% and 35%) (23,24),
and above what is seen in the general population (around
13%) (25).
In the ﬁrst report on the METOCARD-CNIC trial, we
documented an average 20% smaller infarct size in patients
randomized to IV metoprolol, as evaluated by MRI 1 week
after infarction (9). At 6 months, total infarct size difference
between groups had been attenuated (15.6 g in the IV
metoprolol group vs. 18.6 g in the control group, p ¼ 0.07).
Thus, despite the infarct size still beingz17% smaller in the
active treatment group, the natural shrinkage of scar tissue
narrowed the absolute difference (26). It is also important
to consider that this trial was powered to detect differences
in infarct size in the acute phase (1 week after STEMI).
Beta-blockers have been shown to reduce mortality when
used as secondary prevention after infarction (27), and are an
established part of the pharmacological armamentarium,
with a Class I indication in clinical guidelines (1,2). How-
ever, very early IV administration before reperfusion is not
encouraged, mainly because of the results of the COMMIT
(Efﬁcacy and Safety of Adding Clopidogrel to Aspirin or
Use of Metoprolol in Myocardial Infarction) trial, which
showed no short-term net clinical beneﬁt of early metoprolol
in STEMI patients undergoing thrombolysis (28). The
COMMIT trial recruited all comers with almost no re-
striction. By contrast, the METOCARD-CNIC trial
recruited Killip class !II patients presenting with systolic
blood pressure $120 mmHg, heart rate $60 beats/min, and
reperfused by pPCI within 6 h of infarct onset. Subgroup
analyses of the COMMIT trial (28) suggested that patients
ﬁtting the inclusion criteria of the METOCARD-CNIC
trial beneﬁted from early IV metoprolol in terms of mor-
tality reduction. In addition, the clinical beneﬁts associated
with infarct size reduction (and post-infarction LVEF
improvement) are expected to occur late (months to years)
after STEMI (13,29). In the COMMIT trial, clinical
follow-up was <1 month. It is plausible that longer follow-
up of the COMMIT trial would show additional beneﬁt of
early IV metoprolol in survivors. Thus, an important lesson
from the COMMIT trial is that not all STEMI patients
beneﬁt from very early IV metoprolol, a deduction supported
by the results reported here.
Study limitations. This trial was not powered to detect
differences in hard clinical endpoints, and thus, the results
on this outcome should be taken with caution.
Conclusions
Intravenous metoprolol administered before reperfusion re-
sults in higher long-term LVEF and a lower incidence of
post-infarction severe LVEF depression in anterior STEMI
patients undergoing primary PCI during the ﬁrst 6 h of
infarction. This low-cost therapy could have an important
socioeconomic impact by reducing the number of patients
requiring expensive interventions to treat post-infarction
heart failure and prevent sudden death. The results of the
METOCARD-CNIC trial warrant a large study powered
to detect differences in hard clinical endpoints.
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